<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>International Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1201-9712</issn><issn pub-type="epub">1878-3511</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8459551</article-id><article-id pub-id-type="pmcid-ver">PMC8459551.1</article-id><article-id pub-id-type="pmcaid">8459551</article-id><article-id pub-id-type="pmcaiid">8459551</article-id><article-id pub-id-type="pmid">34563707</article-id><article-id pub-id-type="doi">10.1016/j.ijid.2021.09.045</article-id><article-id pub-id-type="pii">S1201-9712(21)00752-9</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Buchy</surname><given-names initials="P">Philippe</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Buisson</surname><given-names initials="Y">Yves</given-names></name><xref rid="aff0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Cintra</surname><given-names initials="O">Otavio</given-names></name><xref rid="aff0003" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Dwyer</surname><given-names initials="DE">Dominic E.</given-names></name><xref rid="aff0004" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Nissen</surname><given-names initials="M">Michael</given-names></name><xref rid="aff0005" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Ortiz de Lejarazu</surname><given-names initials="R">Raul</given-names></name><xref rid="aff0006" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Petersen</surname><given-names initials="E">Eskild</given-names></name><xref rid="aff0007" ref-type="aff">7</xref><xref rid="aff0008" ref-type="aff">8</xref><xref rid="aff0009" ref-type="aff">9</xref></contrib><aff id="aff0001"><label>1</label>GSK, Singapore, Singapore</aff><aff id="aff0002"><label>2</label>Acad&#233;mie nationale de m&#233;decine, Paris, France</aff><aff id="aff0003"><label>3</label>GSK, Rio de Janeiro, Brazil</aff><aff id="aff0004"><label>4</label>New South Wales Health Pathology &#8211; Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia</aff><aff id="aff0005"><label>5</label>Consultant in Infectious Diseases, University of Queensland, Brisbane, Australia</aff><aff id="aff0006"><label>6</label>Scientific Advisor &amp; Emeritus director at Valladolid NIC (National Influenza Centre) Spain, School of Medicine, Avd Ram&#243;n y Cajal s/n 47005 Valladolid, Spain</aff><aff id="aff0007"><label>7</label>European Society for Clinical Microbiology and Infectious Diseases, Basel, Switzerland</aff><aff id="aff0008"><label>8</label>Department of Molecular Medicine, The University of Pavia, Pavia, Italy</aff><aff id="aff0009"><label>9</label>Department of Clinical, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. Philippe Buchy.</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>23</day><month>9</month><year>2021</year></pub-date><volume>112</volume><issue-id pub-id-type="pmc-issue-id">390504</issue-id><fpage>300</fpage><lpage>317</lpage><history><date date-type="received"><day>21</day><month>4</month><year>2021</year></date><date date-type="rev-recd"><day>17</day><month>9</month><year>2021</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>23</day><month>09</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-09 03:25:33.113"><day>09</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 GlaxoSmithKline Biologicals S.A.</copyright-statement><copyright-year>2021</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0002"><p>Pandemic dynamics and health care responses are markedly different during the COVID-19 pandemic than in earlier outbreaks. Compared with established infectious disease such as influenza, we currently know relatively little about the origin, reservoir, cross-species transmission and evolution of SARS-CoV-2. Health care services, drug availability, laboratory testing, research capacity and global governance are more advanced than during 20th century pandemics, although COVID-19 has highlighted significant gaps. The risk of zoonotic transmission and an associated new pandemic is rising substantially. COVID-19 vaccine development has been done at unprecedented speed, with the usual sequential steps done in parallel. The pandemic has illustrated the feasibility of this approach and the benefits of a globally coordinated response and infrastructure. Some of the COVID-19 vaccines recently developed or currently in development might offer flexibility or sufficiently broad protection to swiftly respond to antigenic drift or emergence of new coronaviruses. Yet many challenges remain, including the large-scale production of sufficient quantity of vaccines, delivery of vaccines to all countries and ensuring vaccination of relevant age groups. This wide vaccine technology approach will be best employed in tandem with active surveillance for emerging variants or new pathogens using antigen mapping, metagenomics and next generation sequencing.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>pandemic</kwd><kwd>vaccine</kwd><kwd>COVID-19</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><title>Introduction</title><p id="para0006">Since the 1980s, at least 30 new infectious disease threats have emerged (<xref rid="bib0156" ref-type="bibr">Mukherjee,&#160;2017</xref>). Of emerging infectious diseases (EIDs) identified since 1940, 60% were zoonotic in nature, of which 70% originated in wildlife (<xref rid="bib0115" ref-type="bibr">Jones&#160;et&#160;al., 2008</xref>). This trend is expected to rise because of increased human&#8211;animal contact, climate change, land use changes, global population growth, and increased global interconnectedness (<xref rid="bib0115" ref-type="bibr">Jones&#160;et&#160;al., 2008</xref>, <xref rid="bib0156" ref-type="bibr">Mukherjee,&#160;2017</xref>, <xref rid="bib0172" ref-type="bibr">Petersen&#160;et&#160;al., 2018</xref>).</p><p id="para0007">Pandemics and epidemics have increased in frequency since the Middle Ages: bubonic plague (started 1347), smallpox (early 1500s), influenza 'Great Pandemic' (1833), cholera (1881), Spanish influenza (1918), Asian influenza (1957), hepatitis C (1960s), Hong Kong influenza (1968), Russian influenza (1977), human immunodeficiency virus (HIV, 1981), severe acute respiratory syndrome coronavirus (SARS-CoV-1, 2003), swine influenza (2009), Middle East respiratory syndrome coronavirus (MERS-CoV, 2012), West Africa Ebola virus (2013), chikungunya virus (2013), Zika virus (2015) and coronavirus disease 2019 (COVID-19) (SARS-CoV-2, 2019). Although the World Health Organization (WHO) includes coronavirus as a priority pathogen, until the COVID-19 pandemic, influenza was considered to be the most likely causal pathogen of the next significant pandemic, and modelling suggested an annual 1% chance of an influenza pandemic that would result in 6 million global deaths (Madhav et&#160;al., 2018).</p><p id="para0008">The first difficulty in drawing lessons from previous influenza A pandemics is that the COVID-19 outbreak is the first and only pandemic caused by a coronavirus during the scientific era (<xref rid="bib0042" ref-type="bibr">CDCP,&#160;2018a</xref>, <xref rid="bib0100" ref-type="bibr">Honigsbaum,&#160;2020</xref>, <xref rid="bib0244" ref-type="bibr">WHO,&#160;2020a</xref>). The biological differences between influenza A viruses and coronaviruses are substantial (<xref rid="bib0001" ref-type="bibr">Abdelrahman&#160;et&#160;al., 2020</xref>). The ultimate goal in declaring a pandemic or a Public Health Emergency of International Concern (PHEIC) is to create a global alert (<xref rid="bib0070" ref-type="bibr">Durrheim&#160;et&#160;al., 2020</xref>). The term pandemic has been used for approximately 40 years and was not widely adopted during the pandemic events of 1957 and 1968. It is more than 50 years since the occurrence of a pandemic with similar severity and extent to the current COVID-19 pandemic. Mortality in the 1957 Asian and 1968 Hong Kong influenza pandemics was comparable to that of COVID-19 so far (<xref rid="bib0100" ref-type="bibr">Honigsbaum,&#160;2020</xref>). However, severity and mortality were substantially lower in the 2009 influenza A pandemic than in the current COVID-19 pandemic (<xref rid="bib0073" ref-type="bibr">Faust&#160;and Del Rio,&#160;2020</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). Human contact has been far greater with the H1N1 influenza A virus subtype than with other influenza viruses (<xref rid="bib0166" ref-type="bibr">Palese&#160;and Wang,&#160;2011</xref>). One reason for the mildness of the 2009 pandemic could be the intrinsic pathogenicity and virulence of the H1 subtype (<xref rid="bib0025" ref-type="bibr">Belser&#160;et&#160;al., 2010</xref>) and the presence of partial immunity against the A/California/04/2009 (H1N1) virus among older adults (<xref rid="bib0092" ref-type="bibr">Hancock&#160;et&#160;al., 2009</xref>).</p><p id="para0009">While there is a surveillance network made up of 144 national influenza centres all over the world (<xref rid="bib0245" ref-type="bibr">WHO,&#160;2020b</xref>), there is nothing similar for the surveillance of other diseases. In the current COVID-19 pandemic, surveillance has been implemented with the same tools used for influenza surveillance (<xref rid="bib0249" ref-type="bibr">WHO,&#160;2021a</xref>).</p></sec><sec id="sec0002"><title>Key features of previous influenza pandemics</title><p id="para0010">Features of previous pandemics are summarised in <xref rid="tbl0001" ref-type="table">Table&#160;1</xref>
.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Features of 20th and 21st century influenza pandemics</p></caption><alt-text id="alt0004">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Pandemic</th><th valign="top" colspan="1" rowspan="1">Dates</th><th valign="top" colspan="1" rowspan="1">Influenza virus</th><th valign="top" colspan="1" rowspan="1">No. waves</th><th valign="top" colspan="1" rowspan="1">No. deaths</th><th valign="top" colspan="1" rowspan="1">Age groups with highest mortality</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Spanish influenza</td><td valign="top" colspan="1" rowspan="1">1918&#8211;1920</td><td valign="top" colspan="1" rowspan="1">A/H1N1</td><td valign="top" colspan="1" rowspan="1">3(<xref rid="bib0021" ref-type="bibr">Barry,&#160;2005</xref>)</td><td valign="top" colspan="1" rowspan="1">20&#8211;100 million (<xref rid="bib0021" ref-type="bibr">Barry,&#160;2005</xref>, <xref rid="bib0114" ref-type="bibr">Johnson&#160;and Mueller,&#160;2002</xref>, <xref rid="bib0116" ref-type="bibr">Jordan,&#160;1927</xref>, <xref rid="bib0160" ref-type="bibr">Nicholson&#160;et&#160;al., 2019</xref>)</td><td valign="top" colspan="1" rowspan="1">Infants, young adults (20&#8211;40 years), elderly (<xref rid="bib0210" ref-type="bibr">Taubenberger&#160;and Morens,&#160;2006</xref>)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Asian influenza</td><td valign="top" colspan="1" rowspan="1">1957&#8211;1958</td><td valign="top" colspan="1" rowspan="1">A/H2N2</td><td valign="top" colspan="1" rowspan="1">2(<xref rid="bib0184" ref-type="bibr">Rogers&#160;2020</xref>)</td><td valign="top" colspan="1" rowspan="1">1&#8211;2 million (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>)</td><td valign="top" colspan="1" rowspan="1">Infants, children (5&#8211;14 years), young adults (15&#8211;24 years), elderly (<xref rid="bib0226" ref-type="bibr">Viboud&#160;et&#160;al., 2016</xref>)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Hong Kong influenza</td><td valign="top" colspan="1" rowspan="1">1968&#8211;1969</td><td valign="top" colspan="1" rowspan="1">A/H3N2</td><td valign="top" colspan="1" rowspan="1">2(<xref rid="bib0056" ref-type="bibr">Cockburn&#160;et&#160;al., 1969</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>)</td><td valign="top" colspan="1" rowspan="1">0.5&#8211;2 million (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>)</td><td valign="top" colspan="1" rowspan="1">&gt;65 years (<xref rid="bib0045" ref-type="bibr">Centers&#160;for Disease Control and Prevention 2019b</xref>)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Russian influenza</td><td valign="top" colspan="1" rowspan="1">1977&#8211;1979</td><td valign="top" colspan="1" rowspan="1">A/H1N1</td><td valign="top" colspan="1" rowspan="1">1(<xref rid="bib0089" ref-type="bibr">Gregg&#160;et&#160;al., 1978</xref>)</td><td valign="top" colspan="1" rowspan="1">700,000 (<xref rid="bib0089" ref-type="bibr">Gregg&#160;et&#160;al., 1978</xref>)</td><td valign="top" colspan="1" rowspan="1">Infants, young adults (&lt;25 years) (<xref rid="bib0089" ref-type="bibr">Gregg&#160;et&#160;al., 1978</xref>)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Swine influenza</td><td valign="top" colspan="1" rowspan="1">2009&#8211;2010</td><td valign="top" colspan="1" rowspan="1">A/H1N1pdm09</td><td valign="top" colspan="1" rowspan="1">2 or 3 depending on location(<xref rid="bib0111" ref-type="bibr">Jhung&#160;et&#160;al., 2011</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>)</td><td valign="top" colspan="1" rowspan="1">123,000&#8211;203,000 (<xref rid="bib0202" ref-type="bibr">Simonsen&#160;et&#160;al., 2013</xref>)</td><td valign="top" colspan="1" rowspan="1">5&#8211;59 years (<xref rid="bib0050" ref-type="bibr">Charu&#160;et&#160;al., 2011</xref>)</td></tr></tbody></table></table-wrap></p><sec id="sec0003"><title>Pandemic dynamics and cultural contexts</title><p id="para0011">The spread of the presumed influenza 'Great Pandemic' in 1833 occurred via transatlantic shipping between the Americas and Africa (<xref rid="bib0169" ref-type="bibr">Patterson,&#160;1986</xref>). The first outbreak of the 1918 pandemic was identified in military camps across USA towards the end of World War 1 (<xref rid="bib0021" ref-type="bibr">Barry,&#160;2005</xref>). The pandemic spread globally over nine months (<xref rid="bib0021" ref-type="bibr">Barry,&#160;2005</xref>, <xref rid="bib0032" ref-type="bibr">Byerly,&#160;2010</xref>). War-related factors might have promoted high transmission levels and hampered efforts to contain the pandemic (National Academies of Sciences et&#160;al., 2019). In the US, it was illegal to be critical of the government during the war (<xref rid="bib0160" ref-type="bibr">Nicholson&#160;et&#160;al., 2019</xref>), whilst the UK mounted one of the least effective responses to the pandemic largely because health care professionals underplayed its importance (<xref rid="bib0217" ref-type="bibr">Tomkins,&#160;1992</xref>). The causal agent is now known to be influenza A/H1N1. Influenza A virus was first isolated only in 1933 by Smith, Andrewes and Laidlaw, followed by influenza B virus by Francis in 1936 (<xref rid="bib0204" ref-type="bibr">Smith&#160;et&#160;al., 1933</xref>, <xref rid="bib0044" ref-type="bibr">CDCP,&#160;2019a</xref>).</p><p id="para0012">In February 1957, a new reassorting A/H2N2 influenza strain (Asian influenza pandemic) emerged in the Yunnan Province of China, and rapidly spread globally (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). A second wave affected the Northern hemisphere in November 1957 which was more severe than the first (<xref rid="bib0184" ref-type="bibr">Rogers, 2020</xref>). Most global transmission occurred via land and sea routes (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). In 1957, the existence of the avian reservoir and the phenomena of antigenic drift and genetic reassortment were not recognised (<xref rid="bib0121" ref-type="bibr">Kilbourne,&#160;1980</xref>, <xref rid="bib0122" ref-type="bibr">Kilbourne,&#160;2006</xref>).</p><p id="para0013">First reported in July 1968, a new A/H3N2 pandemic strain (a reassortment of the Asian influenza strain with an avian influenza H3 subtype) resulted in the Hong Kong influenza pandemic (<xref rid="bib0056" ref-type="bibr">Cockburn&#160;et&#160;al., 1969</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). By autumn, the virus had been detected in several Asian countries and the US, before spreading more widely (<xref rid="bib0056" ref-type="bibr">Cockburn&#160;et&#160;al., 1969</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). The 1968 pandemic was the first in which air travel played a significant role in transmission (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). Russian influenza emerged in the former Soviet Union during November 1977 and had spread elsewhere by early 1978 (<xref rid="bib0089" ref-type="bibr">Gregg&#160;et&#160;al., 1978</xref>). It was caused by an influenza A/H1N1 virus that had circulated worldwide during the 1950s, and mainly affected individuals younger than 25 years of age (<xref rid="bib0089" ref-type="bibr">Gregg&#160;et&#160;al., 1978</xref>).</p><p id="para0014">The 2009 influenza pandemic was caused by the influenza A/H1N1pdm09 virus (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>), a triple reassortment virus containing genes from classic swine influenza A viruses, North American lineage avian influenza viruses and human influenza A viruses (<xref rid="bib0063" ref-type="bibr">Dawood&#160;et&#160;al., 2009</xref>). The first case was recorded in April 2009 in Mexico and the US. It was declared a pandemic by the WHO in June 2009 (<xref rid="bib0049" ref-type="bibr">Chan,&#160;2009</xref>). The pattern of the pandemic varied between countries (<xref rid="bib0111" ref-type="bibr">Jhung&#160;et&#160;al., 2011</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). School cycles were shown to be important in transmission dynamics in Mexico and Hong Kong (<xref rid="bib0053" ref-type="bibr">Chowell&#160;et&#160;al., 2011</xref>, <xref rid="bib0254" ref-type="bibr">Wu&#160;et&#160;al., 2010</xref>).</p></sec><sec id="sec0004"><title>Morbidity and mortality</title><p id="para0015">Mortality during the &#8216;Great Pandemic&#8217; in 1833 was up to 80%, with a high death toll for people between 21 and 40 years of age (<xref rid="bib0169" ref-type="bibr">Patterson,&#160;1986</xref>). The Spanish influenza pandemic infected approximately 500 million people, roughly one-third of the world's population at the time, with mortality estimates of 20&#8211;100 million deaths worldwide (<xref rid="bib0021" ref-type="bibr">Barry,&#160;2005</xref>, <xref rid="bib0114" ref-type="bibr">Johnson&#160;and Mueller,&#160;2002</xref>, <xref rid="bib0116" ref-type="bibr">Jordan,&#160;1927</xref>, <xref rid="bib0160" ref-type="bibr">Nicholson&#160;et&#160;al., 2019</xref>). The overall mortality was &gt;2.5% (<xref rid="bib0210" ref-type="bibr">Taubenberger&#160;and Morens,&#160;2006</xref>), but with wide differences; for example, mortality was high where populations were naive to influenza such as islands in Oceania (e.g. 22% in Western Samoa)(<xref rid="bib0199" ref-type="bibr">Shanks&#160;et&#160;al., 2018</xref>) or Alaska and Eskimo populations (e.g. up to 38% in Alaska and up to 75% in Labrador)(<xref rid="bib0144" ref-type="bibr">Mamelund&#160;et&#160;al., 2013</xref>). Age-specific death rates followed a W-shaped curve, with high death rates in the very young and the elderly (as observed with seasonal influenza), but with the addition of a third peak of deaths in adults 20&#8211;40 years of age (<xref rid="bib0210" ref-type="bibr">Taubenberger&#160;and Morens,&#160;2006</xref>). Nearly half of the influenza deaths during the 1918 pandemic occurred in persons 20&#8211;40 years of age (<xref rid="bib0210" ref-type="bibr">Taubenberger&#160;and Morens,&#160;2006</xref>). Total mortality in Europe has been estimated at 2.64 million i.e. 1.1% of the total population (<xref rid="bib0013" ref-type="bibr">Ansart&#160;et&#160;al., 2009</xref>). Mortality varied more than 30-fold across countries, with poorer countries disproportionately affected (<xref rid="bib0158" ref-type="bibr">Murray&#160;et&#160;al., 2006</xref>). Extrapolating mortality rates to the 2004 population estimated that a similar pandemic would result in 62 million deaths (<xref rid="bib0158" ref-type="bibr">Murray&#160;et&#160;al., 2006</xref>).</p><p id="para0016">The 1957 Asian influenza was relatively mild and resulted in approximately 1&#8211;2 million deaths worldwide (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). A study using historical mortality data estimated an average pandemic-associated excess respiratory mortality rate of 1.9 per 10,000 persons (<xref rid="bib0226" ref-type="bibr">Viboud&#160;et&#160;al., 2016</xref>). The Hong Kong influenza (1968) pandemic is estimated to have caused half a million to 2 million deaths worldwide (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>), with most deaths occurring in people &gt;65 years of age (CDC, 2019b). All-cause mortality rose by between 3.6% in Canada to 13.0% in England and Wales (<xref rid="bib0225" ref-type="bibr">Viboud&#160;et&#160;al., 2005</xref>). Mortality in the 1977 Russian influenza pandemic was estimated at 700,000 (<xref rid="bib0089" ref-type="bibr">Gregg&#160;et&#160;al., 1978</xref>).</p><p id="para0017">Global respiratory deaths from the 2009 A/H1N1 pandemic have been estimated at 123,000&#8211;203,000, approximately 10 times as high as the WHO's laboratory-confirmed count (<xref rid="bib0202" ref-type="bibr">Simonsen&#160;et&#160;al., 2013</xref>). Another modelling study estimated 105,700&#8211;395,600 respiratory deaths globally with a further 46,000&#8211;179,900 cardiovascular deaths (<xref rid="bib0064" ref-type="bibr">Dawood&#160;et&#160;al., 2012</xref>); up to 85% of deaths occurred in people under 65 years of age (<xref rid="bib0064" ref-type="bibr">Dawood&#160;et&#160;al., 2012</xref>, <xref rid="bib0202" ref-type="bibr">Simonsen&#160;et&#160;al., 2013</xref>). Another study estimated that 71% of deaths in Mexico occurred in people under 60 years of age (<xref rid="bib0050" ref-type="bibr">Charu&#160;et&#160;al., 2011</xref>). Pregnant women were also identified to be at particular risk (<xref rid="bib0138" ref-type="bibr">Louie&#160;et&#160;al., 2010</xref>).</p></sec><sec id="sec0005"><title>Pandemic responses: non-pharmaceutical interventions, treatments and vaccination</title><p id="para0018">Mitigation efforts in the 1918 pandemic relied upon non-pharmaceutical interventions (NPI) such as wearing face masks, quarantines, restriction of activities and gatherings, closures of schools and churches (<xref rid="bib0160" ref-type="bibr">Nicholson&#160;et&#160;al., 2019</xref>). Concurrent school closures and public gathering bans were the most commonly implemented interventions and resulted in a statistically significant reduction in excess pneumonia and influenza deaths (<xref rid="bib0145" ref-type="bibr">Markel&#160;et&#160;al., 2007</xref>). Although no antibiotics, antivirals or modern vaccines were available, passive immunisation with immunoglobulins was implemented (<xref rid="bib0139" ref-type="bibr">Luke&#160;et&#160;al., 2006</xref>). Mortality later in the pandemic is believed to be the result of secondary bacterial infections (<xref rid="bib0028" ref-type="bibr">Brundage,&#160;2006</xref>, <xref rid="bib0155" ref-type="bibr">Morens&#160;et&#160;al., 2010</xref>).</p><p id="para0019">The 1957 influenza pandemic was the first in which a previous vaccine was available; however, it took 6 months before it could be rolled out because the developers needed to adjust its formulation with the new pandemic strain. Only 30 million vaccine doses were distributed globally and inadequate coverage meant that vaccination had little impact on the pandemic (<xref rid="bib0098" ref-type="bibr">Henderson&#160;et&#160;al., 2009</xref>, <xref rid="bib0109" ref-type="bibr">Jensen&#160;et&#160;al., 1958</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). The generally mild nature of the 1968 pandemic again meant that NPIs were not considered necessary (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). However, vaccines became available only after the pandemic had peaked (<xref rid="bib0184" ref-type="bibr">Rogers,&#160;2020</xref>).</p><p id="para0020">School closures and other NPIs were implemented swiftly in Mexico after the outbreak of the 2009 A/H1N1 pandemic, followed by similar measures in many other countries (<xref rid="bib0053" ref-type="bibr">Chowell&#160;et&#160;al., 2011</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). This was the first pandemic to employ both vaccination and use of antivirals (<xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). Data from the first vaccine clinical trial became available in August 2009, 4 months after the outbreak was first identified (<xref rid="bib0240" ref-type="bibr">WHO,&#160;2012</xref>). A month later, the WHO identified that the amount of vaccine that could be produced within a year would be substantially less than the 4.9 billion doses previously estimated (<xref rid="bib0253" ref-type="bibr">WHO,&#160;2012</xref>). However, the vaccine could be administered as a 1-dose instead of 2-dose series (<xref rid="bib0240" ref-type="bibr">WHO,&#160;2012</xref>). Vaccination rates in Europe varied from 0.6% in the Czech Republic to 59% in Sweden (<xref rid="bib0193" ref-type="bibr">Samanlioglu&#160;and Bilge,&#160;2016</xref>), while the rate in Canada was estimated at 41% (<xref rid="bib0081" ref-type="bibr">Gilmour&#160;and Hofmann,&#160;2010</xref>), in the US at between 20% and 37% depending on age group (<xref rid="bib0041" ref-type="bibr">CDCP,&#160;2010</xref>) and in Brazil at 86% (<xref rid="bib0068" ref-type="bibr">Domingues&#160;and de Oliveira,&#160;2012</xref>). The WHO Pandemic Influenza A(H1N1) Vaccine Deployment Initiative facilitated access to the pandemic vaccine in developing countries. However, demand from countries varied considerably and sufficient vaccine was delivered to provide coverage ranging from 0.4% to &gt;100% of the population, with a median coverage of 9.9% (<xref rid="bib0240" ref-type="bibr">WHO,&#160;2012</xref>).</p></sec><sec id="sec0006"><title>Economic impact</title><p id="para0021">It has been estimated that the Spanish influenza pandemic reduced per capita Gross Domestic Product (GDP) by 6% compared with an 8% reduction resulting from World War 1 (<xref rid="bib0020" ref-type="bibr">Barro&#160;et&#160;al., 2020</xref>). However, economic recovery was swift, with a 25.5% rebound in industrial production in the US between March 1919 and January 1920 (<xref rid="bib0009" ref-type="bibr">Anderson,&#160;1979</xref>, <xref rid="bib0086" ref-type="bibr">Grant,&#160;2014</xref>, <xref rid="bib0223" ref-type="bibr">Vernon,&#160;1991</xref>). An analysis of the post-1940 US population showed that unborn children at the time of the pandemic had lower educational attainment, income and socioeconomic status compared with other birth cohorts (<xref rid="bib0005" ref-type="bibr">Almond,&#160;2006</xref>). In contrast, the economic impact of the Asian, Hong Kong and 2009 A/H1N1 influenza pandemics was small (<xref rid="bib0098" ref-type="bibr">Henderson&#160;et&#160;al., 2009</xref>, <xref rid="bib0107" ref-type="bibr">James&#160;and Sargent,&#160;2006</xref>, <xref rid="bib0195" ref-type="bibr">Saunders-Hastings&#160;and Krewski,&#160;2016</xref>). A systematic review of the cost effectiveness of pandemic interventions concluded that, at a threshold of $45,000 per disability-adjusted life-year (DALY), hospital quarantine and vaccination were cost-effective options, but school closures and social distancing were not (<xref rid="bib0168" ref-type="bibr">Pasquini-Descomps&#160;et&#160;al., 2017</xref>). Cost-effectiveness ratios for antivirals ranged from $350 to $3500 per DALY or quality-adjusted life-year (QALY) in lethal epidemics but were as high as $40,000 to $250,000 for less severe infections (<xref rid="bib0168" ref-type="bibr">Pasquini-Descomps&#160;et&#160;al., 2017</xref>).</p></sec></sec><sec id="sec0007"><title>Coronavirus PHEIC threats (SARS 2003 and MERS 2012) and COVID-19 pandemic</title><p id="para0022">Coronaviruses are positive, single-stranded RNA viruses belonging to the family <italic toggle="yes">Coronaviridae</italic> (<xref rid="bib0130" ref-type="bibr">Li,&#160;2016</xref>, <xref rid="bib0207" ref-type="bibr">Su&#160;et&#160;al., 2016</xref>). They are classified into four genera: <italic toggle="yes">Alphacoronavirus, Betacoronavirus, Gammacoronavirus</italic> and <italic toggle="yes">Deltacoronavirus</italic> (<xref rid="bib0130" ref-type="bibr">Li,&#160;2016</xref>, <xref rid="bib0207" ref-type="bibr">Su&#160;et&#160;al., 2016</xref>). There are four endemic coronaviruses that circulate widely in humans. These cause mainly upper and mild respiratory infections such as the common cold, but also less frequently result in more severe respiratory syndromes including pneumonia in vulnerable and immunocompromised hosts (<xref rid="bib0207" ref-type="bibr">Su&#160;et&#160;al., 2016</xref>). Two of these four coronaviruses are <italic toggle="yes">Betacoronavirus</italic> (HCoV-OC43 and HCoV-HKU1) and two are <italic toggle="yes">Alphacoronavirus</italic> (HCoV-229E and HCoV-NL63) (<xref rid="bib0075" ref-type="bibr">Forni&#160;et&#160;al., 2017</xref>, <xref rid="bib0088" ref-type="bibr">Greenberg,&#160;2016</xref>, <xref rid="bib0207" ref-type="bibr">Su&#160;et&#160;al., 2016</xref>). There are a further two epidemic coronaviruses: MERS-CoV that produces epidemic outbreaks with short chains of transmission and without clear adaptation to spread widely in humans, and SARS-CoV-1 which has been eradicated by control measures. Both are <italic toggle="yes">Betacoronavirus</italic>, with MERS-CoV belonging to lineage C (subgenus <italic toggle="yes">merbecovirus</italic> from etymology &#8220;MER&#8221; &#8220;BEta&#8221; &#8220;COronavirus&#8221;) and SARS-CoV-1 belonging to lineage B (subgenus <italic toggle="yes">sarbecovirus</italic> &#8220;SARs&#8221; &#8220;BEta&#8221; &#8220;COronavirus&#8221;)(<xref rid="bib0088" ref-type="bibr">Greenberg,&#160;2016</xref>, <xref rid="bib0208" ref-type="bibr">Tang&#160;et&#160;al., 2020</xref>). Pandemic SARS-CoV-2 also belongs to <italic toggle="yes">Betacoronavirus</italic> and to the <italic toggle="yes">sarbecovirus</italic> subgenus (<xref rid="bib0260" ref-type="bibr">Zhu&#160;et&#160;al., 2020</xref>). Bats or rodents are believed to be the original, natural hosts of all seven human coronaviruses, with cattle, camels, civets and mink implicated as probable intermediate hosts (<xref rid="bib0075" ref-type="bibr">Forni&#160;et&#160;al., 2017</xref>, <xref rid="bib0224" ref-type="bibr">Hul&#160;et&#160;al., 2021</xref>, <xref rid="bib0208" ref-type="bibr">Tang&#160;et&#160;al., 2020</xref>, <xref rid="bib0218" ref-type="bibr">Tu&#160;et&#160;al., 2004</xref>).</p><p id="para0023">SARS-CoV-1 first emerged in China in November 2002 and spread to 26 countries, although most cases were concentrated in China, Taiwan, Hong Kong, Singapore and Toronto (Canada) (<xref rid="bib0233" ref-type="bibr">Wilder-Smith&#160;et&#160;al., 2020</xref>). The outbreak was short-lived and was brought under control by July 2003, by which time it had resulted in 8098 cases and 774 deaths (case fatality rate 9.5%) (<xref rid="bib0233" ref-type="bibr">Wilder-Smith&#160;et&#160;al., 2020</xref>). MERS-CoV emerged in 2012 in Saudi Arabia, but was never defined as having pandemic potential. So far, it has resulted in 2562 laboratory-confirmed cases and 881 deaths (case fatality rate 34.4%) (<xref rid="bib0243" ref-type="bibr">WHO,&#160;2019</xref>). SARS-CoV-2 was first identified in Wuhan, China in December 2019 and has rapidly spread throughout the world. As of 21 March 2021, more than 123 million cases and 2.7 million deaths had been reported globally (Johns Hopkins University, 2020). The death rate per 100,000 population reported varies enormously over time and in different countries, probably because of different testing and reporting policies (Johns Hopkins University, 2020). A systematic review including data up to June 2020 has estimated the infection fatality rate of SARS-CoV-2 at 0.68% (range 0.09&#8211;1.60) (<xref rid="bib0151" ref-type="bibr">Meyerowitz-Katz&#160;and Merone,&#160;2020</xref>).</p><p id="para0024">Individual and community-based NPIs such as isolation, physical distancing, mask use, and closure of public places were widely implemented during the SARS 2003 outbreak, as were hospital isolation facilities and widespread use of personal protective equipment (<xref rid="bib0233" ref-type="bibr">Wilder-Smith&#160;et&#160;al., 2020</xref>). There was a strong political will in affected countries to implement effective public health measures (<xref rid="bib0233" ref-type="bibr">Wilder-Smith&#160;et&#160;al., 2020</xref>). SARS-CoV-1 viral loads in the lungs peaked at 6&#8211;11 days after the onset of illness and the number of secondary cases was substantially reduced if an infected individual could be isolated within four days of symptom appearance (<xref rid="bib0051" ref-type="bibr">Cheng&#160;et&#160;al., 2004</xref>, <xref rid="bib0133" ref-type="bibr">Li&#160;et&#160;al., 2004</xref>). Fortunately, person-to-person transmission of MERS-CoV was substantially lower than SARS-CoV-1 (<xref rid="bib0170" ref-type="bibr">Peeri&#160;et&#160;al., 2020</xref>), although hospital transmission was significant (<xref rid="bib0007" ref-type="bibr">Al-Tawfiq&#160;and Auwaerter,&#160;2019</xref>).</p><p id="para0025">Some countries, for example Taiwan, Vietnam, South Korea and New Zealand, were successful in controlling COVID-19 (<xref rid="bib0015" ref-type="bibr">Bacay&#160;Watson,&#160;2020</xref>). Vietnam closed its border with China and implemented testing, contact tracing and social distancing (<xref rid="bib0015" ref-type="bibr">Bacay&#160;Watson,&#160;2020</xref>). New Zealand banned entry from China and mandated a strict quarantine for visitors very early, followed by a stringent national lockdown and extensive testing (<xref rid="bib0015" ref-type="bibr">Bacay&#160;Watson,&#160;2020</xref>). Many other countries have relied upon physical distancing, handwashing, mask wearing in public spaces, national lockdowns and contact tracing (<xref rid="bib0173" ref-type="bibr">Petersen&#160;et&#160;al., 2020</xref>). A study concluded that the most effective measures were closure or restriction of places where people gather, including businesses, educational institutions, bars, restaurants, etc (<xref rid="bib0093" ref-type="bibr">Haug&#160;et&#160;al., 2020</xref>). However, less intrusive measures such as border restrictions and risk communication strategies were also effective (<xref rid="bib0093" ref-type="bibr">Haug&#160;et&#160;al., 2020</xref>).</p><p id="para0026">SARS-CoV-2 has spread at a massively higher rate than SARS-CoV-1. Several factors might account for this. Firstly, there was pre-epidemic circulation in the months before the initial outbreak, and the first major outbreak occurred at the time of a Chinese holiday in a city of over 11 million people that is also a large transport hub, facilitating early spread (<xref rid="bib0233" ref-type="bibr">Wilder-Smith&#160;et&#160;al., 2020</xref>). Secondly, there is a marked difference in virus shedding between SARS-CoV-1 and MERS-CoV versus SARS-CoV-2. In the former two, the virus primarily replicates in the lower airways, but more in the upper airways in the latter (<xref rid="bib0051" ref-type="bibr">Cheng&#160;et&#160;al., 2004</xref>, <xref rid="bib0173" ref-type="bibr">Petersen&#160;et&#160;al., 2020</xref>, <xref rid="bib0236" ref-type="bibr">W&#246;lfel&#160;et&#160;al., 2020</xref>). Peak viral loads in nasopharyngeal aspirates of SARS-CoV-1 occur 6&#8211;11 days after symptom onset; in contrast, viral loads of SARS-CoV-2 peak during the first few days of infection, including before the patient becomes symptomatic.(<xref rid="bib0051" ref-type="bibr">Cheng&#160;et&#160;al., 2004</xref>, <xref rid="bib0215" ref-type="bibr">To&#160;et&#160;al., 2020</xref>, <xref rid="bib0236" ref-type="bibr">W&#246;lfel&#160;et&#160;al., 2020</xref>). In addition, many SARS-CoV-2 infections remain asymptomatic (<xref rid="bib0065" ref-type="bibr">Day,&#160;2020</xref>, <xref rid="bib0131" ref-type="bibr">Li&#160;et&#160;al., 2020</xref>, <xref rid="bib0173" ref-type="bibr">Petersen&#160;et&#160;al., 2020</xref>). The &#8220;serial interval&#8221; provides an estimate of the time from symptom onset in a primary case to symptom onset in a secondary case. This has been estimated at 8.4 days for SARS-CoV-1, but only 4.0 days for SARS-CoV-2 (<xref rid="bib0136" ref-type="bibr">Lipsitch&#160;et&#160;al., 2003</xref>, <xref rid="bib0161" ref-type="bibr">Nishiura&#160;et&#160;al., 2020</xref>). A third factor is the very high transmissibility of SARS-CoV-2. The basic reproduction number, R<sub>0</sub>, of SARS-CoV-2 was estimated in the European Union at 0.91&#8211;6.33 at the beginning of the outbreak, with a mean of 4.22 (<xref rid="bib0135" ref-type="bibr">Linka&#160;et&#160;al., 2020</xref>). In contrast, the R<sub>0</sub> values for MERS-CoV and SARS-CoV-1 were estimated at 0.6&#8211;0.7 and 2&#8211;4, respectively, before mitigation measures were put in place (<xref rid="bib0027" ref-type="bibr">Breban&#160;et&#160;al., 2013</xref>, <xref rid="bib0237" ref-type="bibr">WHO,&#160;2003</xref>).</p></sec><sec id="sec0008"><title>Pandemics now: where are we in 2021?</title><p id="para0027">The present situation differs significantly from that of 1918. In 2021, we have substantially improved health care and no intense combat or world war. We also have in place the WHO, other international governance mechanisms and the Global Health Security Agenda (GHSA) (<xref rid="bib0160" ref-type="bibr">Nicholson&#160;et&#160;al., 2019</xref>). In this section, we review the current situation with regard to likely pandemic dynamics and health care responses. We discuss the role of new vaccine technology later in the paper.</p><sec id="sec0009"><title>Risk of zoonotic transmission</title><p id="para0028">The COVID-19 pandemic has led to increasingly urgent calls to change how humans impact on the environment (<xref rid="bib0198" ref-type="bibr">Settele&#160;et&#160;al.</xref>). Land use change, climate change, mining, urbanisation, population growth, wild animal markets and modern human-animal interactions, travel and globalisation all act to bring humans into closer contact both with each other and with animals that host novel pathogens (<xref rid="bib0023" ref-type="bibr">Bedford&#160;et&#160;al., 2019</xref>, <xref rid="bib0198" ref-type="bibr">Settele&#160;et&#160;al.</xref>). A study of EIDs between 1940 and 2004 showed that human population density was an independent predictor of zoonotic EIDs and wildlife host species richness was an additional predictor of zoonotic EIDs of wildlife origin (<xref rid="bib0115" ref-type="bibr">Jones&#160;et&#160;al., 2008</xref>). Another study showed that in areas with substantial human activity, wildlife that hosts pathogens shared with humans comprised a higher proportion of local species compared with nearby undisturbed areas (<xref rid="bib0079" ref-type="bibr">Gibb&#160;et&#160;al., 2020</xref>). Both analyses concluded that conserving wildlife diversity by reducing human activity is likely to contribute to reducing zoonotic disease (<xref rid="bib0079" ref-type="bibr">Gibb&#160;et&#160;al., 2020</xref>, <xref rid="bib0115" ref-type="bibr">Jones&#160;et&#160;al., 2008</xref>).</p><p id="para0029">The One Health initiative is a collaborative, transdisciplinary approach with focus on the interconnection between people, animals, plants and their shared environment (<xref rid="fig0001" ref-type="fig">Figure&#160;1</xref>
) (<xref rid="bib0043" ref-type="bibr">CDCP,&#160;2018b</xref>). A number of tools and programmes using the One Health approach have been developed (<xref rid="bib0043" ref-type="bibr">CDCP,&#160;2018b</xref>, <xref rid="bib0181" ref-type="bibr">Rist&#160;et&#160;al., 2014</xref>, <xref rid="bib0192" ref-type="bibr">Salyer&#160;et&#160;al., 2017</xref>). PREDICT, part of USAID's Emerging Pandemic Threats programme, was established in 2009 to conduct and build capacity for surveillance for zoonotic pathogens with pandemic potential (<xref rid="bib0219" ref-type="bibr">USAID&#160;PREDICT,&#160;2020</xref>). However, funding for PREDICT ended in early 2020 (<xref rid="bib0036" ref-type="bibr">Carlson,&#160;2020</xref>). The related Global Virome Project has the ambitious goal of detecting the majority of zoonotic viral threats to human health and food security within 10 years (<xref rid="bib0083" ref-type="bibr">Global&#160;Virome Project,&#160;2020</xref>). The project has estimated that there are between 631,000 and 827,000 unknown viruses with zoonotic potential in mammal and bird hosts (<xref rid="bib0037" ref-type="bibr">Carroll&#160;et&#160;al., 2018</xref>).<fig id="fig0001" position="float" orientation="portrait"><label>Figure 1</label><caption><p>The One Health concept.</p></caption><alt-text id="alt0001">Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p></sec><sec id="sec0010"><title>Virus variability and the human immune response</title><p id="para0030">Bats, and particularly those of the genus <italic toggle="yes">Rhinolophus,</italic> are believed to be the main natural reservoir of SARS- and MERS-related coronaviruses (<xref rid="bib0102" ref-type="bibr">Hu&#160;et&#160;al., 2015</xref>, <xref rid="bib0132" ref-type="bibr">Li&#160;et&#160;al., 2005</xref>). However, the origin and reservoir of SARS-CoV-2 still remain unclear (<xref rid="bib0143" ref-type="bibr">Mallapaty,&#160;2020</xref>). In contrast, the origin, reservoir, cross-species transmission, genetic and antigenic evolution of influenza viruses are much better understood (<xref rid="bib0234" ref-type="bibr">Wille&#160;and Holmes,&#160;2020</xref>). The antigenic drift in influenza virus means that the formulation of seasonal influenza vaccines must be updated regularly (<xref rid="bib0174" ref-type="bibr">Petrova&#160;and Russell,&#160;2018</xref>). The SARS-CoV-2 genome experiences lower mutation rates (<xref rid="bib0006" ref-type="bibr">Alouane&#160;et&#160;al., 2020</xref>) but it is too early to predict whether regular reformulation of COVID vaccines will be necessary. The recent emergence and rapid spread in different parts of the world of SARS-CoV-2 virus variants that harbour point mutations in the spike protein is a matter of concern (<xref rid="bib0125" ref-type="bibr">Kupferschmidt,&#160;2021</xref>, <xref rid="bib0128" ref-type="bibr">Lauring&#160;and Hodcroft,&#160;2021</xref>, <xref rid="bib0212" ref-type="bibr">Tegally&#160;et&#160;al., 2020</xref>), and it has been shown that such mutations are associated with reduced neutralising activity of convalescent serum antibodies (<xref rid="bib0087" ref-type="bibr">Greaney&#160;et&#160;al., 2021</xref>). Vaccination will progressively increase the population's immunity against the virus but might also contribute to the selection of some specific escape mutants (<xref rid="bib0125" ref-type="bibr">Kupferschmidt,&#160;2021</xref>).</p></sec><sec id="sec0011"><title>Drugs for pandemic use</title><p id="para0031">Bacterial co-infection, secondary infection and superinfection are common during virus pandemics (<xref rid="bib0028" ref-type="bibr">Brundage,&#160;2006</xref>, <xref rid="bib0052" ref-type="bibr">Chertow&#160;and Memoli,&#160;2013</xref>). Studies of autopsy data found bacterial infection in nearly all deaths in the 1918 influenza pandemic (<xref rid="bib0154" ref-type="bibr">Morens&#160;et&#160;al., 2008</xref>) and up to 55% of deaths in the 2009 A/H1N1 pandemic (<xref rid="bib0040" ref-type="bibr">CDC,&#160;2009</xref>, <xref rid="bib0080" ref-type="bibr">Gill&#160;et&#160;al., 2010</xref>). Antibiotics are often overused or misused in both humans and animals, leading to development of antimicrobial resistance (<xref rid="bib0031" ref-type="bibr">Buchy&#160;et&#160;al., 2020</xref>). A recent systematic review of patients with confirmed COVID-19 found that bacterial co-infection was identified in 3.5% of patients and secondary bacterial infection in 14.3%; however, 71.9% received treatment with antibiotics (<xref rid="bib0127" ref-type="bibr">Langford&#160;et&#160;al., 2020</xref>). The WHO considers antimicrobial resistance as one of the top 10 threats to global health (World Health Organization).</p><p id="para0032">Antivirals are likely to be of significant benefit in reducing morbidity and mortality and are the only specific intervention available before a vaccine is developed, however supplies are limited (<xref rid="bib0242" ref-type="bibr">WHO,&#160;2018</xref>). Traditional antivirals used in influenza infection are the adamantane derivatives, amantadine and rimantadine, and the neuraminidase inhibitors, oseltamivir, zanamivir, peramivir and laninamivir (<xref rid="bib0177" ref-type="bibr">Principi&#160;et&#160;al., 2019</xref>). However, resistance to amantadine and rimantadine is widespread (<xref rid="bib0046" ref-type="bibr">Centers&#160;for Disease Control and Prevention 2020</xref>). A Cochrane review and meta-analysis found that oseltamivir reduced the time to symptom alleviation, although it was not possible to determine whether serious influenza complications such as pneumonia were reduced (<xref rid="bib0108" ref-type="bibr">Jefferson&#160;et&#160;al., 2014</xref>).</p><p id="para0033">Baloxavir marboxil is a new drug against influenza virus targeting the endonuclease function of the viral PA polymerase subunit. It has been licensed in Japan and the US since 2018 and acts by inhibiting viral replication without cytotoxicity (<xref rid="bib0177" ref-type="bibr">Principi&#160;et&#160;al., 2019</xref>). It has been shown to be as effective as oseltamivir at alleviating symptoms of uncomplicated influenza and is also effective at preventing influenza infection among household contacts (<xref rid="bib0095" ref-type="bibr">Hayden&#160;et&#160;al., 2018</xref>, <xref rid="bib0103" ref-type="bibr">Ikematsu&#160;et&#160;al., 2020</xref>, <xref rid="bib0106" ref-type="bibr">Ison&#160;et&#160;al., 2020</xref>). The clinical development of pimodivir for the treatment of influenza A infection has recently been halted (<xref rid="bib0012" ref-type="bibr">Anon,&#160;2020</xref>).</p><p id="para0034">Several monoclonal antibodies against the conserved stalk region of the influenza A haemagglutinin (HA) protein are in development and have demonstrated antiviral activity in phase 2 trials (<xref rid="bib0004" ref-type="bibr">Ali&#160;et&#160;al., 2018</xref>, <xref rid="bib0099" ref-type="bibr">Hershberger&#160;et&#160;al., 2019</xref>, <xref rid="bib0149" ref-type="bibr">McBride&#160;et&#160;al., 2017</xref>). A systematic review and meta-analysis concluded that convalescent plasma might reduce mortality in severe influenza and SARS-CoV-1 infection (<xref rid="bib0142" ref-type="bibr">Mair-Jenkins&#160;et&#160;al., 2015</xref>); however, a meta-analysis of randomised, controlled trials in severe influenza found no benefit (<xref rid="bib0256" ref-type="bibr">Xu&#160;et&#160;al., 2020</xref>). A Cochrane review of convalescent plasma used in patients with COVID-19 concluded that its benefit is as yet uncertain (<xref rid="bib0175" ref-type="bibr">Piechotta&#160;et&#160;al., 2020</xref>).</p><p id="para0035">Numerous drugs are being evaluated for the treatment of COVID-19. As of March 2021, the Milken Institute listed over 300 new or repurposed drugs being investigated (<xref rid="bib0152" ref-type="bibr">Milken&#160;Institute,&#160;2021</xref>). The WHO SOLIDARITY trial evaluated four repurposed drugs: remdesivir, hydroxychloroquine, lopinavir-ritonavir fixed dose combination and interferon-&#946;1a in patients hospitalised for COVID-19 (<xref rid="bib0167" ref-type="bibr">Pan&#160;et&#160;al., 2021</xref>). None of the study drugs reduced mortality, initiation of ventilation or duration of hospital stay (<xref rid="bib0167" ref-type="bibr">Pan&#160;et&#160;al., 2021</xref>). Two previously published randomised trials had shown non-significant improvements with remdesivir versus placebo (<xref rid="bib0024" ref-type="bibr">Beigel&#160;et&#160;al., 2020</xref>, <xref rid="bib0230" ref-type="bibr">Wang&#160;et&#160;al., 2020</xref>). The CoDEX randomised trial showed a significant increase in the number of ventilator-free days with dexamethasone compared with standard care, although there was no significant difference in all-cause mortality (<xref rid="bib0216" ref-type="bibr">Tomazini&#160;et&#160;al., 2020</xref>). The RECOVERY trial showed a significant mortality benefit with dexamethasone versus standard care in patients receiving ventilator support or oxygen, but not in patients receiving no respiratory support (<xref rid="bib0101" ref-type="bibr">Horby&#160;et&#160;al., 2020</xref>). A number of neutralising monoclonal antibodies are in development for the treatment of patients with mild to moderate disease who are at high risk of progression to severe disease, with promising results (<xref rid="bib0211" ref-type="bibr">Taylor&#160;et&#160;al., 2021</xref>).</p><p id="para0036">Several guidelines have been published to guide clinical use of treatments for COVID-19 (<xref rid="bib0159" ref-type="bibr">NIH,&#160;2021</xref>, <xref rid="bib0048" ref-type="bibr">Chalmers&#160;et&#160;al., 2021</xref>, <xref rid="bib0250" ref-type="bibr">WHO,&#160;2021b</xref>, <xref rid="bib0026" ref-type="bibr">Bhimraj&#160;et&#160;al., 2021</xref>). Neutralising antibodies are recommended for patients with mild to moderate illness who are high risk of progression (<xref rid="bib0159" ref-type="bibr">NIH,&#160;2021</xref>, <xref rid="bib0026" ref-type="bibr">Bhimraj&#160;et&#160;al., 2021</xref>). Dexamethasone or other systemic corticosteroids are widely recommended in hospitalised patients receiving supplemental oxygen or mechanical ventilation, with the possible additional of remdesivir, baricitinib or tocilizumab (<xref rid="bib0159" ref-type="bibr">NIH,&#160;2021</xref>, <xref rid="bib0048" ref-type="bibr">Chalmers&#160;et&#160;al., 2021</xref>, <xref rid="bib0250" ref-type="bibr">WHO,&#160;2021b</xref>, <xref rid="bib0026" ref-type="bibr">Bhimraj&#160;et&#160;al., 2021</xref>). Guidelines do not recommend drugs such as hydroxychloroquine, azithromycin, ivermectin and protease inhibitors such as lopinavir or ritonavir (<xref rid="bib0159" ref-type="bibr">NIH,&#160;2021</xref>, <xref rid="bib0048" ref-type="bibr">Chalmers&#160;et&#160;al., 2021</xref>, <xref rid="bib0250" ref-type="bibr">WHO,&#160;2021b</xref>, <xref rid="bib0026" ref-type="bibr">Bhimraj&#160;et&#160;al., 2021</xref>).</p></sec><sec id="sec0012"><title>Vaccine acceptance and hesitancy</title><p id="para0037">Even though effective vaccines against COVID-19 are now available, it is still unclear how widely accepted they will be by the public. Vaccine hesitancy has become a significant barrier to uptake (<xref rid="bib0191" ref-type="bibr">Salmon&#160;et&#160;al., 2015</xref>, <xref rid="bib0200" ref-type="bibr">Shetty,&#160;2010</xref>), often fuelled by social media. The Mott Poll Report in the US reported that only 68% of parents intended to have their children vaccinated against influenza in the 2020&#8211;21 season (<xref rid="bib0062" ref-type="bibr">CS&#160;Mott Children's Hospital,&#160;2020</xref>). Vaccine hesitancy might become a barrier to uptake of COVID-19 vaccines (<xref rid="bib0077" ref-type="bibr">French&#160;et&#160;al., 2020</xref>, <xref rid="bib0148" ref-type="bibr">McAteer&#160;et&#160;al., 2020</xref>). A survey in France found that 26% of respondents would be unwilling to receive a SARS-CoV-2 vaccine, rising to 37% among low-income people (<xref rid="bib0057" ref-type="bibr">COCONEL&#160;Group,&#160;2020</xref>). Similarly, a survey in the US reported that 32% of adults were unsure whether they would take a vaccine and 11% stated that they would not (<xref rid="bib0074" ref-type="bibr">Fisher&#160;et&#160;al., 2020</xref>). In contrast, over 90% of adults in China were willing to be vaccinated (<xref rid="bib0231" ref-type="bibr">Wang&#160;et&#160;al., 2020</xref>).</p><p id="para0038">Multi-country studies of likely acceptance of COVID-19 vaccines have shown variation between countries. In a survey of 12 countries, likely vaccine acceptance ranged from 86% in China to 63% in the US and Sweden (<xref rid="bib0120" ref-type="bibr">Kerr&#160;et&#160;al., 2021</xref>). A systematic review of survey studies from 33 countries found likely acceptance rates of over 90% in Ecuador, Malaysia, Indonesia and China, while the lowest acceptance rates were found in France (59%), US (57%), Poland (56%), Russia (55%), Italy (54%), Jordan (28%) and Kuwait (24%) (<xref rid="bib0190" ref-type="bibr">Sallam&#160;2021</xref>). Another study found higher COVID-19 vaccine acceptance in 10 low- and middle-income countries in Asia, Africa and South America (80.3%) compared with Russia (30.4%) and the US (64.6%) (<xref rid="bib0014" ref-type="bibr">Arce&#160;et&#160;al., 2021</xref>). Among the low- and middle-income countries, vaccine acceptance ranged from 66.5% in Pakistan and Burkina Faso to 96.6% in Nepal.</p></sec><sec id="sec0013"><title>Tracking pandemic death rates</title><p id="para0039">Although there are multiple sources of data on the number of deaths caused by COVID-19, the true number is unknown. The statistics available from different countries can be substantially influenced by different definitions used; for example, some countries include only laboratory-confirmed COVID-19-related deaths, whilst others also include suspected deaths. Limited testing capacity in some countries, particularly in the developing world, can lead to considerable underestimation of the death rate. These issues can be avoided, at least to a degree, by calculation of the number of excess deaths, defined as the increase in all-cause mortality over the expected mortality based on historical data. This method has been used to estimate mortality in previous pandemics and seasonal influenza epidemics. Although it does not provide the exact mortality associated with the pandemic or epidemic, it is considered to provide an objective indicator (<xref rid="bib0022" ref-type="bibr">Beaney&#160;et&#160;al., 2020</xref>).</p><p id="para0040">The excess mortality resulting from the COVID-19 pandemic is being tracked by several groups. Data from the World Mortality Dataset, which tracks mortality in 103 countries, found the highest excess mortality per 100,000 population in Latin American and Eastern European countries: Peru (590), Bulgaria (460), North Macedonia (420), Serbia (400), Mexico (360), Ecuador (350), Lithuania (350) and Russia (340) (<xref rid="bib0118" ref-type="bibr">Karlinsky &amp; Kobak&#160;2021</xref>). Some countries, including Uruguay, Australia and New Zealand, had negative excess mortality i.e. fewer deaths than expected. Similar results were obtained from other groups (<xref rid="bib0214" ref-type="bibr">The&#160;Economist,&#160;2021</xref>, <xref rid="bib0194" ref-type="bibr">Sanmarchi&#160;et&#160;al,&#160;2021</xref>). The excess mortality data indicated that the official number of COVID-19-related deaths reported by many countries are underestimates (<xref rid="bib0118" ref-type="bibr">Karlinsky &amp; Kobak,&#160;2021</xref>, <xref rid="bib0214" ref-type="bibr">The&#160;Economist,&#160;2021</xref>, <xref rid="bib0194" ref-type="bibr">Sanmarchi&#160;et&#160;al,&#160;2021</xref>).</p></sec><sec id="sec0014"><title>Health care capacity</title><p id="para0041">The COVID-19 pandemic has highlighted significant gaps in health services. In the US, hospitals were largely operating at full capacity pre-pandemic (<xref rid="bib0002" ref-type="bibr">Ajao&#160;et&#160;al., 2015</xref>). An adequately staffed health workforce cannot be depended on in a pandemic because of high absentee rates, driven by illness or fear (<xref rid="bib0141" ref-type="bibr">Madhav&#160;et&#160;al., 2017 Nov 27</xref>). In addition, influenza vaccination coverage among health care professionals continues to be variable and often suboptimal in many countries (<xref rid="bib0047" ref-type="bibr">CDC,&#160;2021</xref>, <xref rid="bib0094" ref-type="bibr">Haviari&#160;et&#160;al., 2015</xref>). There is a broad recognition among stakeholders that health systems need to change post-COVID-19 to provide a better basis to manage future pandemics. Active debate is taking place regarding initiatives such as improving prevention and early care; strengthening health, public health and social services; integrating elements of global health security with universal health coverage; developing resilience in health care systems; applying equity as a basis for all health care systems; moving from reactive, short-term approaches to planning for longer-term outcomes; maximizing digital health care and information systems; rebuilding trust in governments and healthcare systems; enhancing high-value and eliminating low-value services; (<xref rid="bib0126" ref-type="bibr">Lal&#160;et&#160;al., 2021</xref>, <xref rid="bib0071" ref-type="bibr">EFPIA,&#160;2021</xref>, <xref rid="bib0205" ref-type="bibr">Sorensen&#160;et&#160;al., 2020</xref>, <xref rid="bib0003" ref-type="bibr">Alami&#160;et&#160;al., 2021</xref>).</p></sec><sec id="sec0015"><title>Risk factors for infectious diseases</title><p id="para0042">In many countries, the population is getting older, and many age-related diseases such as diabetes and renal disease predispose people to infections (<xref rid="bib0157" ref-type="bibr">Muller&#160;et&#160;al., 2005</xref>, <xref rid="bib0229" ref-type="bibr">Wang&#160;et&#160;al., 2011</xref>). Treatments for cancer lead to immunosuppression and increased susceptibility to infection, as do immunosenescence and frailty in elderly people (<xref rid="bib0008" ref-type="bibr">American&#160;Cancer Society,&#160;2020</xref>, <xref rid="bib0187" ref-type="bibr">Sadighi&#160;Akha,&#160;2018</xref>). The COVID-19 pandemic has illustrated the high risk of viral transmission in elderly care facilities (<xref rid="bib0018" ref-type="bibr">Barnett&#160;et&#160;al., 2020</xref>, <xref rid="bib0085" ref-type="bibr">Graham&#160;et&#160;al., 2020</xref>). Moreover, immunosenescence leads to a poorer immune response to vaccination, meaning that vaccines are often less effective in the elderly (<xref rid="bib0061" ref-type="bibr">Crooke&#160;et&#160;al., 2019</xref>); at present, it is unknown whether this will impact upon effectiveness of COVID-19 vaccines. Obesity has become a serious health care concern, even in low- and middle-income countries, and is associated with increased risk for diseases such as cancer, diabetes and cardiovascular disease, as well as with a weaker immune system. Numerous studies have shown that obese patients with COVID-19 have a higher risk of severe disease outcomes and death, and the highest death rates have been seen in countries with the highest proportion of overweight individuals (<xref rid="bib0178" ref-type="bibr">Public&#160;Health England,&#160;2020</xref>, World Obesity Federation, 2020, <xref rid="bib0033" ref-type="bibr">Cai&#160;et&#160;al., 2021</xref>, <xref rid="bib0078" ref-type="bibr">Gao&#160;et&#160;al., 2021</xref>, <xref rid="bib0235" ref-type="bibr">Wise,&#160;2021</xref>).</p></sec><sec id="sec0016"><title>Laboratory and research capacity</title><p id="para0043">The genome of the SARS-CoV-2 virus was fully sequenced within a few weeks of identification of the first patients with unidentified pneumonia in China (<xref rid="bib0260" ref-type="bibr">Zhu&#160;et&#160;al., 2020</xref>). The Global Initiative on Sharing All Influenza Data (GISAID) was launched in 2008 with the aim of sharing influenza genomic data, and the initiative played an important role in the response to the 2009 influenza A/H1N1 pandemic and now to the COVID-19 pandemic (<xref rid="bib0082" ref-type="bibr">GISAID,&#160;2021</xref>, <xref rid="bib0201" ref-type="bibr">Shu&#160;and McCauley,&#160;2017</xref>). As of March 2021, nearly one million SARS-CoV-2 genomic sequences have been made available via the GISAID platform. Genomic epidemiology combines genomics data with epidemiological investigations and is able to answer key questions about virus outbreaks more quickly than traditional epidemiological case tracking (<xref rid="bib0091" ref-type="bibr">Grubaugh&#160;et&#160;al., 2019</xref>, <xref rid="bib0182" ref-type="bibr">Rockett&#160;et&#160;al., 2020</xref>).</p><p id="para0044">Global research networks can be used to assess pandemic characteristics (<xref rid="bib0203" ref-type="bibr">Simonsen&#160;et&#160;al., 2018</xref>). For example, data from two cohort studies of influenza conducted by the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) have been used to estimate the case fatality rate during the 2009 A/H1N1 influenza pandemic (<xref rid="bib0203" ref-type="bibr">Simonsen&#160;et&#160;al., 2018</xref>). Although this was a retrospective analysis, the same methodology could be used to assess an emerging pandemic (<xref rid="bib0203" ref-type="bibr">Simonsen&#160;et&#160;al., 2018</xref>). The COVID-19 pandemic has illustrated how rapidly research can be shared, with extensive use of online journal publications and pre-print uploads.</p><p id="para0045">The Coalition for Epidemic Preparedness Innovations (CEPI) was founded in 2017 as a public&#8211;private partnership to develop vaccines for future epidemics and enable equitable access to vaccines during outbreaks (<xref rid="bib0054" ref-type="bibr">CEPI,&#160;2020a</xref>). During the COVID-19 pandemic, CEPI has formed the COVAX collaboration with the WHO and Gavi, the Vaccine Alliance; it aims to produce 2 billion SARS-CoV-2 vaccine doses for distribution in 2021 and is providing funding for the development of 11 vaccine candidates (<xref rid="bib0055" ref-type="bibr">CEPI,&#160;2020b</xref>).</p></sec><sec id="sec0017"><title>Global governance</title><p id="para0046">The International Health Regulations (IHR) 2005 are an international legal agreement between 196 countries, including all WHO Member States, whose implementation is coordinated by the WHO (<xref rid="bib0241" ref-type="bibr">WHO,&#160;2016</xref>). The WHO also coordinates the Global Influenza Programme (GIP) with the aim of providing strategic guidance, technical support and coordination of activities to prepare health systems for seasonal, zoonotic and pandemic influenza threats (<xref rid="bib0246" ref-type="bibr">WHO,&#160;2020c</xref>). Activities include surveillance and monitoring via the Global Influenza Surveillance and Response System (GISRS) and platforms such as FluNet and FluID<sup>125</sup>. It also includes the Pandemic Influenza Preparedness Framework which came into effect in 2011 and whose goals are to improve sharing of influenza viruses with human pandemic potential and to increase access of developing countries to vaccines and other pandemic-related supplies (<xref rid="bib0247" ref-type="bibr">WHO,&#160;2020d</xref>). Under this framework, an advance supply contract with manufacturers, research institutes and other bodies ensures that the WHO receives supplies of vaccines and other products needed to respond to a pandemic.</p><p id="para0047">A 2011 review of the IHR and the response to the 2009 A/H1N1 pandemic made three summary conclusions: (1) The IHR improved preparedness for public health emergencies, but capacities called for in the IHR were not fully operational nor on a path towards timely implementation; (2) The WHO performed well in many ways, confronted systemic difficulties and demonstrated some shortcomings; (3) The world is ill-prepared for a severe influenza pandemic or similar event (<xref rid="bib0239" ref-type="bibr">WHO,&#160;2011</xref>). The review made a total of 15 recommendations, including to accelerate implementation of core capacities, reinforce evidence-based decisions on international travel and trade, develop and apply measures to assess severity, create a more extensive public health reserve workforce, reach agreement on sharing of viruses and access to vaccines and pursue a comprehensive influenza research programme (<xref rid="bib0239" ref-type="bibr">WHO,&#160;2011</xref>).</p></sec><sec id="sec0018"><title>Infodemics and fake news</title><p id="para0048">Misinformation about COVID-19 has spread widely, particularly on, but not limited to, social media. Common misinformation has included erroneous health advice, such as self-injection with bleach and use of hydroxychloroquine, as well as conspiracy theories such as bioengineering of the SARS-CoV-2 virus and the role of 5G networks in spreading the virus (<xref rid="bib0034" ref-type="bibr">Callisher et&#160;al., 2020</xref>, <xref rid="bib0251" ref-type="bibr">World Health Organization 2021c</xref>). Polls in the UK and US have indicated that almost half of the population have been exposed to misinformation about COVID-19 (<xref rid="bib0162" ref-type="bibr">Ofcom,&#160;2020</xref>, <xref rid="bib0153" ref-type="bibr">Mitchell &amp; Oliphant,&#160;2020</xref>) and several studies have identified a high proportion of false or inaccurate information related to COVID-19 in social media content (<xref rid="bib0104" ref-type="bibr">Islam&#160;et&#160;al., 2020</xref>, <xref rid="bib0105" ref-type="bibr">Islam&#160;et&#160;al., 2021</xref>, <xref rid="bib0147" ref-type="bibr">Marwah&#160;et&#160;al., 2021</xref>) Furthermore, exposure to misinformation appears to be associated with the likelihood of rejecting public health guidelines and vaccine hesitancy (<xref rid="bib0220" ref-type="bibr">Uscinski&#160;et&#160;al., 2020</xref>, <xref rid="bib0076" ref-type="bibr">Freeman&#160;et&#160;al., 2020</xref>, <xref rid="bib0186" ref-type="bibr">Romer and Hall Jamieson, 2021</xref>, <xref rid="bib0185" ref-type="bibr">Romer and Hall Jamieson, 2020</xref>). At the same time, the number of scientific papers has proliferated. Unfortunately, the quality of some of the papers is uncertain and the rate of retractions is higher than other related research topics (<xref rid="bib0213" ref-type="bibr">Tentolouris&#160;et&#160;al., 2021</xref>, <xref rid="bib0257" ref-type="bibr">Yeo-Teh &amp; Tang,&#160;2021</xref>).</p></sec></sec><sec id="sec0019"><title>Development of pandemic vaccines</title><p id="para0049">The 2009 A/H1N1 pandemic, in which a vaccine did not become available until after the peak of the pandemic had passed, illustrates the problems associated with traditionally delivered influenza vaccines in the pandemic setting (<xref rid="bib0240" ref-type="bibr">WHO,&#160;2012</xref>). A major problem is the difficulty in predicting which virus will cause the next pandemic and the use of vaccines based on influenza virus cultures in eggs. This method of manufacture cannot be upscaled quickly, in contrast to the adenovirus and RNA-based vaccines that have been developed against SARS-CoV-2. Because it was widely believed that the next pandemic would be caused by an influenza virus, significant effort has been invested in development of 'ready to go' pre-pandemic influenza vaccines (<xref rid="bib0160" ref-type="bibr">Nicholson&#160;et&#160;al., 2019</xref>). As of October 2020, the WHO had identified 41 vaccine candidates against influenza A/H5 viruses, 22 candidates against influenza A/H7 viruses and eight candidates against influenza A/H9N2 virus (<xref rid="bib0248" ref-type="bibr">WHO,&#160;2020e</xref>).</p><p id="para0050">However, it is not sustainable to continuously update multiple candidate vaccines (<xref rid="bib0146" ref-type="bibr">Marston&#160;et&#160;al., 2017</xref>, <xref rid="bib0160" ref-type="bibr">Nicholson&#160;et&#160;al., 2019</xref>). Therefore, the focus in more recent years has changed towards development of vaccine platforms; the theory behind this approach is that any platform can be used to present any immunogen from any pathogen (<xref rid="bib0146" ref-type="bibr">Marston&#160;et&#160;al., 2017</xref>). In addition, for influenza vaccines, substantial work has been done towards development of a universal vaccine capable of eliciting a broad immune response against antigenically diverse influenza viruses (<xref rid="bib0163" ref-type="bibr">Ostrowsky&#160;et&#160;al., 2020</xref>). It is hoped that a similar approach can be adopted towards vaccines against non-influenza pathogens (<xref rid="bib0038" ref-type="bibr">Cassone&#160;and Rappuoli,&#160;2010</xref>).</p><sec id="sec0020"><title>Vaccine platforms</title><p id="para0051">Several vaccine platforms are available or under development (<xref rid="fig0002" ref-type="fig">Figure&#160;2</xref>
). Whole virus vaccines include inactivated virus vaccines and live attenuated virus vaccines. Inactivated vaccines are widely used in licensed vaccines such as influenza, polio and hepatitis A (<xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>). Production infrastructure for inactivated vaccines is well established and there are few safety concerns associated with this type of vaccine (<xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>). However, more than one dose is often needed to elicit a robust immune response or an adjuvant might be required (<xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>). An adjuvant is a vaccine component that modifies or enhances the antigen-specific immune response (<xref rid="bib0066" ref-type="bibr">Di&#160;Pasquale et&#160;al., 2015</xref>). Using an adjuvant allows the dose of antigen to be decreased (antigen-sparing) or the number of doses to be reduced (<xref rid="bib0058" ref-type="bibr">Cohet&#160;et&#160;al., 2019</xref>, <xref rid="bib0066" ref-type="bibr">Di&#160;Pasquale et&#160;al., 2015</xref>).<fig id="fig0002" position="float" orientation="portrait"><label>Figure 2</label><caption><p><bold>Platforms for COVID-19 vaccines.</bold> Adapted from <xref rid="bib0035" ref-type="bibr">Callaway,&#160;2020</xref> and <xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>.</p></caption><alt-text id="alt0002">Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig></p><p id="para0052">Several live attenuated vaccines are also available, including oral polio vaccine, influenza vaccine, measles, mumps and rubella vaccine (MMR), and varicella (chickenpox) vaccine (<xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>, <xref rid="bib0124" ref-type="bibr">Krammer,&#160;2020</xref>, <xref rid="bib0206" ref-type="bibr">Strugnell&#160;et&#160;al., 2011</xref>). Before use of a live attenuated vaccine, it must be clearly shown that the virus cannot revert genetically to become pathogenic (<xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>).</p><p id="para0053">Viral vector platforms include, among others, adenoviruses, alphaviruses, vesicular stomatitis virus (VSV) and Modified Vaccinia Virus Ankara (MVA, poxvirus) (<xref rid="bib0179" ref-type="bibr">Raj&#227;o&#160;and P&#233;rez,&#160;2018</xref>, <xref rid="bib0196" ref-type="bibr">Sebastian&#160;and Lambe,&#160;2018</xref>). Replicating or non-replicating viral vector vaccines use a viral backbone that is genetically engineered to express antigens from the target virus (<xref rid="bib0035" ref-type="bibr">Callaway,&#160;2020</xref>, <xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>). Replicating viral vector vaccines use a weakened viral backbone such as measles; although they can still replicate within cells, they are unable to cause disease (<xref rid="bib0035" ref-type="bibr">Callaway,&#160;2020</xref>, <xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>).</p><p id="para0054">In non-replicating viral vector vaccines, key replication genes in the backbone are disabled (<xref rid="bib0035" ref-type="bibr">Callaway,&#160;2020</xref>, <xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>). The first adenovirus vaccine vectors were based on human adenoviruses such as HAdV-5 (<xref rid="bib0059" ref-type="bibr">Colloca&#160;et&#160;al., 2012</xref>). However, a large proportion of adults have pre-existing neutralising antibodies to human adenoviruses (<xref rid="bib0019" ref-type="bibr">Barouch&#160;et&#160;al., 2011</xref>). High seroprevalence of neutralising antibodies against the vector was largely blamed for the failure of a human adenovirus-based HIV vaccine and the finding that study participants with high titres of anti-adenovirus antibodies were more susceptible to HIV infection than those without such antibodies (<xref rid="bib0029" ref-type="bibr">Buchbinder&#160;et&#160;al., 2008</xref>, <xref rid="bib0150" ref-type="bibr">McElrath&#160;et&#160;al., 2008</xref>, <xref rid="bib0197" ref-type="bibr">Sekaly,&#160;2008</xref>). This problem has since been addressed by development of vectors based on viruses to which humans are naive, including chimpanzee adenoviruses (<xref rid="bib0072" ref-type="bibr">Farina&#160;et&#160;al., 2001</xref>). Licensed viral vector vaccines are available against Ebola, dengue fever and Japanese encephalitis, and the technology for large-scale production already exists (<xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>, <xref rid="bib0196" ref-type="bibr">Sebastian&#160;and Lambe,&#160;2018</xref>).</p><p id="para0055">Protein-based subunit vaccines use an isolated protein or protein fragment from the pathogen (<xref rid="bib0222" ref-type="bibr">Vartak&#160;and Sucheck,&#160;2016</xref>). They show a strong immunogenicity when administered with an adjuvant, as well as safety in immunocompromised individuals (<xref rid="bib0222" ref-type="bibr">Vartak&#160;and Sucheck,&#160;2016</xref>). Virus-like particles (VLPs) comprise empty virus shells that contain no genetic material. Both subunit and VLP technologies are well established, but the vaccines can be poorly immunogenic and might require repeated administration or use of an adjuvant (<xref rid="bib0035" ref-type="bibr">Callaway,&#160;2020</xref>, <xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>).</p><p id="para0056">Nucleic acid vaccines (mRNA or DNA) use only genetic material from the target pathogen, inserted into human cells which then produce copies of the virus protein encoded by the genetic material, leading to acquired immunity (<xref rid="bib0035" ref-type="bibr">Callaway,&#160;2020</xref>, <xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>). RNA vaccines use an RNA-containing vector, such as&#160;lipid nanoparticles, while DNA vaccines use a genetically engineered plasmid to deliver the genetic sequence to the cells. The vaccines are non-infectious, with advantages over other platforms in terms of safety, and are also easy to produce and scale up (<xref rid="bib0035" ref-type="bibr">Callaway,&#160;2020</xref>, <xref rid="bib0110" ref-type="bibr">Jeyanathan&#160;et&#160;al., 2020</xref>).</p></sec><sec id="sec0021"><title>Development of vaccines against human coronaviruses</title><sec id="sec0022"><title>Immunological considerations</title><p id="para0057">Studies have shown that SARS-CoV-1, SARS-CoV-2 and MERS-CoV efficiently suppress activation of the innate immune system, which might explain the long pre-symptomatic period observed with SARS-CoV-2 infection (<xref rid="bib0259" ref-type="bibr">Zhou&#160;et&#160;al., 2020</xref>). Suppression of the innate immune system is likely associated with the dysregulated inflammatory responses observed in severe cases of COVID-19.</p><p id="para0058">The spike protein is the main target for neutralising antibodies, which makes it an essential antigen for vaccine development (<xref rid="bib0030" ref-type="bibr">Buchholz&#160;et&#160;al., 2004</xref>, <xref rid="bib0069" ref-type="bibr">Du&#160;et&#160;al., 2013</xref>). Antibodies that bind to the S1 receptor binding domain of SARS-CoV-1 block its interaction with ACE2, while antibodies binding with other regions of S1 inhibit conformational changes of the S protein (<xref rid="bib0060" ref-type="bibr">Coughlin&#160;et&#160;al., 2007</xref>). Antibodies against the spike protein of SARS-CoV-1 have been shown to be cross-neutralising and to inhibit entry of SARS-CoV-2 into host cells (<xref rid="bib0228" ref-type="bibr">Walls&#160;et&#160;al., 2020</xref>). Neutralising antibodies to SARS-CoV-1 have remained detectable in patients recovering from natural infection for up to 17 years (<xref rid="bib0010" ref-type="bibr">Anderson&#160;et&#160;al., 2020</xref>). High antibody titres against the nucleocapsid protein have also been demonstrated following natural infection with SARS-CoV-2 (<xref rid="bib0215" ref-type="bibr">To&#160;et&#160;al., 2020</xref>), suggesting that this protein could also be a useful target for vaccine development. Currently, no immune correlate of protection has been identified for any of the coronaviruses.</p><p id="para0059">T-cell mediated immunity is also an important element in COVID-19 vaccine design. A study of patients recovering from COVID-19 showed that SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cells were detected in 100% and 70% of patients, respectively (<xref rid="bib0090" ref-type="bibr">Grifoni&#160;et&#160;al., 2020</xref>). Most of the CD4<sup>+</sup> T-cell response was targeted against the spike protein (27%), membrane protein (21%) and nucleocapsid protein (11%) (<xref rid="bib0090" ref-type="bibr">Grifoni&#160;et&#160;al., 2020</xref>). Specific CD4<sup>+</sup> T-cell responses against the spike protein correlated highly with anti-spike antibody titres (<xref rid="bib0090" ref-type="bibr">Grifoni&#160;et&#160;al., 2020</xref>). Other studies have shown that T-cell activation is delayed in SARS-CoV-2 infection (as well as SARS-CoV-1 and MERS-CoV infection), particularly for CD8<sup>+</sup> T-cells (<xref rid="bib0180" ref-type="bibr">Remy&#160;et&#160;al., 2020</xref>, <xref rid="bib0259" ref-type="bibr">Zhou&#160;et&#160;al., 2020</xref>). Further evidence suggests that patients with less severe COVID-19 illness have higher levels of CD8<sup>+</sup> memory T-cells compared with more severe cases (<xref rid="bib0134" ref-type="bibr">Liao&#160;et&#160;al., 2020</xref>, <xref rid="bib0171" ref-type="bibr">Peng&#160;et&#160;al., 2020</xref>).</p></sec><sec id="sec0023"><title>Vaccine-enhanced disease</title><p id="para0060">Two types of vaccine-enhanced disease are currently recognised: antibody-dependent enhancement (ADE) and vaccine-associated enhanced respiratory disease (VAERD) (<xref rid="bib0084" ref-type="bibr">Graham,&#160;2020</xref>). ADE is mediated by the Fc antibody portion, whereby a virus-antibody complex binds more efficiently to cells bearing an Fc receptor, facilitating virus entry to the cell (<xref rid="bib0084" ref-type="bibr">Graham,&#160;2020</xref>). This primarily occurs when vaccination induces neutralising antibodies that are unable to effectively neutralise the virus (<xref rid="bib0084" ref-type="bibr">Graham,&#160;2020</xref>). ADE was reported during preclinical evaluation of a SARS-CoV-1 MVA-based vaccine (<xref rid="bib0232" ref-type="bibr">Weingartl&#160;et&#160;al., 2004</xref>). VAERD was observed in young children in the 1960s during evaluation of measles and respiratory syncytial virus (RSV) whole inactivated vaccines (<xref rid="bib0084" ref-type="bibr">Graham,&#160;2020</xref>). In the RSV trial, it was observed that a high ratio of binding antibody to neutralising antibody could result in immune complex deposition and complement activation (<xref rid="bib0084" ref-type="bibr">Graham,&#160;2020</xref>).</p><p id="para0061">In the context of COVID-19 vaccine development, the risk of vaccine-enhanced disease can be reduced by demonstrating induction of neutralising antibodies in early clinical studies, as well as protection against virus replication and disease in animal models (<xref rid="bib0084" ref-type="bibr">Graham,&#160;2020</xref>). It is also important to use conformationally correct antigens to induce high quality antibodies and to avoid induction of T<sub>H</sub>2-biased immune responses (<xref rid="bib0084" ref-type="bibr">Graham,&#160;2020</xref>). Finally, study of lung pathology in animal challenge studies might help to predict abnormal pathology in vaccine recipients (<xref rid="bib0084" ref-type="bibr">Graham,&#160;2020</xref>).</p></sec><sec id="sec0024"><title>Vaccine candidates against SARS-CoV-1 and MERS-CoV</title><p id="para0062">Several candidate vaccines for SARS-CoV-1 and MERS-CoV were developed, but none reached commercial development, likely because there was little incentive to continue vaccine development for an outbreak that resolved within months (SARS-CoV-1) or resulted in relatively few cases (MERS-CoV) (<xref rid="bib0165" ref-type="bibr">Padron-Regalado,&#160;2020</xref>). For both viruses, vaccines based on inactivated virus, live-attenuated virus, viral vectors, protein-based subunits, VLPs and DNA were evaluated (<xref rid="bib0165" ref-type="bibr">Padron-Regalado,&#160;2020</xref>). The spike protein and nucleocapsid protein were the primary targets for non-whole virus vaccines (<xref rid="bib0165" ref-type="bibr">Padron-Regalado,&#160;2020</xref>).</p></sec><sec id="sec0025"><title>Vaccine candidates against SARS-CoV-2</title><p id="para0063">As of 22 March 2021, the WHO listed 82 COVID-19 candidate vaccines in clinical development (<xref rid="tbl0002" ref-type="table">Table&#160;2</xref>
) and 182 in preclinical development (<xref rid="bib0252" ref-type="bibr">WHO,&#160;2021d</xref>). The candidate vaccines use a wide range of vaccine platforms (<xref rid="fig0003" ref-type="fig">Figure&#160;3</xref>
). Vaccines based on mRNA, adenovirus vector and inactivated virus technologies have advanced most rapidly. The Pfizer/BioNTech vaccine (BNT162b2) is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding the full-length spike protein (<xref rid="bib0176" ref-type="bibr">Polack&#160;et&#160;al., 2020</xref>). A phase 2/3 study demonstrated 95.0% (95% CI: 90.0&#8211;97.9) vaccine efficacy in preventing COVID-19 disease after two vaccine doses; notably, the cumulative incidence of cases in the vaccine and placebo groups began to diverge by 12 days after the first vaccine dose (<xref rid="bib0176" ref-type="bibr">Polack&#160;et&#160;al., 2020</xref>). The vaccine was well tolerated (<xref rid="bib0176" ref-type="bibr">Polack&#160;et&#160;al., 2020</xref>). Another lipid nanoparticle-formulated mRNA vaccine encoding the spike protein (mRNA-1273; Moderna) has reported 94.5% (95% CI: 86.5&#8211;97.8) vaccine efficacy against COVID-19 disease after two doses and raised no safety concerns during a phase 3 clinical trial (<xref rid="bib0016" ref-type="bibr">Baden&#160;et&#160;al., 2021</xref>). A phase 1/2 study of the NVX-CoV2373 vaccine, a nanoparticle vaccine adjuvanted with Matrix-M1 developed by Novavax, has demonstrated a high immune response and good safety profile (<xref rid="bib0119" ref-type="bibr">Keech&#160;et&#160;al., 2020</xref>). Phase 3 data have shown 89.7% vaccine efficacy against symptomatic disease (<xref rid="bib0096" ref-type="bibr">Heath&#160;et&#160;al., 2021</xref>).<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>COVID-19 vaccine candidates in clinical development (WHO draft landscape on 22 March 2021) (<xref rid="bib0245" ref-type="bibr">World&#160;Health Organization,&#160;2020b</xref>)</p></caption><alt-text id="alt0005">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Type of candidate vaccine</th><th valign="top" colspan="1" rowspan="1">Developer</th><th valign="top" colspan="1" rowspan="1">Dose and route of administration</th><th valign="top" colspan="1" rowspan="1">Phase 1</th><th valign="top" colspan="1" rowspan="1">Phase 1/2</th><th valign="top" colspan="1" rowspan="1">Phase 2</th><th valign="top" colspan="1" rowspan="1">Phase 2/3</th><th valign="top" colspan="1" rowspan="1">Phase 3</th></tr></thead><tbody><tr><td colspan="8" align="left" valign="top" rowspan="1"><bold>Whole virus vaccines</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Inactivated</td><td valign="top" colspan="1" rowspan="1">Sinovac</td><td valign="top" colspan="1" rowspan="1">D0-14, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Inactivated</td><td valign="top" colspan="1" rowspan="1">Wuhan Institute of Biological Products; Sinopharm; China National Biotech Group</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Inactivated (BBIBP-CorV)</td><td valign="top" colspan="1" rowspan="1">Beijing Institute of Biological Products; Sinopharm; China National Biotech Group</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Inactivated (Vero cells)</td><td valign="top" colspan="1" rowspan="1">Institute of Medical Biology, Chinese Academy of Medical Sciences</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Inactivated QazCovid-in</td><td valign="top" colspan="1" rowspan="1">Research Institute for Biological Safety Problems, Republic of Kazakhstan</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Whole-virion inactivated</td><td valign="top" colspan="1" rowspan="1">Bharat Biotech</td><td valign="top" colspan="1" rowspan="1">D0-14, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Inactivated SARS-CoV-2 vaccine (Vero cell)</td><td valign="top" colspan="1" rowspan="1">Beijing Minhai Biotechnology Co.</td><td valign="top" colspan="1" rowspan="1">Not disclosed, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">COVI-VAC, live attenuated virus</td><td valign="top" colspan="1" rowspan="1">Codagenix/Serum Institute of India</td><td valign="top" colspan="1" rowspan="1">D0 or D0-28, IN</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">VLA2001</td><td valign="top" colspan="1" rowspan="1">Valneva, National Institute for Health Research, UK</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">ERUCOV-VAC, inactivated virus</td><td valign="top" colspan="1" rowspan="1">Erciyes University</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Inactivated</td><td valign="top" colspan="1" rowspan="1">Shifa Pharmed Industrial Co</td><td valign="top" colspan="1" rowspan="1">D0-14, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">FAKHRAVAC (MIVAC)</td><td valign="top" colspan="1" rowspan="1">Organization of Defensive Innovation and Research</td><td valign="top" colspan="1" rowspan="1">D0-14 or D0-14-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td colspan="8" align="left" valign="top" rowspan="1"><bold>Viral vector vaccines</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">ChAdOx1-S</td><td valign="top" colspan="1" rowspan="1">University of Oxford; AstraZeneca</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Adenovirus Type 5 Vector</td><td valign="top" colspan="1" rowspan="1">CanSino Biological Inc; Beijing Institute of Biotechnology</td><td valign="top" colspan="1" rowspan="1">IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Adeno-based (rAd26-S+rAd5-S)</td><td valign="top" colspan="1" rowspan="1">Gamaleya Research Institute; Heath Ministry Russian Federation</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Ad26COVS1</td><td valign="top" colspan="1" rowspan="1">Janssen Pharmaceutical Companies</td><td valign="top" colspan="1" rowspan="1">D0 or D0-56, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">DelNS1-2019-nCoV-RBD-OPT1 (intranasal influenza-based RBD)</td><td valign="top" colspan="1" rowspan="1">University of Hong Kong; Beijing Wantai Biological Pharmacy; Xiamen University</td><td valign="top" colspan="1" rowspan="1">D0, IN</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">MVA-SARS-2-S</td><td valign="top" colspan="1" rowspan="1">Ludwig-Maximilians - University of Munich</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Replication defective Simian adenovirus (GRAd) encoding S</td><td valign="top" colspan="1" rowspan="1">ReiThera; LEUKOCARE; Univercells</td><td valign="top" colspan="1" rowspan="1">D0, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Ad5 adjuvanted oral vaccine platform</td><td valign="top" colspan="1" rowspan="1">Vaxart</td><td valign="top" colspan="1" rowspan="1">D0-28, oral</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Measles-vector based</td><td valign="top" colspan="1" rowspan="1">Merck &amp; Co; Institute Pasteur; Themis; University of Pittsburgh</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Covid-19/aAPC vaccine</td><td valign="top" colspan="1" rowspan="1">Shenzhen Geno-Immune Medical Institute</td><td valign="top" colspan="1" rowspan="1">D0-14-28, SC</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">LV-SMENP-DC vaccine</td><td valign="top" colspan="1" rowspan="1">Shenzhen Geno-Immune Medical Institute</td><td valign="top" colspan="1" rowspan="1">D0, SC &amp; IV</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">hAd5-S-Fusion+N-ETSD vaccine</td><td valign="top" colspan="1" rowspan="1">ImmunityBio, Inc. &amp; NantKwest, Inc.</td><td valign="top" colspan="1" rowspan="1">D0, SC or Oral</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">COH04S1 (MVA-SARS-2-S) &#8211; Modified vaccinia ankara (sMVA) platform&#160;+&#160;synthetic SARS-CoV-2</td><td valign="top" colspan="1" rowspan="1">City of Hope Medical Center&#160;+&#160;National Cancer Institute</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">rVSV-SARS-CoV-2-S Vaccine</td><td valign="top" colspan="1" rowspan="1">Israel Institute for Biological Research</td><td valign="top" colspan="1" rowspan="1">D0, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Dendritic cell vaccine AV-COVID-19</td><td valign="top" colspan="1" rowspan="1">Aivita Biomedical, Inc.National Institute of Health Research and Development, Ministry of Health, Republic of Indonesia</td><td valign="top" colspan="1" rowspan="1">D0, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">AdCLD-CoV19 (adenovirus vector)</td><td valign="top" colspan="1" rowspan="1">Cellid Co., Ltd.</td><td valign="top" colspan="1" rowspan="1">D0, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">AdCOVID (adenovirus vector)</td><td valign="top" colspan="1" rowspan="1">Altimmune, Inc.</td><td valign="top" colspan="1" rowspan="1">D0, IN</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">NDV-HXP-S (Newcastle disease virus vector)</td><td valign="top" colspan="1" rowspan="1">Mahidol University; Government Pharmaceutical Organization; Icahn School of Medicine at Mount Sinai</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">BBV153 (adenovirus vector)</td><td valign="top" colspan="1" rowspan="1">Bharat Biotech International Ltd</td><td valign="top" colspan="1" rowspan="1">D0, IN</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Spike or spike plus T-cell epitopes (chimpanzee adenovirus)</td><td valign="top" colspan="1" rowspan="1">Gritstone Oncology</td><td valign="top" colspan="1" rowspan="1">D0-14-28 or D0-28-56 or D0-112, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td colspan="8" align="left" valign="top" rowspan="1"><bold>mRNA vaccines</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">mRNA-1273</td><td valign="top" colspan="1" rowspan="1">Moderna; NIAID</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">BNT162 (3 LNP-mRNAs)</td><td valign="top" colspan="1" rowspan="1">Pfizer; BioNTech; Fosun Pharma</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">CVnCoV vaccine</td><td valign="top" colspan="1" rowspan="1">Curevac AG</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">ARCT-021</td><td valign="top" colspan="1" rowspan="1">Arcturus Therapeutics</td><td valign="top" colspan="1" rowspan="1">Not disclosed</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">ARCoV</td><td valign="top" colspan="1" rowspan="1">Academy of Military Sciences; Walvax Biotechnology; Suzhou Abogen Biosciences</td><td valign="top" colspan="1" rowspan="1">D0-14 or D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">LNP-nCoVsaRNA</td><td valign="top" colspan="1" rowspan="1">Imperial College London</td><td valign="top" colspan="1" rowspan="1">D0, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">ChulaCov19 mRNA vaccine</td><td valign="top" colspan="1" rowspan="1">Chulalongkorn University</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">m-RNA-1273.351 (B.1.351 variant)</td><td valign="top" colspan="1" rowspan="1">Moderna; NIAID</td><td valign="top" colspan="1" rowspan="1">D0 or D0-28 or D56</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">PTX-COVID19-B</td><td valign="top" colspan="1" rowspan="1">Providence Therapeutics</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">CoV2 self-amplifying RNA LNP</td><td valign="top" colspan="1" rowspan="1">GlaxoSmithKline</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td colspan="8" align="left" valign="top" rowspan="1"><bold>DNA vaccines</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">DNA plasmid vaccine with electroporation</td><td valign="top" colspan="1" rowspan="1">Inovio Pharmaceuticals; International Vaccine Institute; Advaccine (Suzhou) Biopharmaceutical Co Ltd</td><td valign="top" colspan="1" rowspan="1">D0-28, ID</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">DNA plasmid vaccine</td><td valign="top" colspan="1" rowspan="1">Zydud Cadila</td><td valign="top" colspan="1" rowspan="1">D0-28-56, ID</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">DNA vaccine (GX-19)</td><td valign="top" colspan="1" rowspan="1">Genexine Consortium</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">AG0301-COVID19</td><td valign="top" colspan="1" rowspan="1">AnGes; Takara Bio; Osaka University</td><td valign="top" colspan="1" rowspan="1">D0-14, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Covigenix VAX-001&#160;+&#160;PLV</td><td valign="top" colspan="1" rowspan="1">Entos Pharmaceuticals Inc.</td><td valign="top" colspan="1" rowspan="1">D0-14, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">CORVax &#8211; spike protein plasmid DNA vaccine</td><td valign="top" colspan="1" rowspan="1">Providence Health &amp; Services</td><td valign="top" colspan="1" rowspan="1">D0-14, ID</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">bacTRL-Spike oral DNA vaccine</td><td valign="top" colspan="1" rowspan="1">Symvivo Corporation</td><td valign="top" colspan="1" rowspan="1">D0, Oral</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">GLS-5310</td><td valign="top" colspan="1" rowspan="1">GeneOne Life Science, Inc.</td><td valign="top" colspan="1" rowspan="1">D0-56 or D0-84, ID</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">COVID-eVax</td><td valign="top" colspan="1" rowspan="1">Takis; Rottapharm Biotech</td><td valign="top" colspan="1" rowspan="1">IM or IM&#160;+&#160;electroporation</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">COVIGEN</td><td valign="top" colspan="1" rowspan="1">University of Sydney; Bionet Co Ltd; Technovalia</td><td valign="top" colspan="1" rowspan="1">D0-28, IM or ID</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td colspan="8" align="left" valign="top" rowspan="1"><bold>Protein-based vaccines</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M</td><td valign="top" colspan="1" rowspan="1">Novavax</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Recombinant vaccine (CHO cell)</td><td valign="top" colspan="1" rowspan="1">Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology, Chinese Academy of Sciences</td><td valign="top" colspan="1" rowspan="1">D0-28 or D0-28-56, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">KBP-COVID-19 (RBD-based protein subunit)</td><td valign="top" colspan="1" rowspan="1">Kentucky Bioprocessing, Inc</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Protein subunit RBD (baculovirus production expressed in Sf9 cells)</td><td valign="top" colspan="1" rowspan="1">West China Hospital, Sichuan University</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">S protein subunit (baculovirus production)&#160;+&#160;AS03</td><td valign="top" colspan="1" rowspan="1">Sanofi Pasteur; GSK</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">SCB-2019&#160;+&#160;CpG1018 adjuvant plus alum (native-like trimeric subunit spike protein vaccine)</td><td valign="top" colspan="1" rowspan="1">Clover Biopharmaceuticals Inc; Dynavax</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Recombinant spike protein plus adjuvant</td><td valign="top" colspan="1" rowspan="1">Vaxine Pty Ltd; Medytox</td><td valign="top" colspan="1" rowspan="1">D0, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">MF59 adjuvanted SARS-CoV-2 Sclamp vaccine</td><td valign="top" colspan="1" rowspan="1">University of Queensland; CSL; Seqirus</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">MCV-COV1901 (S-2P protein&#160;+&#160;CpG 1018)</td><td valign="top" colspan="1" rowspan="1">Medigen Vaccine Biologics Corporation; NIAID; Dynavax</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">FINLEY-FR1 (RBD&#160;+&#160;adjuvant)</td><td valign="top" colspan="1" rowspan="1">Instituto Finlay de Vacunas, Cuba</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">FINLEY-FR2 (RBD chemically conjugated to tetanus toxoid&#160;+&#160;adjuvant)</td><td valign="top" colspan="1" rowspan="1">Instituto Finlay de Vacunas, Cuba</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Peptide</td><td valign="top" colspan="1" rowspan="1">Federal Budgetary Research Institution State Research Center of Virology and Biotechnology 'Vector'</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">IMP CoVac1 (SARS-CoV-2 HLA-DR peptides)</td><td valign="top" colspan="1" rowspan="1">University Hospital Tuebingen</td><td valign="top" colspan="1" rowspan="1">D0, SC</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">UB612 (multitope peptide-based S1-RBD-protein)</td><td valign="top" colspan="1" rowspan="1">COVAXX; United Biomedical Inc Asia</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">AdimrSC-2f (recombinant RBD +/- aluminium)</td><td valign="top" colspan="1" rowspan="1">Adimmune Corporation</td><td valign="top" colspan="1" rowspan="1">Not disclosed</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">CIGB-669 (RBD+AgnHB)</td><td valign="top" colspan="1" rowspan="1">Center for Genetic Engineering and Biotechnology (CIGB)</td><td valign="top" colspan="1" rowspan="1">D0-14-28 or D0-28-56, IN</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">CIGB-66 (RBD+aluminium hydroxide)</td><td valign="top" colspan="1" rowspan="1">Center for Genetic Engineering and Biotechnology (CIGB)</td><td valign="top" colspan="1" rowspan="1">D0-14-28 or D0-28-56, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">BECOV2</td><td valign="top" colspan="1" rowspan="1">Biological ELimited</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Recombinant SARS-CoV-2 Spike protein, Aluminum adjuvanted</td><td valign="top" colspan="1" rowspan="1">Nanogen Pharmaceutical Biotechnology</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Recombinant protein vaccine S-268019 (baculovirus expression vector system)</td><td valign="top" colspan="1" rowspan="1">Shionogi</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">SARS-CoV-2-RBD-Fc fusion protein</td><td valign="top" colspan="1" rowspan="1">University Medical Center Groningen&#160;+&#160;Akston Biosciences Inc.</td><td valign="top" colspan="1" rowspan="1">SC or IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">COVAC-1 and COVAC-2 sub-unit vaccine (spike protein)&#160;+&#160;SWE adjuvant</td><td valign="top" colspan="1" rowspan="1">University of Saskatchewan</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">EuCorVac-19</td><td valign="top" colspan="1" rowspan="1">POP Biotechnologies; EuBiologics Co Ltd</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">SK SARS-CoV-2 recombinant surface antigen (NBP2001)&#160;+&#160;alum adjuvant</td><td valign="top" colspan="1" rowspan="1">SK Bioscience Co Ltd</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">SpFN (spike ferritin nanoparticle)&#160;+&#160;QS21 adjuvant</td><td valign="top" colspan="1" rowspan="1">Walter Reed Army Institute of Research</td><td valign="top" colspan="1" rowspan="1">D0-28-180, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Razi Cov Pars</td><td valign="top" colspan="1" rowspan="1">Razi Vaccine and Serum Research Institute</td><td valign="top" colspan="1" rowspan="1">D0-21-51, IM and IN</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">GBP510 recombinant surface protein vaccine&#160;+&#160;AS03</td><td valign="top" colspan="1" rowspan="1">SK Bioscience Co Ltd; CEPI; GSK</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td colspan="8" align="left" valign="top" rowspan="1"><bold>VLP-based vaccines</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">RBD-HBsAg VLPs</td><td valign="top" colspan="1" rowspan="1">SpyBiotech; Serum Institute of India; Accelagen Pty</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Plant-derived VLP adjuvanted with GSK or Dynavax adjuvants</td><td valign="top" colspan="1" rowspan="1">Medicago Inc.; Dynavax; GSK</td><td valign="top" colspan="1" rowspan="1">D0-21, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">VBI-2902a</td><td valign="top" colspan="1" rowspan="1">VBI Vaccines Inc</td><td valign="top" colspan="1" rowspan="1">D0-28, IM</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="spara006"><p><sup>a</sup>APC: artificial antigen presenting cells; CHO: Chinese hamster ovary; D: Day of vaccination; DC: dendritic cell; HLA: human leukocyte antigen; ID: intradermal; IM: intramuscular; IN: intranasal; LNP: lipid nanoparticle; LV: lentivirus; MVA: Modified Vaccinia Virus Ankara; PLV: proteo lipid vehicle; RBD: receptor binding domain; sa: self-activating; SC: subcutaneous; VLP: virus-like particle; VSV: vesicular stomatitis virus; WHO: World Health Organization</p></fn><fn id="spara007"><p>The landscape of candidate vaccines is changing constantly. For the latest WHO updates, refer to (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" id="interref0001">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link>).</p></fn></table-wrap-foot></table-wrap><fig id="fig0003" position="float" orientation="portrait"><label>Figure 3</label><caption><p><bold>COVID-19 vaccine candidates in clinical development according to vaccine platform (WHO draft landscape on 22 March 2021, 2021b).</bold> VLP: virus-like particle; WHO: World Health Organization.</p></caption><alt-text id="alt0003">Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3_lrg.jpg"/></fig></p><p id="para0064">The University of Oxford/AstraZeneca vaccine (ChAdOx1 nCoV-19; AZD-1222) is based on a chimpanzee adenovirus vector that was developed some years ago (<xref rid="bib0067" ref-type="bibr">Dicks&#160;et&#160;al., 2012</xref>) and contains a codon-optimised full-length spike protein (S1 and S2 subunits) of SARS-CoV-2 (<xref rid="bib0221" ref-type="bibr">van&#160;Doremalen et&#160;al., 2020</xref>). A pooled analysis of safety from four phase 1/2/3 studies showed that the vaccine is well tolerated (<xref rid="bib0227" ref-type="bibr">Voysey&#160;et&#160;al., 2021</xref>). Recently, however, concerns over rare reports of coagulation disorders with unexpected deaths have been expressed by some European countries. Efficacy against COVID-19 disease was evaluated in two phase 2/3 studies (<xref rid="bib0227" ref-type="bibr">Voysey&#160;et&#160;al., 2021</xref>). In one study, the first vaccination was given at a lower dose than planned to some participants and efficacy data have therefore been presented for two study groups: low dose at first vaccination followed by standard dose at the second vaccination (LD/SD) and both vaccinations given at the standard dose (SD/SD). Vaccine efficacy was 90.0% (95% CI: 67.4&#8211;97.0) in the LD/SD group and 62.1% (95% CI: 41.0&#8211;75.7) in the SD/SD group (<xref rid="bib0227" ref-type="bibr">Voysey&#160;et&#160;al., 2021</xref>). The mechanism for the higher efficacy in the group who received a lower priming dose is as yet unknown.</p><p id="para0065">The Gam-COVID-Vac combined vector vaccine, Sputnik V, developed by the Russian Gamaleya Center, uses two adenovirus vectors (Ad5 and Ad26) containing the spike protein (<xref rid="bib0137" ref-type="bibr">Logunov&#160;et&#160;al., 2021</xref>). A phase 3 study reported vaccine efficacy of 91.6% after two vaccine doses, with no moderate or severe cases of COVID-19 reported in the vaccine group (<xref rid="bib0137" ref-type="bibr">Logunov&#160;et&#160;al., 2021</xref>). A phase 2 study of another adenovirus vector vaccine, Ad26.COV2.S developed by Janssen, has reported a good safety profile and high immune response (<xref rid="bib0188" ref-type="bibr">Sadoff&#160;et&#160;al., 2021a</xref>). A phase 3 trial demonstrated that a single dose offered 66% protection against moderate to severe disease and 85% against severe disease (<xref rid="bib0189" ref-type="bibr">Sadoff&#160;et&#160;al., 2021b</xref>).</p><p id="para0066">Inactivated vaccines created from Vero cells inoculated with SARS-CoV-2 are being developed by the Chinese companies, Sinovac and Sinopharm (<xref rid="bib0255" ref-type="bibr">Xia et&#160;al., 2021</xref>, <xref rid="bib0258" ref-type="bibr">Zhang et&#160;al., 2021</xref>). A phase 2 trial demonstrated that the Sinovac vaccine (CoronaVac) at a dose of 3 &#181;g was well tolerated and resulted in up to 97% seroconversion for neutralising antibodies (<xref rid="bib0258" ref-type="bibr">Zhang&#160;et&#160;al., 2021</xref>). Interim data from a phase 3 trial in Turkey demonstrated vaccine efficacy of 83.5% against symptomatic COVID-19 (<xref rid="bib0209" ref-type="bibr">Tanriover&#160;et&#160;al., 2021</xref>). In a phase 2 trial, the Sinopharm vaccine (BBIBP-CorV) was well tolerated and a 4 &#181;g dose administered in a 2-dose schedule (days 0 and 21 or days 0 and 28) resulted in higher neutralising antibody titres than a 4 &#181;g 2-dose schedule at days 0 and 14 or a single administration of a 8 &#181;g dose (<xref rid="bib0255" ref-type="bibr">Xia&#160;et&#160;al., 2021</xref>). Phase 3 trials of both vaccines are ongoing.</p><p id="para0067">According to Our World in Data, as of 6 September 2021, 40.6% of the world's population and 1.9% of people in low-income countries had received at least one dose of a COVID-19 vaccine (Mathieu et&#160;al., 2021). The proportion of the population who had been fully vaccinated was 28% globally, 49% in Europe (59% in the European Union), 43% in North America, 32% in South America, 29% in Asia and 3% in Africa (Mathieu et&#160;al., 2021). These values illustrate sharply the global inequity in access to COVID-19 vaccines, which is allowing spread of the virus to continue in unvaccinated populations and increasing the risk of emergence of new variants (<xref rid="bib0164" ref-type="bibr">Padma,&#160;2021</xref>).</p></sec></sec><sec id="sec0026"><title>Universal influenza vaccines</title><p id="para0068">The HA and neuraminidase (NA) glycoproteins are the major surface proteins of the influenza virus. Current influenza vaccines are designed to induce neutralising antibodies against HA, which consists of a membrane-distal globular head domain and a membrane-proximal stalk domain (<xref rid="bib0117" ref-type="bibr">Kaminski&#160;and Lee,&#160;2011</xref>). The head domain is immunodominant, meaning that the immune response is mainly directed towards this part of the glycoprotein (<xref rid="bib0011" ref-type="bibr">Angeletti&#160;et&#160;al., 2017</xref>). The head domain has high plasticity and undergoes constant antigenic drift (<xref rid="bib0097" ref-type="bibr">Heaton&#160;et&#160;al., 2013</xref>, <xref rid="bib0123" ref-type="bibr">Kirkpatrick&#160;et&#160;al., 2018</xref>). This means that antibodies against the head domain are highly strain-specific and become ineffective when the virus mutates. The aim for a universal influenza virus vaccine is to elicit a robust and durable immune response to all influenza virus strains and subtypes.</p><p id="para0069">The Universal Influenza Vaccine Technology Landscape is a publicly available database of universal influenza vaccine technologies that have reached clinical or late pre-clinical development (<xref rid="bib0039" ref-type="bibr">CIDRAP,&#160;2020</xref>, <xref rid="bib0163" ref-type="bibr">Ostrowsky&#160;et&#160;al., 2020</xref>). It includes 22 vaccine candidates in clinical development and 74 in late pre-clinical development, utilising a variety of vaccine platforms (<xref rid="bib0039" ref-type="bibr">CIDRAP,&#160;2020</xref>, <xref rid="bib0163" ref-type="bibr">Ostrowsky&#160;et&#160;al., 2020</xref>). Target antigens are aimed at inducing neutralising antibody responses, cross-reactive T-cell responses or a combination of both. Targets for neutralising antibodies include the stalk domain of the HA glycoprotein, the NA glycoprotein and the matrix 2 membrane protein (M2). T-cell targets are mainly focused on internal proteins such as nucleoprotein, matrix protein (M1) and nonstructural proteins (<xref rid="bib0039" ref-type="bibr">CIDRAP,&#160;2020</xref>, <xref rid="bib0163" ref-type="bibr">Ostrowsky&#160;et&#160;al., 2020</xref>).</p></sec></sec><sec id="sec0027"><title>Conclusions</title><p id="para0070">For pandemic use, an ideal platform would allow progress within a few weeks or months from viral sequencing to clinical trials, demonstrate consistent immune responses with different pathogens and be suitable for large-scale manufacture regardless of the pathogen included in the vaccine (<xref rid="bib0140" ref-type="bibr">Lurie&#160;et&#160;al., 2020</xref>). It has been suggested that pandemic vaccines can be developed using a new pandemic paradigm with a rapid start and the usual sequential steps done in parallel (<xref rid="bib0140" ref-type="bibr">Lurie&#160;et&#160;al., 2020</xref>). The COVID-19 pandemic has illustrated the feasibility of this approach and the benefits of a globally coordinated response and infrastructure (<xref rid="bib0017" ref-type="bibr">Ball,&#160;2021</xref>). Adequate financial support and a system for fair allocation of vaccine is essential for this approach to be successful (<xref rid="bib0017" ref-type="bibr">Ball,&#160;2021</xref>, <xref rid="bib0140" ref-type="bibr">Lurie&#160;et&#160;al., 2020</xref>).</p><p id="para0071">The current pandemic has also demonstrated these new vaccines can be developed at high speed without compromising safety. Yet, the development of mRNA and viral vector COVID-19 vaccines benefited from years of research on these technologies (e.g., Ebola vaccine) and on other coronaviruses (SARS-CoV-1 and MERS-CoV)(<xref rid="bib0017" ref-type="bibr">Ball,&#160;2021</xref>). Some of the COVID-19 vaccines recently developed or currently in development might offer some flexibility or sufficient broad protection to swiftly respond to antigenic drift or emergence of new coronaviruses. Conventional vaccines have several advantages such as long experience of safety, cost and breadth of immune response with adjuvants. However, vaccines based on cultured virus face problems with rapid upscaling of production; future pandemic vaccines will most probably be fully synthetic, as we are witnessing with the new SARS-CoV-2 vaccines.</p><p id="para0072">This wide vaccine technology approach will be best employed in tandem with active surveillance for emerging variants or new pathogens using antigen mapping, metagenomics and next generation sequencing. New generations of vaccines will certainly be developed (<xref rid="bib0129" ref-type="bibr">Lavine&#160;et&#160;al., 2021</xref>). In addition, pandemic preparedness needs to take account of challenges such as the large-scale production of sufficient quantity of vaccines, delivery of vaccines to all countries and ensuring vaccination of relevant age groups. Large harmonised networks of vaccination registries, together with robust infrastructure, are needed to ensure that people of all ages can be vaccinated during inter-pandemic periods. A plain language summary of our observations is presented in Supplementary Figure&#160;1.</p></sec><sec id="sec0028"><title>Conflict of Interest</title><p id="para0073">Philippe Buchy, Otavio Cintra, Michael Nissen are employed by the GSK Group of Companies also have shares in the GSK Group of Companies. They declare financial and non-financial conflict of interest. Dominic E Dwyer, Michael Nissen, Raul Ortiz de Lejarazu, Yves Buisson and Eskild Petersen have nothing to disclose.</p></sec><sec id="sec0029"><title>Funding</title><p id="para0074">This paper was funded by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in all stages of the conduct and analysis of the study and covered the costs associated with the development and the publishing of the present manuscript.</p></sec><sec id="sec0030"><title>Ethical approval</title><p id="para0075">NA.</p></sec><sec id="sec0031"><title>Contributorship</title><p id="para0076">All authors contributed to study conception, interpretation of the data, and critical review of the paper for important intellectual content. All authors are in agreement with the content of the final article and have approved it for submission and publication.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Abdelrahman</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses</article-title><source>Frontiers in Immunology</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">552909</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.552909</pub-id><pub-id pub-id-type="pmcid">PMC7516028</pub-id><pub-id pub-id-type="pmid">33013925</pub-id></element-citation></ref><ref id="bib0002"><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Ajao</surname><given-names>A</given-names></name><name name-style="western"><surname>Nystrom</surname><given-names>SV</given-names></name><name name-style="western"><surname>Koonin</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Assessing the capacity of the US health care system to use additional mechanical ventilators during a large-scale public health emergency</article-title><source>Disaster Med Public Health Prep</source><volume>9</volume><year>2015</year><fpage>634</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1017/dmp.2015.105</pub-id><pub-id pub-id-type="pmid">26450633</pub-id><pub-id pub-id-type="pmcid">PMC4636910</pub-id></element-citation></ref><ref id="bib0003"><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Alami</surname><given-names>H</given-names></name><name name-style="western"><surname>Lehoux</surname><given-names>P</given-names></name><name name-style="western"><surname>Fleet</surname><given-names>R</given-names></name><etal/></person-group><article-title>How can health systems better prepare for the next pandemic? lessons learned from the management of COVID-19 in Quebec (Canada)</article-title><source>Front Public Health</source><year>2021</year><pub-id pub-id-type="doi">10.3389/fpubh.2021.671833</pub-id><pub-id pub-id-type="pmcid">PMC8249772</pub-id><pub-id pub-id-type="pmid">34222176</pub-id></element-citation></ref><ref id="bib0004"><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>SO</given-names></name><name name-style="western"><surname>Takas</surname><given-names>T</given-names></name><name name-style="western"><surname>Nyborg</surname><given-names>A</given-names></name><etal/></person-group><article-title>Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza</article-title><source>Antimicrob Agents Chemother</source><volume>62</volume><year>2018</year><fpage>e00694</fpage><lpage>e00718</lpage><pub-id pub-id-type="doi">10.1128/aac.00694-18</pub-id><pub-id pub-id-type="pmid">30150460</pub-id><pub-id pub-id-type="pmcid">PMC6201130</pub-id></element-citation></ref><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Almond</surname><given-names>D.</given-names></name></person-group><article-title>Is the 1918 influenza pandemic over? Long-term effects of in utero influenza exposure in the post-1940 US population</article-title><source>J Polit Econ</source><volume>114</volume><year>2006</year><fpage>672</fpage><lpage>712</lpage></element-citation></ref><ref id="bib0006"><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Alouane</surname><given-names>T</given-names></name><name name-style="western"><surname>Laamarti</surname><given-names>M</given-names></name><name name-style="western"><surname>Essabbar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genomic diversity and hotspot mutations in 30,983 SARS-CoV-2 genomes: moving toward a universal vaccine for the &#8220;confined virus&#8221;?</article-title><source>Pathogens</source><volume>9</volume><year>2020</year><fpage>829</fpage><pub-id pub-id-type="doi">10.3390/pathogens9100829</pub-id><pub-id pub-id-type="pmid">33050463</pub-id><pub-id pub-id-type="pmcid">PMC7600297</pub-id></element-citation></ref><ref id="bib0007"><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name name-style="western"><surname>Auwaerter</surname><given-names>PG.</given-names></name></person-group><article-title>Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature</article-title><source>J Hosp Infect</source><volume>101</volume><year>2019</year><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2018.05.021</pub-id><pub-id pub-id-type="pmid">29864486</pub-id><pub-id pub-id-type="pmcid">PMC7114594</pub-id></element-citation></ref><ref id="bib0008"><mixed-citation publication-type="other" id="sbref0008">American Cancer Society. Why people with cancer are more likely to get infections. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/why-people-with-cancer-are-at-risk.html" id="interref0003">https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/why-people-with-cancer-are-at-risk.html</ext-link> (accessed December 2020).</mixed-citation></ref><ref id="bib0009"><element-citation publication-type="book" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>BW.</given-names></name></person-group><part-title>Economics and the public welfare: a financial and economic history of the United States, 1914-1946</part-title><year>1979</year><publisher-name>Liberty Press</publisher-name><fpage>61</fpage><lpage>69</lpage></element-citation></ref><ref id="bib0010"><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>DE</given-names></name><name name-style="western"><surname>Tan</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chia</surname><given-names>WN</given-names></name><etal/></person-group><article-title>Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2</article-title><source>Emerg Microbes Infect</source><volume>9</volume><year>2020</year><fpage>900</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1761267</pub-id><pub-id pub-id-type="pmid">32380903</pub-id><pub-id pub-id-type="pmcid">PMC7241448</pub-id></element-citation></ref><ref id="bib0011"><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Angeletti</surname><given-names>D</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>JS</given-names></name><name name-style="western"><surname>Angel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Defining B cell immunodominance to viruses</article-title><source>Nat Immunol</source><volume>18</volume><year>2017</year><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/ni.3680</pub-id><pub-id pub-id-type="pmid">28192417</pub-id><pub-id pub-id-type="pmcid">PMC5360521</pub-id></element-citation></ref><ref id="bib0012"><mixed-citation publication-type="other" id="sbref0012">Anon. Janssen drops pimodivir development program in flu. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.thepharmaletter.com/article/janssen-drops-pimodivir-development-program-in-flu" id="interref0004">https://www.thepharmaletter.com/article/janssen-drops-pimodivir-development-program-in-flu</ext-link> (accessed December 2020).</mixed-citation></ref><ref id="bib0013"><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Ansart</surname><given-names>S</given-names></name><name name-style="western"><surname>Pelat</surname><given-names>C</given-names></name><name name-style="western"><surname>Boelle</surname><given-names>PY</given-names></name><etal/></person-group><article-title>Mortality burden of the 1918&#8211;1919 influenza pandemic in Europe</article-title><source>Influenza Other Respir Viruses</source><volume>3</volume><year>2009</year><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1111/j.1750-2659.2009.00080.x</pub-id><pub-id pub-id-type="pmid">19453486</pub-id><pub-id pub-id-type="pmcid">PMC4634693</pub-id></element-citation></ref><ref id="bib0014"><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Arce</surname><given-names>JS</given-names></name><name name-style="western"><surname>Warren</surname><given-names>SS</given-names></name><name name-style="western"><surname>Meriggi</surname><given-names>NF</given-names></name><etal/></person-group><article-title>COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries</article-title><source>Nat Med</source><volume>27</volume><year>2021</year><fpage>1385</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01454-y</pub-id><pub-id pub-id-type="pmid">34272499</pub-id><pub-id pub-id-type="pmcid">PMC8363502</pub-id></element-citation></ref><ref id="bib0015"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Bacay Watson</surname><given-names>V.</given-names></name></person-group><article-title>Five coronavirus success stories: different, but the same</article-title><source>Security Nexus, Daniel K Inouye Asia-Pacific Center for Security Studies</source><year>2020</year><comment>Available at</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.jstor.org/stable/pdf/resrep24880.pdf" id="interref0005">https://www.jstor.org/stable/pdf/resrep24880.pdf</ext-link><comment>(accessed October 2020)</comment></element-citation></ref><ref id="bib0016"><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficacy ans safety of the mRNA SARS-CoV2 vaccine</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="bib0017"><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Ball</surname><given-names>P.</given-names></name></person-group><article-title>The lightning-fast quest for COVID vaccines &#8211; and what it means for other diseases</article-title><source>Nature</source><volume>589</volume><year>2021</year><fpage>16</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-03626-1</pub-id><pub-id pub-id-type="pmid">33340018</pub-id></element-citation></ref><ref id="bib0018"><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Martin</surname><given-names>T</given-names></name><etal/></person-group><article-title>Mortality, admissions, and patient census at SNFs in 3 US cities during the COVID-19 pandemic</article-title><source>JAMA</source><volume>324</volume><year>2020</year><fpage>507</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.11642</pub-id><pub-id pub-id-type="pmid">32579161</pub-id><pub-id pub-id-type="pmcid">PMC7315390</pub-id></element-citation></ref><ref id="bib0019"><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>DH</given-names></name><name name-style="western"><surname>Kik</surname><given-names>SV</given-names></name><name name-style="western"><surname>Weverling</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>5203</fpage><lpage>5209</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.025</pub-id><pub-id pub-id-type="pmid">21619905</pub-id><pub-id pub-id-type="pmcid">PMC3138857</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Barro</surname><given-names>R</given-names></name><name name-style="western"><surname>Ursua</surname><given-names>J</given-names></name><name name-style="western"><surname>Weng</surname><given-names>J.</given-names></name></person-group><article-title>The coronavirus and the great influenza epidemic: lessons from the &#8220;Spanish Flu&#8221; for the coronavirus&#8217; potential effects on mortality and economic activity</article-title><source>American Enterprise Institute</source><year>2020</year></element-citation></ref><ref id="bib0021"><element-citation publication-type="book" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Barry</surname><given-names>JM.</given-names></name></person-group><part-title>The great influenza: the epic story of the deadliest plague in history</part-title><year>2005</year><publisher-name>Penguin Group</publisher-name><publisher-loc>New York</publisher-loc></element-citation></ref><ref id="bib0022"><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Beaney</surname><given-names>T</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>JM</given-names></name><name name-style="western"><surname>Jain</surname><given-names>V</given-names></name><etal/></person-group><article-title>Excess mortality: the gold standard in measuring the impact of COVID-19 worldwide?</article-title><source>J Royal Soc Med</source><volume>113</volume><year>2020</year><fpage>329</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1177/0141076820956802</pub-id><pub-id pub-id-type="pmcid">PMC7488823</pub-id><pub-id pub-id-type="pmid">32910871</pub-id></element-citation></ref><ref id="bib0023"><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Bedford</surname><given-names>J</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>J</given-names></name><name name-style="western"><surname>Ihekweazu</surname><given-names>C</given-names></name><etal/></person-group><article-title>A new twenty-first century science for effective epidemic response</article-title><source>Nature</source><volume>575</volume><year>2019</year><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1717-y</pub-id><pub-id pub-id-type="pmid">31695207</pub-id><pub-id pub-id-type="pmcid">PMC7095334</pub-id></element-citation></ref><ref id="bib0024"><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>JH</given-names></name><name name-style="western"><surname>Tomashek</surname><given-names>KM</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Remdesivir for the treatment of Covid-19 &#8211; final report</article-title><source>N Engl J Med</source><volume>383</volume><year>2020</year><fpage>1813</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id><pub-id pub-id-type="pmid">32445440</pub-id><pub-id pub-id-type="pmcid">PMC7262788</pub-id></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Belser</surname><given-names>JA</given-names></name><name name-style="western"><surname>Wadford</surname><given-names>DA</given-names></name><name name-style="western"><surname>Pappas</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pathogenesis of pandemic influenza A (H1N1) and triple-reassortant swine influenza A (H1) viruses in mice</article-title><source>J Virol</source><volume>84</volume><year>2010</year><fpage>4194</fpage><lpage>4203</lpage><pub-id pub-id-type="doi">10.1128/jvi.02742-09</pub-id><pub-id pub-id-type="pmid">20181710</pub-id><pub-id pub-id-type="pmcid">PMC2863721</pub-id></element-citation></ref><ref id="bib0026"><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Bhimraj</surname><given-names>A</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>R</given-names></name><name name-style="western"><surname>Hirsch Shumaker</surname><given-names>A</given-names></name><etal/></person-group><article-title>Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19</article-title><source>Infectious Diseases Society of America</source><year>2021</year><comment>version 4.4.1. 2021. Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/" id="interref0006">https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</ext-link><comment>(accessed September 2021)</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa478</pub-id><pub-id pub-id-type="pmcid">PMC7197612</pub-id><pub-id pub-id-type="pmid">32338708</pub-id></element-citation></ref><ref id="bib0027"><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Breban</surname><given-names>R</given-names></name><name name-style="western"><surname>Riou</surname><given-names>J</given-names></name><name name-style="western"><surname>Fontanet</surname><given-names>A.</given-names></name></person-group><article-title>Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk</article-title><source>Lancet</source><volume>382</volume><year>2013</year><fpage>694</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(13)61492-0</pub-id><pub-id pub-id-type="pmid">23831141</pub-id><pub-id pub-id-type="pmcid">PMC7159280</pub-id></element-citation></ref><ref id="bib0028"><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Brundage</surname><given-names>JF.</given-names></name></person-group><article-title>Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness</article-title><source>Lancet Infect Dis</source><volume>6</volume><year>2006</year><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(06)70466-2</pub-id><pub-id pub-id-type="pmid">16631551</pub-id><pub-id pub-id-type="pmcid">PMC7106411</pub-id></element-citation></ref><ref id="bib0029"><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Buchbinder</surname><given-names>SP</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>DV</given-names></name><name name-style="western"><surname>Duerr</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial</article-title><source>Lancet</source><volume>372</volume><year>2008</year><fpage>1881</fpage><lpage>1893</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(08)61591-3</pub-id><pub-id pub-id-type="pmid">19012954</pub-id><pub-id pub-id-type="pmcid">PMC2721012</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Buchholz</surname><given-names>UJ</given-names></name><name name-style="western"><surname>Bukreyev</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</article-title><source>Proc Natl Acad Sci USA</source><volume>101</volume><year>2004</year><fpage>9804</fpage><lpage>9809</lpage><pub-id pub-id-type="doi">10.1073/pnas.0403492101</pub-id><pub-id pub-id-type="pmid">15210961</pub-id><pub-id pub-id-type="pmcid">PMC470755</pub-id></element-citation></ref><ref id="bib0031"><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Buchy</surname><given-names>P</given-names></name><name name-style="western"><surname>Ascioglu</surname><given-names>S</given-names></name><name name-style="western"><surname>Buisson</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impact of vaccines on antimicrobial resistance</article-title><source>Int J Infect Dis</source><volume>90</volume><year>2020</year><fpage>188</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2019.10.005</pub-id><pub-id pub-id-type="pmid">31622674</pub-id></element-citation></ref><ref id="bib0032"><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Byerly</surname><given-names>CR.</given-names></name></person-group><article-title>The U.S. military and the influenza pandemic of 1918&#8211;1919</article-title><source>Public Health Rep</source><volume>125</volume><issue>Suppl 3</issue><year>2010</year><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">20568570</pub-id><pub-id pub-id-type="pmcid">PMC2862337</pub-id></element-citation></ref><ref id="bib0033"><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis</article-title><source>BMC Public Health</source><volume>21</volume><year>2021</year><fpage>1505</fpage><pub-id pub-id-type="doi">10.1186/s12889-021-11546-6</pub-id><pub-id pub-id-type="pmid">34348687</pub-id><pub-id pub-id-type="pmcid">PMC8334342</pub-id></element-citation></ref><ref id="bib0034"><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Callisher</surname><given-names>C</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>D</given-names></name><name name-style="western"><surname>Codwell</surname><given-names>R</given-names></name><etal/></person-group><article-title>Statement in support of the scientists, public health professionals, and medical professionals of China in combatting COVID-19</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>e42</fpage><lpage>e43</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30418-9</pub-id><pub-id pub-id-type="pmid">32087122</pub-id><pub-id pub-id-type="pmcid">PMC7159294</pub-id></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E.</given-names></name></person-group><article-title>The race for coronavirus vaccines: a graphical guide</article-title><source>Nature</source><volume>580</volume><year>2020</year><fpage>576</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-01221-y</pub-id><pub-id pub-id-type="pmid">32346146</pub-id></element-citation></ref><ref id="bib0036"><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Carlson</surname><given-names>CJ.</given-names></name></person-group><article-title>From PREDICT to prevention, one pandemic later</article-title><source>Lancet Microbe</source><volume>1</volume><year>2020</year><fpage>e6</fpage><lpage>e7</lpage><pub-id pub-id-type="doi">10.1016/s2666-5247(20)30002-1</pub-id><pub-id pub-id-type="pmid">32835320</pub-id><pub-id pub-id-type="pmcid">PMC7148715</pub-id></element-citation></ref><ref id="bib0037"><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>D</given-names></name><name name-style="western"><surname>Daszak</surname><given-names>P</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>ND</given-names></name><etal/></person-group><article-title>The Global Virome Project</article-title><source>Science</source><volume>359</volume><year>2018</year><fpage>872</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1126/science.aap7463</pub-id><pub-id pub-id-type="pmid">29472471</pub-id></element-citation></ref><ref id="bib0038"><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Cassone</surname><given-names>A</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group><article-title>Universal vaccines: shifting to one for many</article-title><source>mBio</source><volume>1</volume><year>2010</year><fpage>e00042</fpage><lpage>e000110</lpage><pub-id pub-id-type="doi">10.1128/mBio.00042-10</pub-id><pub-id pub-id-type="pmid">20689748</pub-id><pub-id pub-id-type="pmcid">PMC2912660</pub-id></element-citation></ref><ref id="bib0039"><mixed-citation publication-type="other" id="sbref0039">Center for Infectious Disease Research and Policy (CIDRAP). Universal influenza vaccine technology landscape. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cidrap.umn.edu/universal-influenza-vaccine-technology-landscape" id="interref0007">https://www.cidrap.umn.edu/universal-influenza-vaccine-technology-landscape</ext-link> (acessed October 2020).</mixed-citation></ref><ref id="bib0040"><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><article-title>Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) &#8211; United States, May&#8211;August 2009</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>58</volume><year>2009</year><fpage>1071</fpage><lpage>1074</lpage><pub-id pub-id-type="pmid">19798021</pub-id></element-citation></ref><ref id="bib0041"><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><article-title>Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage &#8211; United States, October 2009&#8211;January 2010</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>59</volume><year>2010</year><fpage>363</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">20360670</pub-id></element-citation></ref><ref id="bib0042"><mixed-citation publication-type="other" id="sbref0042">Centers for Disease Control and Prevention. Past pandemics. 2018a. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/pandemic-resources/basics/past-pandemics.html" id="interref0008">https://www.cdc.gov/flu/pandemic-resources/basics/past-pandemics.html</ext-link> (accessed December 2020).</mixed-citation></ref><ref id="bib0043"><mixed-citation publication-type="other" id="sbref0043">Centers for Disease Control and Prevention. One Health Basics. 2018b. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/onehealth/basics/index.html" id="interref0009">https://www.cdc.gov/onehealth/basics/index.html</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0044"><mixed-citation publication-type="other" id="sbref0044">Centers for Disease Control and Prevention. Influenza historic timeline. 2019a. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-beyond.htm" id="interref0010">https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-beyond.htm</ext-link> (accessed December 2020).</mixed-citation></ref><ref id="bib0045"><mixed-citation publication-type="other" id="sbref0045">Centers for Disease Control and Prevention. 1968 pandemic (H2N2 virus). 2019b. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/pandemic-resources/1968-pandemic.html" id="interref0011">https://www.cdc.gov/flu/pandemic-resources/1968-pandemic.html</ext-link> (accessed December 2020).</mixed-citation></ref><ref id="bib0046"><mixed-citation publication-type="other" id="sbref0046">Centers for Disease Control and Prevention. Influenza antiviral drug resistance. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/treatment/antiviralresistance.htm" id="interref0012">https://www.cdc.gov/flu/treatment/antiviralresistance.htm</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0047"><mixed-citation publication-type="other" id="sbref0047">Centers for Disease Control and Prevention. Influenza vaccination information for health care workers. 2021. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/professionals/healthcareworkers.htm?CDC_AA_refVal=https%3A%2F%2Fwwwcdcgov%2Fflu%2Fhealthcareworkers.htm" id="interref0013">https://www.cdc.gov/flu/professionals/healthcareworkers.htm?CDC_AA_refVal=https%3A%2F%2Fwwwcdcgov%2Fflu%2Fhealthcareworkers.htm</ext-link> (accessed March 2021).</mixed-citation></ref><ref id="bib0048"><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Chalmers</surname><given-names>JD</given-names></name><name name-style="western"><surname>Crichton</surname><given-names>ML</given-names></name><name name-style="western"><surname>Goeminne</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline</article-title><source>Eur Respir J</source><volume>57</volume><issue>4</issue><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00048-2021</pub-id><pub-id pub-id-type="pmcid">PMC7947358</pub-id><pub-id pub-id-type="pmid">33692120</pub-id></element-citation></ref><ref id="bib0049"><mixed-citation publication-type="other" id="sbref0049">Chan M. World now at the start of 2009 influenza pandemic. 2009. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/" id="interref0014">https://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="bib0050"><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Charu</surname><given-names>V</given-names></name><name name-style="western"><surname>Chowell</surname><given-names>G</given-names></name><name name-style="western"><surname>Palacio Mejia</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Mortality burden of the A/H1N1 pandemic in Mexico: a comparison of deaths and years of life lost to seasonal influenza</article-title><source>Clin Infect Dis</source><volume>53</volume><year>2011</year><fpage>985</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1093/cid/cir644</pub-id><pub-id pub-id-type="pmid">21976464</pub-id><pub-id pub-id-type="pmcid">PMC3202315</pub-id></element-citation></ref><ref id="bib0051"><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>PK</given-names></name><name name-style="western"><surname>Wong</surname><given-names>DA</given-names></name><name name-style="western"><surname>Tong</surname><given-names>LK</given-names></name><etal/></person-group><article-title>Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome</article-title><source>Lancet</source><volume>363</volume><year>2004</year><fpage>1699</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(04)16255-7</pub-id><pub-id pub-id-type="pmid">15158632</pub-id><pub-id pub-id-type="pmcid">PMC7112423</pub-id></element-citation></ref><ref id="bib0052"><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Chertow</surname><given-names>DS</given-names></name><name name-style="western"><surname>Memoli</surname><given-names>MJ.</given-names></name></person-group><article-title>Bacterial coinfection in influenza: a grand rounds review</article-title><source>JAMA</source><volume>309</volume><year>2013</year><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.194139</pub-id><pub-id pub-id-type="pmid">23321766</pub-id></element-citation></ref><ref id="bib0053"><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Chowell</surname><given-names>G</given-names></name><name name-style="western"><surname>Echevarr&#237;a-Zuno</surname><given-names>S</given-names></name><name name-style="western"><surname>Viboud</surname><given-names>C</given-names></name><etal/></person-group><article-title>Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico</article-title><source>PLoS Med</source><volume>8</volume><year>2011</year><object-id pub-id-type="publisher-id">e1000436</object-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1000436</pub-id><pub-id pub-id-type="pmcid">PMC3101203</pub-id><pub-id pub-id-type="pmid">21629683</pub-id></element-citation></ref><ref id="bib0054"><mixed-citation publication-type="other" id="sbref0054">CEPI (Coalition for Epidemic Preparedness Innovations). New vaccines for a safer world. 2020a. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cepi.net" id="interref0015">https://cepi.net</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0055"><mixed-citation publication-type="other" id="sbref0055">CEPI (Coalition for Epidemic Preparedness Innovations). How COVAX will work. 2020b. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cepi.net/COVAX/" id="interref0016">https://cepi.net/COVAX/</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0056"><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Cockburn</surname><given-names>WC</given-names></name><name name-style="western"><surname>Delon</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>W.</given-names></name></person-group><article-title>Origin and progress of the 1968&#8211;69 Hong Kong influenza epidemic</article-title><source>Bull World Health Organ</source><volume>41</volume><year>1969</year><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">5309437</pub-id><pub-id pub-id-type="pmcid">PMC2427756</pub-id></element-citation></ref><ref id="bib0057"><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><collab>COCONEL Group</collab></person-group><article-title>A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>769</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30426-6</pub-id><pub-id pub-id-type="pmid">32445713</pub-id><pub-id pub-id-type="pmcid">PMC7239623</pub-id></element-citation></ref><ref id="bib0058"><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Cohet</surname><given-names>C</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>R</given-names></name><name name-style="western"><surname>Bauchau</surname><given-names>V</given-names></name><etal/></person-group><article-title>Safety of AS03-adjuvanted influenza vaccines: a review of the evidence</article-title><source>Vaccine</source><volume>37</volume><year>2019</year><fpage>3006</fpage><lpage>3021</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.048</pub-id><pub-id pub-id-type="pmid">31031030</pub-id></element-citation></ref><ref id="bib0059"><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Colloca</surname><given-names>S</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>E</given-names></name><name name-style="western"><surname>Folgori</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species</article-title><source>Sci Transl Med</source><volume>4</volume><year>2012</year><fpage>:115ra112</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002925</pub-id><pub-id pub-id-type="pmcid">PMC3627206</pub-id><pub-id pub-id-type="pmid">22218691</pub-id></element-citation></ref><ref id="bib0060"><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Coughlin</surname><given-names>M</given-names></name><name name-style="western"><surname>Lou</surname><given-names>G</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>O</given-names></name><etal/></person-group><article-title>Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse</article-title><source>Virology</source><volume>361</volume><year>2007</year><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.09.029</pub-id><pub-id pub-id-type="pmid">17161858</pub-id><pub-id pub-id-type="pmcid">PMC7103293</pub-id></element-citation></ref><ref id="bib0061"><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Crooke</surname><given-names>SN</given-names></name><name name-style="western"><surname>Ovsyannikova</surname><given-names>IG</given-names></name><name name-style="western"><surname>Poland</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Immunosenescence and human vaccine immune responses</article-title><source>Immun Ageing</source><volume>16</volume><year>2019</year><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/s12979-019-0164-9</pub-id><pub-id pub-id-type="pmid">31528180</pub-id><pub-id pub-id-type="pmcid">PMC6743147</pub-id></element-citation></ref><ref id="bib0062"><mixed-citation publication-type="other" id="sbref0062">CS Mott Children's Hospital. Mott Poll Report. Flu vaccine for children in the time of COVID. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mottpoll.org/reports/flu-vaccine-children-time-covid" id="interref0017">https://mottpoll.org/reports/flu-vaccine-children-time-covid</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0063"><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name name-style="western"><surname>Dawood</surname><given-names>FS</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Finelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Emergence of a novel swine-origin influenza A (H1N1) virus in humans</article-title><source>N Engl J Med</source><volume>360</volume><year>2009</year><fpage>2605</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0903810</pub-id><pub-id pub-id-type="pmid">19423869</pub-id></element-citation></ref><ref id="bib0064"><element-citation publication-type="journal" id="sbref0064"><person-group person-group-type="author"><name name-style="western"><surname>Dawood</surname><given-names>FS</given-names></name><name name-style="western"><surname>Iuliano</surname><given-names>AD</given-names></name><name name-style="western"><surname>Reed</surname><given-names>C</given-names></name><etal/></person-group><article-title>Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study</article-title><source>Lancet Infect Dis</source><volume>12</volume><year>2012</year><fpage>687</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(12)70121-4</pub-id><pub-id pub-id-type="pmid">22738893</pub-id></element-citation></ref><ref id="bib0065"><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>M.</given-names></name></person-group><article-title>Covid-19: four fifths of cases are asymptomatic, China figures indicate</article-title><source>BMJ</source><volume>369</volume><year>2020</year><fpage>m1375</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1375</pub-id><pub-id pub-id-type="pmid">32241884</pub-id></element-citation></ref><ref id="bib0066"><element-citation publication-type="journal" id="sbref0066"><person-group person-group-type="author"><name name-style="western"><surname>Di Pasquale</surname><given-names>A</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>S</given-names></name><name name-style="western"><surname>Tavares Da Silva</surname><given-names>F</given-names></name><etal/></person-group><article-title>Vaccine adjuvants: from 1920 to 2015 and beyond</article-title><source>Vaccines</source><volume>3</volume><year>2015</year><fpage>320</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.3390/vaccines3020320</pub-id><pub-id pub-id-type="pmid">26343190</pub-id><pub-id pub-id-type="pmcid">PMC4494348</pub-id></element-citation></ref><ref id="bib0067"><element-citation publication-type="journal" id="sbref0067"><person-group person-group-type="author"><name name-style="western"><surname>Dicks</surname><given-names>MD</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity</article-title><source>PloS One</source><volume>7</volume><year>2012</year><fpage>e40385</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0040385</pub-id><pub-id pub-id-type="pmid">22808149</pub-id><pub-id pub-id-type="pmcid">PMC3396660</pub-id></element-citation></ref><ref id="bib0068"><element-citation publication-type="journal" id="sbref0068"><person-group person-group-type="author"><name name-style="western"><surname>Domingues</surname><given-names>CM</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>WK.</given-names></name></person-group><article-title>Uptake of pandemic influenza (H1N1)-2009 vaccines in Brazil, 2010</article-title><source>Vaccine</source><volume>30</volume><year>2012</year><fpage>4744</fpage><lpage>4751</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.05.007</pub-id><pub-id pub-id-type="pmid">22609010</pub-id></element-citation></ref><ref id="bib0069"><element-citation publication-type="journal" id="sbref0069"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development</article-title><source>J Virol</source><volume>87</volume><year>2013</year><fpage>9939</fpage><lpage>9942</lpage><pub-id pub-id-type="doi">10.1128/jvi.01048-13</pub-id><pub-id pub-id-type="pmid">23824801</pub-id><pub-id pub-id-type="pmcid">PMC3754113</pub-id></element-citation></ref><ref id="bib0070"><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Durrheim</surname><given-names>DN</given-names></name><name name-style="western"><surname>Gostin</surname><given-names>LO</given-names></name><name name-style="western"><surname>Moodley</surname><given-names>K.</given-names></name></person-group><article-title>When does a major outbreak become a public health emergency of international concern?</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>887</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30401-1</pub-id><pub-id pub-id-type="pmid">32442526</pub-id><pub-id pub-id-type="pmcid">PMC7237181</pub-id></element-citation></ref><ref id="bib0071"><mixed-citation publication-type="other" id="sbref0071">European Federation of Pharmaceutical Industries and Associations (EFPIA). Health systems after COVID-19. A perspective on the future of European health systems. 2021. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwjQ-tPdj-3yAhUNHcAKHY0BCgQQFnoECCAQAQ&amp;url=https%3A%2F%2Fwww.efpia.eu%2Fmedia%2F602847%2Fhealth-systems-after-covid-19_en.pdf&amp;usg=AOvVaw374s2OdtBAx9zStoyh-ZSL" id="interref0018">https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwjQ-tPdj-3yAhUNHcAKHY0BCgQQFnoECCAQAQ&amp;url=https%3A%2F%2Fwww.efpia.eu%2Fmedia%2F602847%2Fhealth-systems-after-covid-19_en.pdf&amp;usg=AOvVaw374s2OdtBAx9zStoyh-ZSL</ext-link> (accessed September 2021).</mixed-citation></ref><ref id="bib0072"><element-citation publication-type="journal" id="sbref0072"><person-group person-group-type="author"><name name-style="western"><surname>Farina</surname><given-names>SF</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GP</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>ZQ</given-names></name><etal/></person-group><article-title>Replication-defective vector based on a chimpanzee adenovirus</article-title><source>J Virol</source><volume>75</volume><year>2001</year><fpage>11603</fpage><lpage>11613</lpage><pub-id pub-id-type="doi">10.1128/jvi.75.23.11603-11613.2001</pub-id><pub-id pub-id-type="pmid">11689642</pub-id><pub-id pub-id-type="pmcid">PMC114747</pub-id></element-citation></ref><ref id="bib0073"><element-citation publication-type="journal" id="sbref0073"><person-group person-group-type="author"><name name-style="western"><surname>Faust</surname><given-names>JS</given-names></name><name name-style="western"><surname>Del Rio</surname><given-names>C.</given-names></name></person-group><article-title>Assessment of deaths from COVID-19 and from seasonal influenza</article-title><source>JAMA Intern Med</source><volume>180</volume><year>2020</year><fpage>1045</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2020.2306</pub-id><pub-id pub-id-type="pmid">32407441</pub-id></element-citation></ref><ref id="bib0074"><element-citation publication-type="journal" id="sbref0074"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>KA</given-names></name><name name-style="western"><surname>Bloomstone</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Walder</surname><given-names>J</given-names></name><etal/></person-group><article-title>Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. adults</article-title><source>Ann Intern Med</source><volume>173</volume><year>2020</year><fpage>964</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.7326/m20-3569</pub-id><pub-id pub-id-type="pmid">32886525</pub-id><pub-id pub-id-type="pmcid">PMC7505019</pub-id></element-citation></ref><ref id="bib0075"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name name-style="western"><surname>Forni</surname><given-names>D</given-names></name><name name-style="western"><surname>Cagliani</surname><given-names>R</given-names></name><name name-style="western"><surname>Clerici</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular evolution of human coronavirus genomes</article-title><source>Trends Microbiol</source><volume>25</volume><year>2017</year><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.09.001</pub-id><pub-id pub-id-type="pmid">27743750</pub-id><pub-id pub-id-type="pmcid">PMC7111218</pub-id></element-citation></ref><ref id="bib0076"><element-citation publication-type="journal" id="sbref0076"><person-group person-group-type="author"><name name-style="western"><surname>Freeman</surname><given-names>D</given-names></name><name name-style="western"><surname>Waite</surname><given-names>F</given-names></name><name name-style="western"><surname>Rosebrock</surname><given-names>L</given-names></name><etal/></person-group><article-title>Coronavirus conspiracy beliefs, mistrust, and compliance with government guidelines in England</article-title><source>Psychol Med</source><year>2020</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1017/S0033291720001890</pub-id><pub-id pub-id-type="pmcid">PMC7264452</pub-id><pub-id pub-id-type="pmid">32436485</pub-id></element-citation></ref><ref id="bib0077"><element-citation publication-type="journal" id="sbref0077"><person-group person-group-type="author"><name name-style="western"><surname>French</surname><given-names>J</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>S</given-names></name><name name-style="western"><surname>Evans</surname><given-names>W</given-names></name><etal/></person-group><article-title>Key guidelines in developing a pre-emptive COVID-19 vaccination uptake promotion strategy</article-title><source>Int J Environ Res Public Health</source><volume>17</volume><year>2020</year><fpage>5893</fpage><pub-id pub-id-type="doi">10.3390/ijerph17165893</pub-id><pub-id pub-id-type="pmid">32823775</pub-id><pub-id pub-id-type="pmcid">PMC7459701</pub-id></element-citation></ref><ref id="bib0078"><element-citation publication-type="journal" id="sbref0078"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>M</given-names></name><name name-style="western"><surname>Piernas</surname><given-names>C</given-names></name><name name-style="western"><surname>Astbury</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study</article-title><source>Lancet Diabetes Endocrinol</source><volume>9</volume><year>2021</year><fpage>350</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(21)00089-9</pub-id><pub-id pub-id-type="pmid">33932335</pub-id><pub-id pub-id-type="pmcid">PMC8081400</pub-id></element-citation></ref><ref id="bib0079"><element-citation publication-type="journal" id="sbref0079"><person-group person-group-type="author"><name name-style="western"><surname>Gibb</surname><given-names>R</given-names></name><name name-style="western"><surname>Redding</surname><given-names>DW</given-names></name><name name-style="western"><surname>Chin</surname><given-names>KQ</given-names></name><etal/></person-group><article-title>Zoonotic host diversity increases in human-dominated ecosystems</article-title><source>Nature</source><volume>584</volume><year>2020</year><fpage>398</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2562-8</pub-id><pub-id pub-id-type="pmid">32759999</pub-id></element-citation></ref><ref id="bib0080"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>JR</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Ely</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections</article-title><source>Arch Pathol Lab Med</source><volume>134</volume><year>2010</year><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1043/1543-2165-134.2.235</pub-id><pub-id pub-id-type="pmid">20121613</pub-id><pub-id pub-id-type="pmcid">PMC2819217</pub-id></element-citation></ref><ref id="bib0081"><element-citation publication-type="journal" id="sbref0081"><person-group person-group-type="author"><name name-style="western"><surname>Gilmour</surname><given-names>H</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>N.</given-names></name></person-group><article-title>H1N1 vaccination</article-title><source>Health Rep</source><volume>21</volume><year>2010</year><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">21269013</pub-id></element-citation></ref><ref id="bib0082"><mixed-citation publication-type="other" id="sbref0082">GISAID. 2021. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gisaid.org" id="interref0019">https://www.gisaid.org</ext-link> (accessed March 2021).</mixed-citation></ref><ref id="bib0083"><mixed-citation publication-type="other" id="sbref0083">Global Virome Project. Preparing for the next pandemic. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.globalviromeproject.org" id="interref0020">www.globalviromeproject.org</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0084"><element-citation publication-type="journal" id="sbref0084"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>BS.</given-names></name></person-group><article-title>Rapid COVID-19 vaccine development</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>945</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1126/science.abb8923</pub-id><pub-id pub-id-type="pmid">32385100</pub-id></element-citation></ref><ref id="bib0085"><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>NSN</given-names></name><name name-style="western"><surname>Junghans</surname><given-names>C</given-names></name><name name-style="western"><surname>Downes</surname><given-names>R</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes</article-title><source>J Infect</source><volume>81</volume><year>2020</year><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.05.073</pub-id><pub-id pub-id-type="pmid">32504743</pub-id><pub-id pub-id-type="pmcid">PMC7836316</pub-id></element-citation></ref><ref id="bib0086"><element-citation publication-type="book" id="sbref0086"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>J.</given-names></name></person-group><part-title>The forgotten depression: 1921, the crash that cured itself</part-title><year>2014</year><publisher-name>Simon and Schuster</publisher-name></element-citation></ref><ref id="bib0087"><mixed-citation publication-type="other" id="sbref0087">Greaney A, Loes A, Crawford K, et&#160;al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. bioRxiv: the preprint server for biology 2021. doi: 10.1101/2020.12.31.425021.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2021.02.003</pub-id><pub-id pub-id-type="pmcid">PMC7869748</pub-id><pub-id pub-id-type="pmid">33592168</pub-id></mixed-citation></ref><ref id="bib0088"><element-citation publication-type="journal" id="sbref0088"><person-group person-group-type="author"><name name-style="western"><surname>Greenberg</surname><given-names>SB.</given-names></name></person-group><article-title>Update on human rhinovirus and coronavirus infections</article-title><source>Semin Respir Crit Care Med</source><volume>37</volume><year>2016</year><fpage>555</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1055/s-0036-1584797</pub-id><pub-id pub-id-type="pmid">27486736</pub-id><pub-id pub-id-type="pmcid">PMC7171723</pub-id></element-citation></ref><ref id="bib0089"><element-citation publication-type="journal" id="sbref0089"><person-group person-group-type="author"><name name-style="western"><surname>Gregg</surname><given-names>MB</given-names></name><name name-style="western"><surname>Hinman</surname><given-names>AR</given-names></name><name name-style="western"><surname>Craven</surname><given-names>RB.</given-names></name></person-group><article-title>The Russian flu. Its history and implications for this year's influenza season</article-title><source>JAMA</source><volume>240</volume><year>1978</year><fpage>2260</fpage><lpage>2263</lpage><pub-id pub-id-type="pmid">702749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.240.21.2260</pub-id></element-citation></ref><ref id="bib0090"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></name><etal/></person-group><article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>1489</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmid">32473127</pub-id><pub-id pub-id-type="pmcid">PMC7237901</pub-id></element-citation></ref><ref id="bib0091"><element-citation publication-type="journal" id="sbref0091"><person-group person-group-type="author"><name name-style="western"><surname>Grubaugh</surname><given-names>ND</given-names></name><name name-style="western"><surname>Ladner</surname><given-names>JT</given-names></name><name name-style="western"><surname>Lemey</surname><given-names>P</given-names></name><etal/></person-group><article-title>Tracking virus outbreaks in the twenty-first century</article-title><source>Nat Microbiol</source><volume>4</volume><year>2019</year><fpage>10</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0296-2</pub-id><pub-id pub-id-type="pmid">30546099</pub-id><pub-id pub-id-type="pmcid">PMC6345516</pub-id></element-citation></ref><ref id="bib0092"><element-citation publication-type="journal" id="sbref0092"><person-group person-group-type="author"><name name-style="western"><surname>Hancock</surname><given-names>K</given-names></name><name name-style="western"><surname>Veguilla</surname><given-names>V</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus</article-title><source>N Engl J Med</source><volume>361</volume><year>2009</year><fpage>1945</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0906453</pub-id><pub-id pub-id-type="pmid">19745214</pub-id></element-citation></ref><ref id="bib0093"><element-citation publication-type="journal" id="sbref0093"><person-group person-group-type="author"><name name-style="western"><surname>Haug</surname><given-names>N</given-names></name><name name-style="western"><surname>Geyrhofer</surname><given-names>L</given-names></name><name name-style="western"><surname>Londei</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ranking the effectiveness of worldwide COVID-19 government interventions</article-title><source>Nat Hum Behav</source><volume>4</volume><year>2020</year><fpage>1303</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1038/s41562-020-01009-0</pub-id><pub-id pub-id-type="pmid">33199859</pub-id></element-citation></ref><ref id="bib0094"><element-citation publication-type="journal" id="sbref0094"><person-group person-group-type="author"><name name-style="western"><surname>Haviari</surname><given-names>S</given-names></name><name name-style="western"><surname>B&#233;net</surname><given-names>T</given-names></name><name name-style="western"><surname>Saadatian-Elahi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vaccination of healthcare workers: a review</article-title><source>Hum Vaccin Immunother</source><volume>11</volume><year>2015</year><fpage>2522</fpage><lpage>2537</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1082014</pub-id><pub-id pub-id-type="pmid">26291642</pub-id><pub-id pub-id-type="pmcid">PMC4685699</pub-id></element-citation></ref><ref id="bib0095"><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>FG</given-names></name><name name-style="western"><surname>Sugaya</surname><given-names>N</given-names></name><name name-style="western"><surname>Hirotsu</surname><given-names>N</given-names></name><etal/></person-group><article-title>Baloxavir marboxil for uncomplicated influenza in adults and adolescents</article-title><source>N Engl J Med</source><volume>379</volume><year>2018</year><fpage>913</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1716197</pub-id><pub-id pub-id-type="pmid">30184455</pub-id></element-citation></ref><ref id="bib0096"><element-citation publication-type="journal" id="sbref0096"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name><name name-style="western"><surname>Galiza</surname><given-names>EP</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>DN</given-names></name><etal/></person-group><article-title>Safety and efficacy of NVX-CoV2373 Covid-19 vaccine</article-title><source>N Engl J Med</source><year>2021</year><pub-id pub-id-type="doi">10.1056/NEJMoa2107659</pub-id><pub-id pub-id-type="pmcid">PMC8262625</pub-id><pub-id pub-id-type="pmid">34192426</pub-id></element-citation></ref><ref id="bib0097"><element-citation publication-type="journal" id="sbref0097"><person-group person-group-type="author"><name name-style="western"><surname>Heaton</surname><given-names>NS</given-names></name><name name-style="western"><surname>Sachs</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins</article-title><source>Proc Natl Acad Sci USA</source><volume>110</volume><year>2013</year><fpage>20248</fpage><lpage>20253</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320524110</pub-id><pub-id pub-id-type="pmid">24277853</pub-id><pub-id pub-id-type="pmcid">PMC3864309</pub-id></element-citation></ref><ref id="bib0098"><element-citation publication-type="journal" id="sbref0098"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>DA</given-names></name><name name-style="western"><surname>Courtney</surname><given-names>B</given-names></name><name name-style="western"><surname>Inglesby</surname><given-names>TV</given-names></name><etal/></person-group><article-title>Public health and medical responses to the 1957&#8211;58 influenza pandemic</article-title><source>Biosecur Bioterror</source><volume>7</volume><year>2009</year><fpage>265</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1089/bsp.2009.0729</pub-id><pub-id pub-id-type="pmid">19656012</pub-id></element-citation></ref><ref id="bib0099"><element-citation publication-type="journal" id="sbref0099"><person-group person-group-type="author"><name name-style="western"><surname>Hershberger</surname><given-names>E</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>S</given-names></name><name name-style="western"><surname>Narayan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study</article-title><source>EBioMedicine</source><volume>40</volume><year>2019</year><fpage>574</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.12.051</pub-id><pub-id pub-id-type="pmid">30638863</pub-id><pub-id pub-id-type="pmcid">PMC6412085</pub-id></element-citation></ref><ref id="bib0100"><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name name-style="western"><surname>Honigsbaum</surname><given-names>M.</given-names></name></person-group><article-title>Revisiting the 1957 and 1968 influenza pandemics</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1824</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)31201-0</pub-id><pub-id pub-id-type="pmid">32464113</pub-id><pub-id pub-id-type="pmcid">PMC7247790</pub-id></element-citation></ref><ref id="bib0101"><element-citation publication-type="journal" id="sbref0101"><person-group person-group-type="author"><name name-style="western"><surname>Horby</surname><given-names>P</given-names></name><name name-style="western"><surname>Lim</surname><given-names>WS</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Dexamethasone in hospitalized patients with Covid-19 &#8211; preliminary report</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id><pub-id pub-id-type="pmcid">PMC7383595</pub-id><pub-id pub-id-type="pmid">32678530</pub-id></element-citation></ref><ref id="bib0102"><element-citation publication-type="journal" id="sbref0102"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Ge</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Bat origin of human coronaviruses</article-title><source>Virol J</source><volume>12</volume><year>2015</year><fpage>221</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0422-1</pub-id><pub-id pub-id-type="pmid">26689940</pub-id><pub-id pub-id-type="pmcid">PMC4687304</pub-id></element-citation></ref><ref id="bib0103"><element-citation publication-type="journal" id="sbref0103"><person-group person-group-type="author"><name name-style="western"><surname>Ikematsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>FG</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Baloxavir marboxil for prophylaxis against influenza in household contacts</article-title><source>N Engl J Med</source><volume>383</volume><year>2020</year><fpage>309</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1915341</pub-id><pub-id pub-id-type="pmid">32640124</pub-id></element-citation></ref><ref id="bib0104"><element-citation publication-type="journal" id="sbref0104"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>MS</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>T</given-names></name><name name-style="western"><surname>Khan</surname><given-names>SH</given-names></name><etal/></person-group><article-title>COVID-19-related infodemic and its impact on public health: a global social media analysis</article-title><source>Am J Trop Med Hyg</source><volume>103</volume><year>2020</year><fpage>1621</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.20-0812</pub-id><pub-id pub-id-type="pmid">32783794</pub-id><pub-id pub-id-type="pmcid">PMC7543839</pub-id></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>MS</given-names></name><name name-style="western"><surname>Mostofa Kamal</surname><given-names>A-H</given-names></name><name name-style="western"><surname>Kabir</surname><given-names>A</given-names></name><etal/></person-group><article-title>COVID-19 vaccine rumors and conspiracy theories: The need for cognitive inoculation against misinformation to improve vaccine adherence</article-title><source>PLoS One</source><volume>16</volume><year>2021</year><object-id pub-id-type="publisher-id">e0251605</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0251605</pub-id><pub-id pub-id-type="pmcid">PMC8115834</pub-id><pub-id pub-id-type="pmid">33979412</pub-id></element-citation></ref><ref id="bib0106"><element-citation publication-type="journal" id="sbref0106"><person-group person-group-type="author"><name name-style="western"><surname>Ison</surname><given-names>MG</given-names></name><name name-style="western"><surname>Portsmouth</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>1204</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30004-9</pub-id><pub-id pub-id-type="pmid">32526195</pub-id></element-citation></ref><ref id="bib0107"><element-citation publication-type="book" id="sbref0107"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>S</given-names></name><name name-style="western"><surname>Sargent</surname><given-names>T.</given-names></name></person-group><part-title>The economic impact of an influenza pandemic</part-title><source>Working paper 2004&#8211;2007</source><year>2006</year><comment>Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dsp-psd.pwgsc.gc.ca/collection_2008/fin/F21-8-2007-4E.pdf" id="interref0021">http://dsp-psd.pwgsc.gc.ca/collection_2008/fin/F21-8-2007-4E.pdf</ext-link><comment>(accessed September 2020)</comment></element-citation></ref><ref id="bib0108"><element-citation publication-type="journal" id="sbref0108"><person-group person-group-type="author"><name name-style="western"><surname>Jefferson</surname><given-names>T</given-names></name><name name-style="western"><surname>Jones</surname><given-names>MA</given-names></name><name name-style="western"><surname>Doshi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children</article-title><source>Cochrane Database Syst Rev</source><volume>2014</volume><year>2014</year><object-id pub-id-type="publisher-id">Cd008965</object-id><pub-id pub-id-type="doi">10.1002/14651858.CD008965.pub4</pub-id><pub-id pub-id-type="pmcid">PMC10941719</pub-id><pub-id pub-id-type="pmid">20166059</pub-id></element-citation></ref><ref id="bib0109"><element-citation publication-type="journal" id="sbref0109"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>KE</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>FL</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>RQ</given-names></name></person-group><article-title>Influenza, 1957: a variant and the pandemic</article-title><source>Prog Med Virol</source><volume>1</volume><year>1958</year><fpage>165</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">13579008</pub-id></element-citation></ref><ref id="bib0110"><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name name-style="western"><surname>Jeyanathan</surname><given-names>M</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>S</given-names></name><name name-style="western"><surname>Smaill</surname><given-names>F</given-names></name><etal/></person-group><article-title>Immunological considerations for COVID-19 vaccine strategies</article-title><source>Nat Rev Immunol</source><volume>20</volume><year>2020</year><fpage>615</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00434-6</pub-id><pub-id pub-id-type="pmid">32887954</pub-id><pub-id pub-id-type="pmcid">PMC7472682</pub-id></element-citation></ref><ref id="bib0111"><element-citation publication-type="journal" id="sbref0111"><person-group person-group-type="author"><name name-style="western"><surname>Jhung</surname><given-names>MA</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>D</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Epidemiology of 2009 pandemic influenza A (H1N1) in the United States</article-title><source>Clin Infect Dis</source><volume>52</volume><issue>Suppl 1</issue><year>2011</year><fpage>S13</fpage><lpage>S26</lpage><pub-id pub-id-type="doi">10.1093/cid/ciq008</pub-id><pub-id pub-id-type="pmid">21342884</pub-id></element-citation></ref><ref id="bib0114"><element-citation publication-type="journal" id="sbref0114"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>NP</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>J.</given-names></name></person-group><article-title>Updating the accounts: global mortality of the 1918&#8211;1920 "Spanish" influenza pandemic</article-title><source>Bull Hist Med</source><volume>76</volume><year>2002</year><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1353/bhm.2002.0022</pub-id><pub-id pub-id-type="pmid">11875246</pub-id></element-citation></ref><ref id="bib0115"><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>KE</given-names></name><name name-style="western"><surname>Patel</surname><given-names>NG</given-names></name><name name-style="western"><surname>Levy</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Global trends in emerging infectious diseases</article-title><source>Nature</source><volume>451</volume><year>2008</year><fpage>990</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1038/nature06536</pub-id><pub-id pub-id-type="pmid">18288193</pub-id><pub-id pub-id-type="pmcid">PMC5960580</pub-id></element-citation></ref><ref id="bib0116"><element-citation publication-type="book" id="sbref0116"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>EO.</given-names></name></person-group><part-title>Epidemic influenza: a survey</part-title><year>1927</year><publisher-name>American Medical Association</publisher-name><publisher-loc>Chicago</publisher-loc></element-citation></ref><ref id="bib0117"><element-citation publication-type="journal" id="sbref0117"><person-group person-group-type="author"><name name-style="western"><surname>Kaminski</surname><given-names>DA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>FE.</given-names></name></person-group><article-title>Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design</article-title><source>Front Immunol</source><volume>2</volume><year>2011</year><fpage>76</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2011.00076</pub-id><pub-id pub-id-type="pmid">22566865</pub-id><pub-id pub-id-type="pmcid">PMC3342000</pub-id></element-citation></ref><ref id="bib0118"><element-citation publication-type="journal" id="sbref0118"><person-group person-group-type="author"><name name-style="western"><surname>Karlinsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Kobak</surname><given-names>D.</given-names></name></person-group><article-title>Tracking excess mortality across countries during the COVID-119 pandemic with the World Mortality Dataset</article-title><source>eLife</source><volume>10</volume><year>2021</year><fpage>e69336</fpage><pub-id pub-id-type="doi">10.7554/eLife.69336</pub-id><pub-id pub-id-type="pmid">34190045</pub-id><pub-id pub-id-type="pmcid">PMC8331176</pub-id></element-citation></ref><ref id="bib0119"><element-citation publication-type="journal" id="sbref0119"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I</given-names></name><etal/></person-group><article-title>Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N Engl J Med</source><volume>383</volume><year>2020</year><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation></ref><ref id="bib0120"><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>JR</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>CR</given-names></name><name name-style="western"><surname>Recchia</surname><given-names>G</given-names></name><etal/></person-group><article-title>Correlates of intended COVID-19 vaccine acceptance across time and countries: results from a series of cross-sectional surveys</article-title><source>BMJ Open</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">e048021</object-id><pub-id pub-id-type="doi">10.1136/bmjopen-2020-048025</pub-id><pub-id pub-id-type="pmcid">PMC8331327</pub-id><pub-id pub-id-type="pmid">34341047</pub-id></element-citation></ref><ref id="bib0121"><element-citation publication-type="journal" id="sbref0121"><person-group person-group-type="author"><name name-style="western"><surname>Kilbourne</surname><given-names>ED.</given-names></name></person-group><article-title>Influenza: viral determinants of the pathogenicity and epidemicity of an invariant disease of variable occurrence</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><volume>288</volume><year>1980</year><fpage>291</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1098/rstb.1980.0004</pub-id><pub-id pub-id-type="pmid">6103545</pub-id></element-citation></ref><ref id="bib0122"><element-citation publication-type="journal" id="sbref0122"><person-group person-group-type="author"><name name-style="western"><surname>Kilbourne</surname><given-names>ED.</given-names></name></person-group><article-title>Influenza pandemics of the 20th century</article-title><source>Emerg Infect Dis</source><volume>12</volume><year>2006</year><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3201/eid1201.051254</pub-id><pub-id pub-id-type="pmid">16494710</pub-id><pub-id pub-id-type="pmcid">PMC3291411</pub-id></element-citation></ref><ref id="bib0123"><element-citation publication-type="journal" id="sbref0123"><person-group person-group-type="author"><name name-style="western"><surname>Kirkpatrick</surname><given-names>E</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>PC</given-names></name><etal/></person-group><article-title>The influenza virus hemagglutinin head evolves faster than the stalk domain</article-title><source>Sci Rep</source><volume>8</volume><year>2018</year><fpage>10432</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-28706-1</pub-id><pub-id pub-id-type="pmid">29992986</pub-id><pub-id pub-id-type="pmcid">PMC6041311</pub-id></element-citation></ref><ref id="bib0124"><element-citation publication-type="journal" id="sbref0124"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 vaccines in development</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>516</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2798-3</pub-id><pub-id pub-id-type="pmid">32967006</pub-id></element-citation></ref><ref id="bib0125"><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name name-style="western"><surname>Kupferschmidt</surname><given-names>K.</given-names></name></person-group><article-title>New coronavirus variants could cause more reinfections, require updated vaccines</article-title><source>Science</source><year>2021</year><pub-id pub-id-type="doi">10.1126/science.abg6028</pub-id></element-citation></ref><ref id="bib0126"><element-citation publication-type="journal" id="sbref0126"><person-group person-group-type="author"><name name-style="western"><surname>Lal</surname><given-names>A</given-names></name><name name-style="western"><surname>Erondu</surname><given-names>NE</given-names></name><name name-style="western"><surname>Heymann</surname><given-names>DL</given-names></name><name name-style="western"><surname>Gitahi</surname><given-names>G</given-names></name><name name-style="western"><surname>Yates</surname><given-names>R.</given-names></name></person-group><article-title>Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage</article-title><source>Lancet</source><volume>397</volume><year>2021</year><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32228-5</pub-id><pub-id pub-id-type="pmid">33275906</pub-id><pub-id pub-id-type="pmcid">PMC7834479</pub-id></element-citation></ref><ref id="bib0127"><element-citation publication-type="journal" id="sbref0127"><person-group person-group-type="author"><name name-style="western"><surname>Langford</surname><given-names>BJ</given-names></name><name name-style="western"><surname>So</surname><given-names>M</given-names></name><name name-style="western"><surname>Raybardhan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis</article-title><source>Clin Microbiol Infect</source><volume>26</volume><year>2020</year><fpage>1622</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.016</pub-id><pub-id pub-id-type="pmid">32711058</pub-id><pub-id pub-id-type="pmcid">PMC7832079</pub-id></element-citation></ref><ref id="bib0128"><element-citation publication-type="journal" id="sbref0128"><person-group person-group-type="author"><name name-style="western"><surname>Lauring</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hodcroft</surname><given-names>EB.</given-names></name></person-group><article-title>Genetic variants of SARS-CoV-2 &#8211; what do they mean?</article-title><source>JAMA</source><year>2021</year><pub-id pub-id-type="doi">10.1001/jama.2020.27124</pub-id><pub-id pub-id-type="pmid">33404586</pub-id></element-citation></ref><ref id="bib0129"><element-citation publication-type="journal" id="sbref0129"><person-group person-group-type="author"><name name-style="western"><surname>Lavine</surname><given-names>JS</given-names></name><name name-style="western"><surname>Bjornstad</surname><given-names>ON</given-names></name><name name-style="western"><surname>Antia</surname><given-names>R.</given-names></name></person-group><article-title>Immunological characteristics govern the transition of COVID-19 to endemicity</article-title><source>Science</source><year>2021</year><fpage>eabe6522</fpage><pub-id pub-id-type="doi">10.1126/science.abe6522</pub-id><pub-id pub-id-type="pmcid">PMC7932103</pub-id><pub-id pub-id-type="pmid">33436525</pub-id></element-citation></ref><ref id="bib0130"><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike proteins</article-title><source>Annu Rev Virol</source><volume>3</volume><year>2016</year><fpage>237</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-110615-042301</pub-id><pub-id pub-id-type="pmid">27578435</pub-id><pub-id pub-id-type="pmcid">PMC5457962</pub-id></element-citation></ref><ref id="bib0131"><element-citation publication-type="journal" id="sbref0131"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><etal/></person-group><article-title>Asymptomatic and presymptomatic infectors: hidden sources of COVID-19 disease</article-title><source>Clin Infect Dis</source><volume>71</volume><year>2020</year><fpage>2018</fpage><pub-id pub-id-type="doi">10.1093/cid/ciaa418</pub-id><pub-id pub-id-type="pmid">32271372</pub-id><pub-id pub-id-type="pmcid">PMC7184467</pub-id></element-citation></ref><ref id="bib0132"><element-citation publication-type="journal" id="sbref0132"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bats are natural reservoirs of SARS-like coronaviruses</article-title><source>Science</source><volume>310</volume><year>2005</year><fpage>676</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1126/science.1118391</pub-id><pub-id pub-id-type="pmid">16195424</pub-id></element-citation></ref><ref id="bib0133"><element-citation publication-type="journal" id="sbref0133"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>IT</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Predicting super spreading events during the 2003 severe acute respiratory syndrome epidemics in Hong Kong and Singapore</article-title><source>Am J Epidemiol</source><volume>160</volume><year>2004</year><fpage>719</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1093/aje/kwh273</pub-id><pub-id pub-id-type="pmid">15466494</pub-id><pub-id pub-id-type="pmcid">PMC7109976</pub-id></element-citation></ref><ref id="bib0134"><element-citation publication-type="journal" id="sbref0134"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title><source>Nat Med</source><volume>26</volume><year>2020</year><fpage>842</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><pub-id pub-id-type="pmid">32398875</pub-id></element-citation></ref><ref id="bib0135"><mixed-citation publication-type="other" id="sbref0135">Linka K, Peirlinck M, Kuhl E. The reproduction number of COVID-19 and its correlation with public health interventions. medRxiv: the preprint server for health sciences 2020. doi: 10.1101/2020.05.01.20088047.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00466-020-01880-8</pub-id><pub-id pub-id-type="pmcid">PMC7385940</pub-id><pub-id pub-id-type="pmid">32836597</pub-id></mixed-citation></ref><ref id="bib0136"><element-citation publication-type="journal" id="sbref0136"><person-group person-group-type="author"><name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>T</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>B</given-names></name><etal/></person-group><article-title>Transmission dynamics and control of severe acute respiratory syndrome</article-title><source>Science</source><volume>300</volume><year>2003</year><fpage>1966</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1126/science.1086616</pub-id><pub-id pub-id-type="pmid">12766207</pub-id><pub-id pub-id-type="pmcid">PMC2760158</pub-id></element-citation></ref><ref id="bib0137"><element-citation publication-type="journal" id="sbref0137"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></name><etal/></person-group><article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</article-title><source>Lancet</source><year>2021</year><pub-id pub-id-type="doi">10.1016/s0140-6736(21)00234-8</pub-id><comment>S0140&#8211;6736(21)00234-8</comment><pub-id pub-id-type="pmcid">PMC7852454</pub-id><pub-id pub-id-type="pmid">33545094</pub-id></element-citation></ref><ref id="bib0138"><element-citation publication-type="journal" id="sbref0138"><person-group person-group-type="author"><name name-style="western"><surname>Louie</surname><given-names>JK</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>M</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Severe 2009 H1N1 influenza in pregnant and postpartum women in California</article-title><source>N Engl J Med</source><volume>362</volume><year>2010</year><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0910444</pub-id><pub-id pub-id-type="pmid">20032319</pub-id></element-citation></ref><ref id="bib0139"><element-citation publication-type="journal" id="sbref0139"><person-group person-group-type="author"><name name-style="western"><surname>Luke</surname><given-names>TC</given-names></name><name name-style="western"><surname>Kilbane</surname><given-names>EM</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?</article-title><source>Ann Intern Med</source><volume>145</volume><year>2006</year><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-145-8-200610170-00139</pub-id><pub-id pub-id-type="pmid">16940336</pub-id></element-citation></ref><ref id="bib0140"><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></name><etal/></person-group><article-title>Developing Covid-19 vaccines at pandemic speed</article-title><source>N Engl J Med</source><volume>382</volume><year>2020</year><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2005630</pub-id><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="bib0141"><element-citation publication-type="book" id="sbref0141"><person-group person-group-type="author"><name name-style="western"><surname>Madhav</surname><given-names>N</given-names></name><name name-style="western"><surname>Oppenheim</surname><given-names>B</given-names></name><name name-style="western"><surname>Gallivan</surname><given-names>M</given-names></name><etal/></person-group><part-title>Pandemics: risks, impacts, and mitigation</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Jamison</surname><given-names>DT</given-names></name><name name-style="western"><surname>Gelband</surname><given-names>H</given-names></name><name name-style="western"><surname>Horton</surname><given-names>S</given-names></name><name name-style="western"><surname>Jha</surname><given-names>P</given-names></name><name name-style="western"><surname>Laxminarayan</surname><given-names>R</given-names></name><name name-style="western"><surname>Mock</surname><given-names>CN</given-names></name><name name-style="western"><surname>Nugent</surname><given-names>R</given-names></name></person-group><source>Disease control priorities: improving health and reducing poverty</source><year>2017 Nov 27</year><publisher-name>The International Bank for Reconstruction and Development /The World Bank</publisher-name><publisher-loc>Washington (DC)</publisher-loc><comment>Chapter 17</comment><pub-id pub-id-type="pmid">30212058</pub-id></element-citation></ref><ref id="bib0142"><element-citation publication-type="journal" id="sbref0142"><person-group person-group-type="author"><name name-style="western"><surname>Mair-Jenkins</surname><given-names>J</given-names></name><name name-style="western"><surname>Saavedra-Campos</surname><given-names>M</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>JK</given-names></name><etal/></person-group><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title><source>J Infect Dis</source><volume>211</volume><year>2015</year><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu396</pub-id><pub-id pub-id-type="pmid">25030060</pub-id><pub-id pub-id-type="pmcid">PMC4264590</pub-id></element-citation></ref><ref id="bib0143"><element-citation publication-type="journal" id="sbref0143"><person-group person-group-type="author"><name name-style="western"><surname>Mallapaty</surname><given-names>S.</given-names></name></person-group><article-title>Coronaviruses closely related to the pandemic virus discovered in Japan and Cambodia</article-title><source>Nature</source><volume>588</volume><year>2020</year><fpage>15</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-03217-0</pub-id><pub-id pub-id-type="pmid">33230273</pub-id></element-citation></ref><ref id="bib0144"><element-citation publication-type="journal" id="sbref0144"><person-group person-group-type="author"><name name-style="western"><surname>Mamelund</surname><given-names>S</given-names></name><name name-style="western"><surname>Sattenspiel</surname><given-names>L</given-names></name><name name-style="western"><surname>Dimka</surname><given-names>J.</given-names></name></person-group><article-title>Influenza-associated mortality during the 1918&#8211;1919 influenza pandemic in Alaska and Labrador</article-title><source>Soc Sci Hist</source><volume>37</volume><year>2013</year><fpage>177</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1215/01455532-2074420</pub-id></element-citation></ref><ref id="bib0145"><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name name-style="western"><surname>Markel</surname><given-names>H</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>HB</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Nonpharmaceutical interventions implemented by US cities during the 1918&#8211;1919 influenza pandemic</article-title><source>JAMA</source><volume>298</volume><year>2007</year><fpage>644</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1001/jama.298.6.644</pub-id><pub-id pub-id-type="pmid">17684187</pub-id></element-citation></ref><ref id="bib0146"><element-citation publication-type="journal" id="sbref0146"><person-group person-group-type="author"><name name-style="western"><surname>Marston</surname><given-names>HD</given-names></name><name name-style="western"><surname>Paules</surname><given-names>CI</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS.</given-names></name></person-group><article-title>The critical role of biomedical research in pandemic preparedness</article-title><source>JAMA</source><volume>318</volume><year>2017</year><fpage>1757</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.15033</pub-id><pub-id pub-id-type="pmid">28979970</pub-id></element-citation></ref><ref id="bib0147"><element-citation publication-type="journal" id="sbref0147"><person-group person-group-type="author"><name name-style="western"><surname>Marwah</surname><given-names>HK</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>K</given-names></name><name name-style="western"><surname>Rosseau</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Videos, views, and vaccines: evaluating the quality of COVID-19 communications on YouTube</article-title><source>Disaster Med Public Health Prep</source><year>2021</year><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1017/dmp.2021.284</pub-id><pub-id pub-id-type="pmcid">PMC8529354</pub-id><pub-id pub-id-type="pmid">34462047</pub-id></element-citation></ref><ref id="bib0148"><element-citation publication-type="journal" id="sbref0148"><person-group person-group-type="author"><name name-style="western"><surname>McAteer</surname><given-names>J</given-names></name><name name-style="western"><surname>Yildirim</surname><given-names>I</given-names></name><name name-style="western"><surname>Chahroudi</surname><given-names>A.</given-names></name></person-group><article-title>The VACCINES Act: deciphering vaccine hesitancy in the time of COVID-19</article-title><source>Clin Infect Dis</source><volume>71</volume><year>2020</year><fpage>703</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa433</pub-id><pub-id pub-id-type="pmid">32282038</pub-id><pub-id pub-id-type="pmcid">PMC7184475</pub-id></element-citation></ref><ref id="bib0149"><element-citation publication-type="journal" id="sbref0149"><person-group person-group-type="author"><name name-style="western"><surname>McBride</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>T</given-names></name><etal/></person-group><article-title>Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model</article-title><source>Antimicrob Agents Chemother</source><volume>61</volume><year>2017</year><fpage>e01154</fpage><lpage>e01217</lpage><pub-id pub-id-type="doi">10.1128/aac.01154-17</pub-id><pub-id pub-id-type="pmcid">PMC5655070</pub-id><pub-id pub-id-type="pmid">28807912</pub-id></element-citation></ref><ref id="bib0150"><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name name-style="western"><surname>McElrath</surname><given-names>MJ</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>SC</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>Z</given-names></name><etal/></person-group><article-title>HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis</article-title><source>Lancet</source><volume>372</volume><year>2008</year><fpage>1894</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(08)61592-5</pub-id><pub-id pub-id-type="pmid">19012957</pub-id><pub-id pub-id-type="pmcid">PMC2774110</pub-id></element-citation></ref><ref id="bib0151"><element-citation publication-type="journal" id="sbref0151"><person-group person-group-type="author"><name name-style="western"><surname>Meyerowitz-Katz</surname><given-names>G</given-names></name><name name-style="western"><surname>Merone</surname><given-names>L.</given-names></name></person-group><article-title>A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates</article-title><source>Int J Infect Dis</source><volume>101</volume><year>2020</year><fpage>138</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.09.1464</pub-id><pub-id pub-id-type="pmid">33007452</pub-id><pub-id pub-id-type="pmcid">PMC7524446</pub-id></element-citation></ref><ref id="bib0152"><mixed-citation publication-type="other" id="sbref0152">Milken Institute. COVID-19 treatment and vaccine tracker. 2021. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covid-19tracker.milkeninstitute.org/" id="interref0024">https://covid-19tracker.milkeninstitute.org/</ext-link> (accessed March 2021).</mixed-citation></ref><ref id="bib0153"><element-citation publication-type="journal" id="sbref0153"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>A</given-names></name><name name-style="western"><surname>Oliphant</surname><given-names>JB.</given-names></name></person-group><article-title>Americans immersed in COVID-19 news; most think media are doing fairly well covering it</article-title><source>Pew Research Center</source><year>2020</year><comment>Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.journalism.org/2020/03/18/americans-immersed-in-covid-19-news-most-think-media-are-doing-fairly-well-covering-it/" id="interref0025">https://www.journalism.org/2020/03/18/americans-immersed-in-covid-19-news-most-think-media-are-doing-fairly-well-covering-it/</ext-link><comment>(accessed September 2021)</comment></element-citation></ref><ref id="bib0154"><element-citation publication-type="journal" id="sbref0154"><person-group person-group-type="author"><name name-style="western"><surname>Morens</surname><given-names>DM</given-names></name><name name-style="western"><surname>Taubenberger</surname><given-names>JK</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS.</given-names></name></person-group><article-title>Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness</article-title><source>J Infect Dis</source><volume>198</volume><year>2008</year><fpage>962</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1086/591708</pub-id><pub-id pub-id-type="pmid">18710327</pub-id><pub-id pub-id-type="pmcid">PMC2599911</pub-id></element-citation></ref><ref id="bib0155"><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name name-style="western"><surname>Morens</surname><given-names>DM</given-names></name><name name-style="western"><surname>Taubenberger</surname><given-names>JK</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>HA</given-names></name><etal/></person-group><article-title>The 1918 influenza pandemic: lessons for 2009 and the future</article-title><source>Crit Care Med</source><volume>38</volume><year>2010</year><fpage>e10</fpage><lpage>e20</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181ceb25b</pub-id><pub-id pub-id-type="pmid">20048675</pub-id><pub-id pub-id-type="pmcid">PMC3180813</pub-id></element-citation></ref><ref id="bib0156"><element-citation publication-type="journal" id="sbref0156"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group><article-title>Emerging infectious diseases: epidemiological perspective</article-title><source>Indian J Dermatol</source><volume>62</volume><issue>5</issue><year>2017</year><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.4103/ijd.IJD_379_17</pub-id><pub-id pub-id-type="pmid">28979007</pub-id><pub-id pub-id-type="pmcid">PMC5618832</pub-id></element-citation></ref><ref id="bib0157"><element-citation publication-type="journal" id="sbref0157"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>LM</given-names></name><name name-style="western"><surname>Gorter</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Hak</surname><given-names>E</given-names></name><etal/></person-group><article-title>Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus</article-title><source>Clin Infect Dis</source><volume>41</volume><year>2005</year><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1086/431587</pub-id><pub-id pub-id-type="pmid">16007521</pub-id></element-citation></ref><ref id="bib0158"><element-citation publication-type="journal" id="sbref0158"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>AD</given-names></name><name name-style="western"><surname>Chin</surname><given-names>B</given-names></name><etal/></person-group><article-title>Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918&#8211;20 pandemic: a quantitative analysis</article-title><source>Lancet</source><volume>368</volume><year>2006</year><fpage>2211</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(06)69895-4</pub-id><pub-id pub-id-type="pmid">17189032</pub-id></element-citation></ref><ref id="bib0159"><mixed-citation publication-type="other" id="sbref0159">National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2021. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.covid19treatmentguidelines.nih.gov/" id="interref0026">https://www.covid19treatmentguidelines.nih.gov/</ext-link> (accessed 31 August). Accessed September 2021.<pub-id pub-id-type="pmid">34003615</pub-id></mixed-citation></ref><ref id="bib0160"><element-citation publication-type="book" id="sbref0160"><person-group person-group-type="author"><name name-style="western"><surname>Nicholson</surname><given-names>A</given-names></name><name name-style="western"><surname>Shah</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>VA.</given-names></name><collab>National Academies of Sciences, Engineering, Medicine</collab></person-group><part-title>Exploring lessons learned from a century of outbreaks: readiness for 2030: proceedings of a workshop</part-title><year>2019</year><publisher-name>National Academies Press (US)</publisher-name><publisher-loc>Washington (DC)</publisher-loc><pub-id pub-id-type="pmid">31310459</pub-id></element-citation></ref><ref id="bib0161"><element-citation publication-type="journal" id="sbref0161"><person-group person-group-type="author"><name name-style="western"><surname>Nishiura</surname><given-names>H</given-names></name><name name-style="western"><surname>Linton</surname><given-names>NM</given-names></name><name name-style="western"><surname>Akhmetzhanov</surname><given-names>AR.</given-names></name></person-group><article-title>Serial interval of novel coronavirus (COVID-19) infections</article-title><source>Int J Infect Dis</source><volume>93</volume><year>2020</year><fpage>284</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.02.060</pub-id><pub-id pub-id-type="pmid">32145466</pub-id><pub-id pub-id-type="pmcid">PMC7128842</pub-id></element-citation></ref><ref id="bib0162"><mixed-citation publication-type="other" id="sbref0162">Ofcom. Half of UK adults exposed to false claims about coronavirus. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ofcom.org.uk/about-ofcom/latest/features-and-news/half-of-uk-adults-exposed-to-false-claims-about-coronavirus" id="interref0027">https://www.ofcom.org.uk/about-ofcom/latest/features-and-news/half-of-uk-adults-exposed-to-false-claims-about-coronavirus</ext-link> (accessed September 2021).</mixed-citation></ref><ref id="bib0163"><element-citation publication-type="journal" id="sbref0163"><person-group person-group-type="author"><name name-style="western"><surname>Ostrowsky</surname><given-names>J</given-names></name><name name-style="western"><surname>Arpey</surname><given-names>M</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K</given-names></name><etal/></person-group><article-title>Tracking progress in universal influenza vaccine development</article-title><source>Curr Opin Virol</source><volume>40</volume><year>2020</year><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2020.02.003</pub-id><pub-id pub-id-type="pmid">32279026</pub-id></element-citation></ref><ref id="bib0164"><element-citation publication-type="journal" id="sbref0164"><person-group person-group-type="author"><name name-style="western"><surname>Padma</surname><given-names>TV.</given-names></name></person-group><article-title>COVID vaccines to reach poorest countries in 2023 - despite recent pledges</article-title><source>Nature</source><volume>595</volume><year>2021</year><fpage>342</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/d41586-021-01762-w</pub-id><pub-id pub-id-type="pmid">34226742</pub-id></element-citation></ref><ref id="bib0165"><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name name-style="western"><surname>Padron-Regalado</surname><given-names>E.</given-names></name></person-group><article-title>Vaccines for SARS-CoV-2: lessons from other coronavirus strains</article-title><source>Infect Dis Ther</source><volume>9</volume><year>2020</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s40121-020-00300-x</pub-id><pub-id pub-id-type="pmid">32328406</pub-id><pub-id pub-id-type="pmcid">PMC7177048</pub-id></element-citation></ref><ref id="bib0166"><element-citation publication-type="journal" id="sbref0166"><person-group person-group-type="author"><name name-style="western"><surname>Palese</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>TT.</given-names></name></person-group><article-title>Why do influenza virus subtypes die out? A hypothesis</article-title><source>mBio</source><volume>2</volume><year>2011</year><fpage>e00150</fpage><lpage>e00211</lpage><pub-id pub-id-type="doi">10.1128/mBio.00150-11</pub-id><pub-id pub-id-type="pmid">21878571</pub-id><pub-id pub-id-type="pmcid">PMC3163940</pub-id></element-citation></ref><ref id="bib0167"><element-citation publication-type="journal" id="sbref0167"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><name name-style="western"><surname>Peto</surname><given-names>R</given-names></name><name name-style="western"><surname>Henao-Restrep</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial results</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>497</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">33264556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2023184</pub-id><pub-id pub-id-type="pmcid">PMC7727327</pub-id></element-citation></ref><ref id="bib0168"><element-citation publication-type="journal" id="sbref0168"><person-group person-group-type="author"><name name-style="western"><surname>Pasquini-Descomps</surname><given-names>H</given-names></name><name name-style="western"><surname>Brender</surname><given-names>N</given-names></name><name name-style="western"><surname>Maradan</surname><given-names>D.</given-names></name></person-group><article-title>Value for money in H1N1 influenza: a systematic review of the cost-effectiveness of pandemic interventions</article-title><source>Value Health</source><volume>20</volume><year>2017</year><fpage>819</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2016.05.005</pub-id><pub-id pub-id-type="pmid">28577700</pub-id></element-citation></ref><ref id="bib0169"><element-citation publication-type="book" id="sbref0169"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>KD.</given-names></name></person-group><part-title>Pandemic influenza, 1700&#8211;1900: a study in historical epidemiology</part-title><year>1986</year><publisher-name>Rowman &amp; Littlefield</publisher-name><publisher-loc>Lanham, MD</publisher-loc></element-citation></ref><ref id="bib0170"><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name name-style="western"><surname>Peeri</surname><given-names>NC</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>N</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>MS</given-names></name><etal/></person-group><article-title>The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?</article-title><source>Int J Epidemiol</source><volume>49</volume><year>2020</year><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1093/ije/dyaa033</pub-id><pub-id pub-id-type="pmid">32086938</pub-id><pub-id pub-id-type="pmcid">PMC7197734</pub-id></element-citation></ref><ref id="bib0171"><mixed-citation publication-type="other" id="sbref0171">Peng Y, Mentzer AJ, Liu G, et&#160;al. Broad and strong memory CD4 (+) and CD8 (+) T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. 2020. bioRxiv 2020 8;2020.06.05.134551. doi: 10.1101/2020.06.05.134551.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-020-0782-6</pub-id><pub-id pub-id-type="pmcid">PMC7611020</pub-id><pub-id pub-id-type="pmid">32887977</pub-id></mixed-citation></ref><ref id="bib0172"><element-citation publication-type="journal" id="sbref0172"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>E</given-names></name><name name-style="western"><surname>Petrosillo</surname><given-names>N</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>M.</given-names></name></person-group><article-title>Emerging infections - an increasingly important topic: review by the Emerging Infections Task Force</article-title><source>Clin Microbiol Infect</source><volume>24</volume><year>2018</year><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2017.10.035</pub-id><pub-id pub-id-type="pmid">29155018</pub-id><pub-id pub-id-type="pmcid">PMC7129920</pub-id></element-citation></ref><ref id="bib0173"><element-citation publication-type="journal" id="sbref0173"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>E</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>M</given-names></name><name name-style="western"><surname>Go</surname><given-names>U</given-names></name><etal/></person-group><article-title>Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>e238</fpage><lpage>e244</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30484-9</pub-id><pub-id pub-id-type="pmid">32628905</pub-id><pub-id pub-id-type="pmcid">PMC7333991</pub-id></element-citation></ref><ref id="bib0174"><element-citation publication-type="journal" id="sbref0174"><person-group person-group-type="author"><name name-style="western"><surname>Petrova</surname><given-names>VN</given-names></name><name name-style="western"><surname>Russell</surname><given-names>CA.</given-names></name></person-group><article-title>The evolution of seasonal influenza viruses</article-title><source>Nat Rev Microbiol</source><volume>16</volume><year>2018</year><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.118</pub-id><pub-id pub-id-type="pmid">29081496</pub-id></element-citation></ref><ref id="bib0175"><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name name-style="western"><surname>Piechotta</surname><given-names>V</given-names></name><name name-style="western"><surname>Chai</surname><given-names>KL</given-names></name><name name-style="western"><surname>Valk</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review</article-title><source>Cochrane Database Syst Rev</source><volume>7</volume><year>2020</year><object-id pub-id-type="publisher-id">CD013600</object-id><pub-id pub-id-type="doi">10.1002/14651858.CD013600.pub2</pub-id><pub-id pub-id-type="pmcid">PMC7389743</pub-id><pub-id pub-id-type="pmid">32648959</pub-id></element-citation></ref><ref id="bib0176"><element-citation publication-type="journal" id="sbref0176"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>N Engl J Med</source><volume>383</volume><year>2020</year><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="bib0177"><element-citation publication-type="journal" id="sbref0177"><person-group person-group-type="author"><name name-style="western"><surname>Principi</surname><given-names>N</given-names></name><name name-style="western"><surname>Camilloni</surname><given-names>B</given-names></name><name name-style="western"><surname>Alunno</surname><given-names>A</given-names></name><etal/></person-group><article-title>Drugs for influenza treatment: is there significant news?</article-title><source>Front Med</source><volume>6</volume><year>2019</year><fpage>109</fpage><pub-id pub-id-type="doi">10.3389/fmed.2019.00109</pub-id><pub-id pub-id-type="pmcid">PMC6546914</pub-id><pub-id pub-id-type="pmid">31192211</pub-id></element-citation></ref><ref id="bib0178"><mixed-citation publication-type="other" id="sbref0178">Public Health England. Excess weight and COVID-19: insights from new evidence. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/excess-weight-and-covid-19-insights-from-new-evidence" id="interref0028">https://www.gov.uk/government/publications/excess-weight-and-covid-19-insights-from-new-evidence</ext-link> (accessed September 2021).</mixed-citation></ref><ref id="bib0179"><element-citation publication-type="journal" id="sbref0179"><person-group person-group-type="author"><name name-style="western"><surname>Raj&#227;o</surname><given-names>DS</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>DR.</given-names></name></person-group><article-title>Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture</article-title><source>Front Microbiol</source><volume>9</volume><year>2018</year><fpage>123</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.00123</pub-id><pub-id pub-id-type="pmid">29467737</pub-id><pub-id pub-id-type="pmcid">PMC5808216</pub-id></element-citation></ref><ref id="bib0180"><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name name-style="western"><surname>Remy</surname><given-names>KE</given-names></name><name name-style="western"><surname>Mazer</surname><given-names>M</given-names></name><name name-style="western"><surname>Striker</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections</article-title><source>JCI Insight</source><volume>5</volume><year>2020</year><object-id pub-id-type="publisher-id">e140329</object-id><pub-id pub-id-type="doi">10.1172/jci.insight.140329</pub-id><pub-id pub-id-type="pmcid">PMC7526441</pub-id><pub-id pub-id-type="pmid">32687484</pub-id></element-citation></ref><ref id="bib0181"><element-citation publication-type="journal" id="sbref0181"><person-group person-group-type="author"><name name-style="western"><surname>Rist</surname><given-names>CL</given-names></name><name name-style="western"><surname>Arriola</surname><given-names>CS</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>C.</given-names></name></person-group><article-title>Prioritizing zoonoses: a proposed one health tool for collaborative decision-making</article-title><source>PloS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e109986</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109986</pub-id><pub-id pub-id-type="pmcid">PMC4193859</pub-id><pub-id pub-id-type="pmid">25302612</pub-id></element-citation></ref><ref id="bib0182"><element-citation publication-type="journal" id="sbref0182"><person-group person-group-type="author"><name name-style="western"><surname>Rockett</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Arnott</surname><given-names>A</given-names></name><name name-style="western"><surname>Lam</surname><given-names>C</given-names></name><etal/></person-group><article-title>Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling</article-title><source>Nat Med</source><volume>26</volume><year>2020</year><fpage>1398</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1000-7</pub-id><pub-id pub-id-type="pmid">32647358</pub-id></element-citation></ref><ref id="bib0184"><mixed-citation publication-type="other" id="sbref0184">Rogers K. Hong Kong flu of 1968. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.britannica.com/event/Hong-Kong-flu-of-1968" id="interref0030">http://www.britannica.com/event/Hong-Kong-flu-of-1968</ext-link> (accessed 25 September 2020).</mixed-citation></ref><ref id="bib0185"><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name name-style="western"><surname>Romer</surname><given-names>D</given-names></name><name name-style="western"><surname>Hall Jamieson</surname><given-names>K</given-names></name></person-group><article-title>Conspiracy theories as barriers to controlling the spread of COVID-19 in the US</article-title><source>Soc Sci med</source><volume>263</volume><year>2020</year><object-id pub-id-type="publisher-id">113356</object-id><pub-id pub-id-type="doi">10.1016/j.socscimed.2020.113356</pub-id><pub-id pub-id-type="pmcid">PMC7502362</pub-id><pub-id pub-id-type="pmid">32967786</pub-id></element-citation></ref><ref id="bib0186"><element-citation publication-type="journal" id="sbref0186"><person-group person-group-type="author"><name name-style="western"><surname>Romer</surname><given-names>D</given-names></name><name name-style="western"><surname>Hall Jamieson</surname><given-names>K</given-names></name></person-group><article-title>Patterns of media use, strength of belief in COVID-19 conspiracy theories, and the prevention of COVID-19 From March to July 2020 in the United States: survey study</article-title><source>J Med Internet Res</source><volume>23</volume><year>2021</year><fpage>e25215</fpage><pub-id pub-id-type="doi">10.2196/25215</pub-id><pub-id pub-id-type="pmid">33857008</pub-id><pub-id pub-id-type="pmcid">PMC8083953</pub-id></element-citation></ref><ref id="bib0187"><element-citation publication-type="journal" id="sbref0187"><person-group person-group-type="author"><name name-style="western"><surname>Sadighi Akha</surname><given-names>AA.</given-names></name></person-group><article-title>Aging and the immune system: an overview</article-title><source>J Immunol Methods</source><volume>463</volume><year>2018</year><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2018.08.005</pub-id><pub-id pub-id-type="pmid">30114401</pub-id></element-citation></ref><ref id="bib0188"><element-citation publication-type="journal" id="sbref0188"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></name><etal/></person-group><article-title>Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>1824</fpage><lpage>1835</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034201</pub-id><pub-id pub-id-type="pmid">33440088</pub-id><pub-id pub-id-type="pmcid">PMC7821985</pub-id></element-citation></ref><ref id="bib0189"><element-citation publication-type="journal" id="sbref0189"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A</given-names></name><etal/></person-group><article-title>Safety and efficacy of single-dose Ad26CoV2.S vaccine against Covid-19</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>2187</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2101544</pub-id><pub-id pub-id-type="pmid">33882225</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id></element-citation></ref><ref id="bib0190"><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name name-style="western"><surname>Sallam</surname><given-names>M.</given-names></name></person-group><article-title>COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates</article-title><source>Vaccines (Basel)</source><volume>9</volume><year>2021</year><fpage>160</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020160</pub-id><pub-id pub-id-type="pmid">33669441</pub-id><pub-id pub-id-type="pmcid">PMC7920465</pub-id></element-citation></ref><ref id="bib0191"><element-citation publication-type="journal" id="sbref0191"><person-group person-group-type="author"><name name-style="western"><surname>Salmon</surname><given-names>DA</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Glanz</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Vaccine hesitancy: causes, consequences, and a call to action</article-title><source>Vaccine</source><volume>33</volume><issue>Suppl 4</issue><year>2015</year><fpage>D66</fpage><lpage>D71</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.035</pub-id><pub-id pub-id-type="pmid">26615171</pub-id></element-citation></ref><ref id="bib0192"><element-citation publication-type="journal" id="sbref0192"><person-group person-group-type="author"><name name-style="western"><surname>Salyer</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Silver</surname><given-names>R</given-names></name><name name-style="western"><surname>Simone</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prioritizing zoonoses for global health capacity building &#8211; themes from one health zoonotic disease workshops in 7 countries, 2014&#8211;2016</article-title><source>Emerg Infect Dis</source><volume>23</volume><year>2017</year><fpage>S55</fpage><lpage>S64</lpage><pub-id pub-id-type="doi">10.3201/eid2313.170418</pub-id><pub-id pub-id-type="pmid">29155664</pub-id><pub-id pub-id-type="pmcid">PMC5711306</pub-id></element-citation></ref><ref id="bib0193"><element-citation publication-type="journal" id="sbref0193"><person-group person-group-type="author"><name name-style="western"><surname>Samanlioglu</surname><given-names>F</given-names></name><name name-style="western"><surname>Bilge</surname><given-names>AH.</given-names></name></person-group><article-title>An Overview of the 2009 A(H1N1) pandemic in Europe: efficiency of the vaccination and healthcare strategies</article-title><source>J Healthc Eng</source><volume>2016</volume><year>2016</year><object-id pub-id-type="publisher-id">5965836</object-id><pub-id pub-id-type="doi">10.1155/2016/5965836</pub-id><pub-id pub-id-type="pmcid">PMC5058565</pub-id><pub-id pub-id-type="pmid">27195658</pub-id></element-citation></ref><ref id="bib0194"><element-citation publication-type="journal" id="sbref0194"><person-group person-group-type="author"><name name-style="western"><surname>Sanmarchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Golinelli</surname><given-names>D</given-names></name><name name-style="western"><surname>Lenzi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Exploring the gap between excess mortality and COVID-19 deaths in 67 countries</article-title><source>JAMA Network Open</source><volume>4</volume><year>2021</year><object-id pub-id-type="publisher-id">e2117359</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.17359</pub-id><pub-id pub-id-type="pmcid">PMC8285734</pub-id><pub-id pub-id-type="pmid">34269809</pub-id></element-citation></ref><ref id="bib0195"><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name name-style="western"><surname>Saunders-Hastings</surname><given-names>PR</given-names></name><name name-style="western"><surname>Krewski</surname><given-names>D.</given-names></name></person-group><article-title>Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission</article-title><source>Pathogens</source><volume>5</volume><year>2016</year><fpage>66</fpage><pub-id pub-id-type="doi">10.3390/pathogens5040066</pub-id><pub-id pub-id-type="pmid">27929449</pub-id><pub-id pub-id-type="pmcid">PMC5198166</pub-id></element-citation></ref><ref id="bib0196"><element-citation publication-type="journal" id="sbref0196"><person-group person-group-type="author"><name name-style="western"><surname>Sebastian</surname><given-names>S</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T.</given-names></name></person-group><article-title>Clinical advances in viral-vectored influenza vaccines</article-title><source>Vaccines</source><volume>6</volume><year>2018</year><fpage>29</fpage><pub-id pub-id-type="doi">10.3390/vaccines6020029</pub-id><pub-id pub-id-type="pmid">29794983</pub-id><pub-id pub-id-type="pmcid">PMC6027524</pub-id></element-citation></ref><ref id="bib0197"><element-citation publication-type="journal" id="sbref0197"><person-group person-group-type="author"><name name-style="western"><surname>Sekaly</surname><given-names>RP.</given-names></name></person-group><article-title>The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?</article-title><source>J Exp Med</source><volume>205</volume><year>2008</year><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1084/jem.20072681</pub-id><pub-id pub-id-type="pmid">18195078</pub-id><pub-id pub-id-type="pmcid">PMC2234358</pub-id></element-citation></ref><ref id="bib0198"><mixed-citation publication-type="other" id="sbref0198">Settele J, Diaz S, Brondizio E, et&#160;al. COVID-19 stimulus measures must save lives, protect livelihoods, and safeguard nature to reduce the risk of future pandemics. IBPES Expert Guest Article, 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ipbes.net/covid19stimulus" id="interref0031">https://ipbes.net/covid19stimulus</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0199"><element-citation publication-type="journal" id="sbref0199"><person-group person-group-type="author"><name name-style="western"><surname>Shanks</surname><given-names>GD</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>N</given-names></name><name name-style="western"><surname>Kippen</surname><given-names>R</given-names></name><etal/></person-group><article-title>The unusually diverse mortality patterns in the Pacific region during the 1918&#8211;21 influenza pandemic: reflections at the pandemic's centenary</article-title><source>Lancet Infect Dis</source><volume>18</volume><year>2018</year><fpage>e323</fpage><lpage>e332</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(18)30178-6</pub-id><pub-id pub-id-type="pmid">29754745</pub-id></element-citation></ref><ref id="bib0200"><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name name-style="western"><surname>Shetty</surname><given-names>P.</given-names></name></person-group><article-title>Experts concerned about vaccination backlash</article-title><source>Lancet</source><volume>375</volume><year>2010</year><fpage>970</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(10)60421-7</pub-id><pub-id pub-id-type="pmid">20333812</pub-id></element-citation></ref><ref id="bib0201"><element-citation publication-type="journal" id="sbref0201"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>Y</given-names></name><name name-style="western"><surname>McCauley</surname><given-names>J</given-names></name></person-group><article-title>GISAID: Global initiative on sharing all influenza data &#8211; from vision to reality</article-title><source>Euro Surveill</source><volume>22</volume><year>2017</year><fpage>30494</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.es.2017.22.13.30494</pub-id><pub-id pub-id-type="pmid">28382917</pub-id><pub-id pub-id-type="pmcid">PMC5388101</pub-id></element-citation></ref><ref id="bib0202"><element-citation publication-type="journal" id="sbref0202"><person-group person-group-type="author"><name name-style="western"><surname>Simonsen</surname><given-names>L</given-names></name><name name-style="western"><surname>Spreeuwenberg</surname><given-names>P</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>R</given-names></name><etal/></person-group><article-title>Global mortality estimates for the 2009 influenza pandemic from the GLaMOR project: a modeling study</article-title><source>PLoS Med</source><volume>10</volume><year>2013</year><object-id pub-id-type="publisher-id">e1001558</object-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001558</pub-id><pub-id pub-id-type="pmcid">PMC3841239</pub-id><pub-id pub-id-type="pmid">24302890</pub-id></element-citation></ref><ref id="bib0203"><element-citation publication-type="journal" id="sbref0203"><person-group person-group-type="author"><name name-style="western"><surname>Simonsen</surname><given-names>L</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>E</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Using clinical research networks to assess severity of an emerging influenza pandemic</article-title><source>Clin Infect Dis</source><volume>67</volume><year>2018</year><fpage>341</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy088</pub-id><pub-id pub-id-type="pmid">29746631</pub-id><pub-id pub-id-type="pmcid">PMC6248856</pub-id></element-citation></ref><ref id="bib0204"><element-citation publication-type="journal" id="sbref0204"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>W</given-names></name><name name-style="western"><surname>Andrewes</surname><given-names>C</given-names></name><name name-style="western"><surname>Laidlaw</surname><given-names>P.</given-names></name></person-group><article-title>A virus obtained from influenza patients</article-title><source>Lancet</source><volume>222</volume><year>1933</year><fpage>66</fpage><lpage>68</lpage></element-citation></ref><ref id="bib0205"><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name name-style="western"><surname>Sorensen</surname><given-names>C</given-names></name><name name-style="western"><surname>Japinga</surname><given-names>M</given-names></name><name name-style="western"><surname>Crook</surname><given-names>H</given-names></name><name name-style="western"><surname>McClellan</surname><given-names>M.</given-names></name></person-group><article-title>Building a better health care system post-COVID-19: steps for reducing low-value and wasteful care</article-title><source>NEJM Catalyst</source><year>2020</year><pub-id pub-id-type="doi">10.1056/CAT.20.0368</pub-id></element-citation></ref><ref id="bib0206"><element-citation publication-type="journal" id="sbref0206"><person-group person-group-type="author"><name name-style="western"><surname>Strugnell</surname><given-names>R</given-names></name><name name-style="western"><surname>Zepp</surname><given-names>F</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vaccine antigens</article-title><source>Perspectives in vaccinology</source><volume>1</volume><year>2011</year><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.pervac.2011.05.003</pub-id></element-citation></ref><ref id="bib0207"><element-citation publication-type="journal" id="sbref0207"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>S</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><etal/></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol</source><volume>24</volume><year>2016</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id><pub-id pub-id-type="pmid">27012512</pub-id><pub-id pub-id-type="pmcid">PMC7125511</pub-id></element-citation></ref><ref id="bib0208"><element-citation publication-type="journal" id="sbref0208"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>D</given-names></name><name name-style="western"><surname>Comish</surname><given-names>P</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.</given-names></name></person-group><article-title>The hallmarks of COVID-19 disease</article-title><source>PLoS Pathog</source><volume>16</volume><year>2020</year><object-id pub-id-type="publisher-id">e1008536</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008536</pub-id><pub-id pub-id-type="pmcid">PMC7244094</pub-id><pub-id pub-id-type="pmid">32442210</pub-id></element-citation></ref><ref id="bib0209"><element-citation publication-type="journal" id="sbref0209"><person-group person-group-type="author"><name name-style="western"><surname>Tanriover</surname><given-names>MD</given-names></name><name name-style="western"><surname>Do&#287;anay</surname><given-names>HL</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey</article-title><source>Lancet</source><volume>398</volume><year>2021</year><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01429-X</pub-id><pub-id pub-id-type="pmid">34246358</pub-id><pub-id pub-id-type="pmcid">PMC8266301</pub-id></element-citation></ref><ref id="bib0210"><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name name-style="western"><surname>Taubenberger</surname><given-names>JK</given-names></name><name name-style="western"><surname>Morens</surname><given-names>DM.</given-names></name></person-group><article-title>1918 Influenza: the mother of all pandemics</article-title><source>Emerg Infect Dis</source><volume>12</volume><year>2006</year><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3201/eid1201.050979</pub-id><pub-id pub-id-type="pmid">16494711</pub-id><pub-id pub-id-type="pmcid">PMC3291398</pub-id></element-citation></ref><ref id="bib0211"><element-citation publication-type="journal" id="sbref0211"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>PC</given-names></name><name name-style="western"><surname>Adams</surname><given-names>AC</given-names></name><name name-style="western"><surname>Hufford</surname><given-names>MM</given-names></name><name name-style="western"><surname>de la Torre</surname><given-names>I</given-names></name><name name-style="western"><surname>Winthrop</surname><given-names>K</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>RL</given-names></name></person-group><article-title>Neutralizing monoclonal antibodies for treatment of COVID-19</article-title><source>Nat Rev Immunol</source><volume>21</volume><year>2021</year><fpage>382</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00542-x</pub-id><pub-id pub-id-type="pmid">33875867</pub-id><pub-id pub-id-type="pmcid">PMC8054133</pub-id></element-citation></ref><ref id="bib0212"><mixed-citation publication-type="other" id="sbref0212">Tegally H, Wilkinson E, Giovanetti M, et&#160;al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. 2021. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1" id="interref0032">https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1</ext-link> (accessed February 2021).</mixed-citation></ref><ref id="bib0213"><element-citation publication-type="journal" id="sbref0213"><person-group person-group-type="author"><name name-style="western"><surname>Tentolouris</surname><given-names>A</given-names></name><name name-style="western"><surname>Ntanasis-Stathopoulos</surname><given-names>I</given-names></name><name name-style="western"><surname>Vlachakis</surname><given-names>PK</given-names></name><name name-style="western"><surname>Tsilimigras</surname><given-names>DI</given-names></name><name name-style="western"><surname>Gavriatopoulou</surname><given-names>M</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>MA.</given-names></name></person-group><article-title>COVID-19: time to flatten the infodemic curve</article-title><source>Clin Exp Med</source><volume>1&#8211;5</volume><year>2021</year><pub-id pub-id-type="doi">10.1007/s10238-020-00680-x</pub-id><comment>(epub ahead of print)</comment><pub-id pub-id-type="pmcid">PMC7790724</pub-id><pub-id pub-id-type="pmid">33417084</pub-id></element-citation></ref><ref id="bib0214"><mixed-citation publication-type="other" id="sbref0214">The Economist. Tracking covid-19 excess deaths across countries. 2021. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.economist.com/graphic-detail/coronavirus-excess-deaths-tracker" id="interref0033">https://www.economist.com/graphic-detail/coronavirus-excess-deaths-tracker</ext-link> (accessed September 2021).</mixed-citation></ref><ref id="bib0215"><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name name-style="western"><surname>To</surname><given-names>KK</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>OT</given-names></name><name name-style="western"><surname>Leung</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30196-1</pub-id><pub-id pub-id-type="pmid">32213337</pub-id><pub-id pub-id-type="pmcid">PMC7158907</pub-id></element-citation></ref><ref id="bib0216"><element-citation publication-type="journal" id="sbref0216"><person-group person-group-type="author"><name name-style="western"><surname>Tomazini</surname><given-names>BM</given-names></name><name name-style="western"><surname>Maia</surname><given-names>IS</given-names></name><name name-style="western"><surname>Cavalcanti</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial</article-title><source>JAMA</source><volume>324</volume><year>2020</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.17021</pub-id><pub-id pub-id-type="pmcid">PMC7489411</pub-id><pub-id pub-id-type="pmid">32876695</pub-id></element-citation></ref><ref id="bib0217"><element-citation publication-type="journal" id="sbref0217"><person-group person-group-type="author"><name name-style="western"><surname>Tomkins</surname><given-names>SM.</given-names></name></person-group><article-title>The failure of expertise: public health policy in Britain during the 1918&#8211;19 influenza epidemic</article-title><source>Soc Hist Med</source><volume>5</volume><year>1992</year><fpage>435</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1093/shm/5.3.435</pub-id><pub-id pub-id-type="pmid">11623115</pub-id></element-citation></ref><ref id="bib0218"><element-citation publication-type="journal" id="sbref0218"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>C</given-names></name><name name-style="western"><surname>Crameri</surname><given-names>G</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Antibodies to SARS coronavirus in civets</article-title><source>Emerg Infect Dis</source><volume>10</volume><year>2004</year><fpage>2244</fpage><lpage>2248</lpage><pub-id pub-id-type="doi">10.3201/eid1012.040520</pub-id><pub-id pub-id-type="pmid">15663874</pub-id><pub-id pub-id-type="pmcid">PMC3323399</pub-id></element-citation></ref><ref id="bib0219"><mixed-citation publication-type="other" id="sbref0219">USAID PREDICT. Reducing pandemic risk, promoting global health. 2020. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.usaid.gov/sites/default/files/documents/1864/predict-global-flyer-508.pdf" id="interref0034">https://www.usaid.gov/sites/default/files/documents/1864/predict-global-flyer-508.pdf</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0220"><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name name-style="western"><surname>Uscinski</surname><given-names>JE</given-names></name><name name-style="western"><surname>Enders</surname><given-names>AM</given-names></name><name name-style="western"><surname>Klofstad</surname><given-names>C</given-names></name><etal/></person-group><article-title>Why do people believe COVID-19 conspiracy theories?</article-title><source>Harvard Kennedy School (HKS) Misinform Rev</source><volume>1</volume><year>2020</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.37016/mr-2020-015</pub-id></element-citation></ref><ref id="bib0221"><element-citation publication-type="journal" id="sbref0221"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name><etal/></person-group><article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>578</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2608-y</pub-id><pub-id pub-id-type="pmid">32731258</pub-id><pub-id pub-id-type="pmcid">PMC8436420</pub-id></element-citation></ref><ref id="bib0222"><element-citation publication-type="journal" id="sbref0222"><person-group person-group-type="author"><name name-style="western"><surname>Vartak</surname><given-names>A</given-names></name><name name-style="western"><surname>Sucheck</surname><given-names>SJ.</given-names></name></person-group><article-title>Recent advances in subunit vaccine carriers</article-title><source>Vaccines</source><volume>4</volume><year>2016</year><fpage>12</fpage><pub-id pub-id-type="doi">10.3390/vaccines4020012</pub-id><pub-id pub-id-type="pmid">27104575</pub-id><pub-id pub-id-type="pmcid">PMC4931629</pub-id></element-citation></ref><ref id="bib0223"><element-citation publication-type="journal" id="sbref0223"><person-group person-group-type="author"><name name-style="western"><surname>Vernon</surname><given-names>JR.</given-names></name></person-group><article-title>The 1920-21 Deflation: the role of aggregate supply</article-title><source>Economic Inquiry</source><volume>29</volume><year>1991</year><fpage>572</fpage><lpage>580</lpage></element-citation></ref><ref id="bib0225"><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name name-style="western"><surname>Viboud</surname><given-names>C</given-names></name><name name-style="western"><surname>Grais</surname><given-names>RF</given-names></name><name name-style="western"><surname>Lafont</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic</article-title><source>J Infect Dis</source><volume>192</volume><year>2005</year><fpage>233</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1086/431150</pub-id><pub-id pub-id-type="pmid">15962218</pub-id></element-citation></ref><ref id="bib0226"><element-citation publication-type="journal" id="sbref0226"><person-group person-group-type="author"><name name-style="western"><surname>Viboud</surname><given-names>C</given-names></name><name name-style="western"><surname>Simonsen</surname><given-names>L</given-names></name><name name-style="western"><surname>Fuentes</surname><given-names>R</given-names></name><etal/></person-group><article-title>Global mortality impact of the 1957&#8211;1959 influenza pandemic</article-title><source>J Infect Dis</source><volume>213</volume><year>2016</year><fpage>738</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv534</pub-id><pub-id pub-id-type="pmid">26908781</pub-id><pub-id pub-id-type="pmcid">PMC4747626</pub-id></element-citation></ref><ref id="bib0227"><element-citation publication-type="journal" id="sbref0227"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>SAC</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><volume>397</volume><year>2021</year><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="bib0228"><element-citation publication-type="journal" id="sbref0228"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><name name-style="western"><surname>Park</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></element-citation></ref><ref id="bib0229"><element-citation publication-type="journal" id="sbref0229"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>HE</given-names></name><name name-style="western"><surname>Gamboa</surname><given-names>C</given-names></name><name name-style="western"><surname>Warnock</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Chronic kidney disease and risk of death from infection</article-title><source>Am J Nephrol</source><volume>34</volume><year>2011</year><fpage>330</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1159/000330673</pub-id><pub-id pub-id-type="pmid">21860228</pub-id><pub-id pub-id-type="pmcid">PMC3169360</pub-id></element-citation></ref><ref id="bib0230"><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jing</surname><given-names>R</given-names></name><name name-style="western"><surname>Lai</surname><given-names>X</given-names></name><etal/></person-group><article-title>Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China</article-title><source>Vaccines</source><volume>8</volume><year>2020</year><fpage>482</fpage><pub-id pub-id-type="doi">10.3390/vaccines8030482</pub-id><pub-id pub-id-type="pmid">32867224</pub-id><pub-id pub-id-type="pmcid">PMC7565574</pub-id></element-citation></ref><ref id="bib0231"><element-citation publication-type="journal" id="sbref0231"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Du</surname><given-names>G</given-names></name><etal/></person-group><article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1569</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)31022-9</pub-id><pub-id pub-id-type="pmid">32423584</pub-id><pub-id pub-id-type="pmcid">PMC7190303</pub-id></element-citation></ref><ref id="bib0232"><element-citation publication-type="journal" id="sbref0232"><person-group person-group-type="author"><name name-style="western"><surname>Weingartl</surname><given-names>H</given-names></name><name name-style="western"><surname>Czub</surname><given-names>M</given-names></name><name name-style="western"><surname>Czub</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</article-title><source>J Virol</source><volume>78</volume><year>2004</year><fpage>12672</fpage><lpage>12676</lpage><pub-id pub-id-type="doi">10.1128/jvi.78.22.12672-12676.2004</pub-id><pub-id pub-id-type="pmid">15507655</pub-id><pub-id pub-id-type="pmcid">PMC525089</pub-id></element-citation></ref><ref id="bib0233"><element-citation publication-type="journal" id="sbref0233"><person-group person-group-type="author"><name name-style="western"><surname>Wilder-Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Chiew</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>VJ.</given-names></name></person-group><article-title>Can we contain the COVID-19 outbreak with the same measures as for SARS?</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>e102</fpage><lpage>e107</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30129-8</pub-id><pub-id pub-id-type="pmid">32145768</pub-id><pub-id pub-id-type="pmcid">PMC7102636</pub-id></element-citation></ref><ref id="bib0234"><element-citation publication-type="journal" id="sbref0234"><person-group person-group-type="author"><name name-style="western"><surname>Wille</surname><given-names>M</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>EC.</given-names></name></person-group><article-title>The ecology and evolution of influenza viruses</article-title><source>Cold Spring Harb Perspect Med</source><volume>10</volume><year>2020</year><object-id pub-id-type="publisher-id">a038489</object-id><pub-id pub-id-type="doi">10.1101/cshperspect.a038489</pub-id><pub-id pub-id-type="pmcid">PMC7328453</pub-id><pub-id pub-id-type="pmid">31871237</pub-id></element-citation></ref><ref id="bib0235"><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name name-style="western"><surname>Wise</surname><given-names>J.</given-names></name></person-group><article-title>Covid-19: highest death rate seen in countries with most overweight populations</article-title><source>BMJ</source><volume>372</volume><year>2021</year><fpage>n623</fpage><pub-id pub-id-type="doi">10.1136/bmj.n623</pub-id><pub-id pub-id-type="pmid">33664055</pub-id></element-citation></ref><ref id="bib0236"><element-citation publication-type="journal" id="sbref0236"><person-group person-group-type="author"><name name-style="western"><surname>W&#246;lfel</surname><given-names>R</given-names></name><name name-style="western"><surname>Corman</surname><given-names>VM</given-names></name><name name-style="western"><surname>Guggemos</surname><given-names>W</given-names></name><etal/></person-group><article-title>Virological assessment of hospitalized patients with COVID-2019</article-title><source>Nature</source><volume>581</volume><year>2020</year><fpage>465</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2196-x</pub-id><pub-id pub-id-type="pmid">32235945</pub-id></element-citation></ref><ref id="bib0224"><mixed-citation publication-type="other" id="tboref0001">Hul V, Karlsson EA, Hassanin A, et&#160;al. A novel SARS-CoV-2 related coronavirus in bats from Cambodia. 2021. bioRxiv preprint doi: <pub-id pub-id-type="doi">10.1101/2021.01.26.428212</pub-id><pub-id pub-id-type="pmcid">PMC8578604</pub-id><pub-id pub-id-type="pmid">34753934</pub-id></mixed-citation></ref><ref id="bib0237"><mixed-citation publication-type="other" id="sbref0237">World Health Organization. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). 2003. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/WHOconsensus.pdf?ua=1" id="interref0035">https://www.who.int/csr/sars/WHOconsensus.pdf?ua=1</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0239"><mixed-citation publication-type="other" id="sbref0239">World Health Organization. Strengthening response to pandemics and other public-health emergencies: report of the review committee on the functioning of the international health regulations (2005) and on Pandemic Influenza (H1N1) 2009. 2011. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/ihr/publications/RC_report/en/" id="interref0037">https://www.who.int/ihr/publications/RC_report/en/</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0240"><mixed-citation publication-type="other" id="sbref0240">World Health Organization. Report of the WHO pandemic influenza A(H1N1) vaccine deployment initiative. 2012. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/44795" id="interref0038">https://apps.who.int/iris/handle/10665/44795</ext-link> (accessed March 2021).</mixed-citation></ref><ref id="bib0241"><mixed-citation publication-type="other" id="sbref0241">World Health Organization. About IHR. 2016. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/ihr/about/en/" id="interref0039">https://www.who.int/ihr/about/en/</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0242"><mixed-citation publication-type="other" id="sbref0242">World Health Organization. Draft thirteenth general programme of work, 2019&#8211;2023. 2018. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_4-en.pdf?ua=1" id="interref0040">http://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_4-en.pdf?ua=1</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0243"><mixed-citation publication-type="other" id="sbref0243">World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). MERS monthly summary, November 2019. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/" id="interref0041">https://www.who.int/emergencies/mers-cov/en/</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0244"><mixed-citation publication-type="other" id="sbref0244">World Health Organization. Pandemic influenza. 2020a. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/pandemic-influenza" id="interref0042">https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/pandemic-influenza</ext-link> (accessed December 2020).</mixed-citation></ref><ref id="bib0245"><mixed-citation publication-type="other" id="sbref0245">World Health Organization. Influenza. Global Influenza Surveillance and Response System (GISRS). 2020b. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/influenza/gisrs_laboratory/en/" id="interref0043">https://www.who.int/influenza/gisrs_laboratory/en/</ext-link> (accessed January 2021).</mixed-citation></ref><ref id="bib0246"><mixed-citation publication-type="other" id="sbref0246">World Health Organization. Influenza. Surveillance and monitoring. 2020c. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/influenza/surveillance_monitoring/en/" id="interref0044">https://www.who.int/influenza/surveillance_monitoring/en/</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0247"><mixed-citation publication-type="other" id="sbref0247">World Health Organization. Pandemic influenza preparedness (PIP) framework. 2020d. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/influenza/pip/en/" id="interref0045">https://www.who.int/influenza/pip/en/</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0248"><mixed-citation publication-type="other" id="sbref0248">World Health Organization. Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness. 2020e. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/influenza/vaccines/virus/202009_zoonotic_vaccinevirusupdate.pdf?ua=1" id="interref0046">https://www.who.int/influenza/vaccines/virus/202009_zoonotic_vaccinevirusupdate.pdf?ua=1</ext-link> (accessed October 2020).</mixed-citation></ref><ref id="bib0249"><mixed-citation publication-type="other" id="sbref0249">World Health Organization. Influenza. COVID-19 sentinel surveillance by GISRS. 2021a. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/influenza/gisrs_laboratory/covid19/en/" id="interref0047">https://www.who.int/influenza/gisrs_laboratory/covid19/en/</ext-link> (accessed January 2021).</mixed-citation></ref><ref id="bib0250"><mixed-citation publication-type="other" id="sbref0250">World Health Organization. Therapeutics and COVID-19 Living Guideline (6 July 2021). 2021b. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2" id="interref0048">https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2</ext-link> (accessed September 2021).</mixed-citation></ref><ref id="bib0251"><mixed-citation publication-type="other" id="sbref0251">World Health Organization. Coronavirus disease (COVID-19) advice for the public: mythbusters. 2021c. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters#virus" id="interref0049">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters#virus</ext-link> (accessed September 2021).</mixed-citation></ref><ref id="bib0252"><mixed-citation publication-type="other" id="sbref0252">World Health Organization. Draft landscape of COVID-19 candidate vaccines. 2021d. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines2020" id="interref0050">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines2020</ext-link> (accessed February 2021).</mixed-citation></ref><ref id="bib0253"><mixed-citation publication-type="other" id="sbref0253">World Obesity Federation. Obesity and COVID-19: policy statement. 2012. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.worldobesity.org/news/obesity-and-covid-19-policy-statement" id="interref0051">https://www.worldobesity.org/news/obesity-and-covid-19-policy-statement</ext-link> (accessed September 2021).</mixed-citation></ref><ref id="bib0254"><element-citation publication-type="journal" id="sbref0254"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JT</given-names></name><name name-style="western"><surname>Cowling</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Lau</surname><given-names>EH</given-names></name><etal/></person-group><article-title>School closure and mitigation of pandemic (H1N1) 2009, Hong Kong</article-title><source>Emerg Infect Dis</source><volume>16</volume><year>2010</year><fpage>538</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.3201/eid1603.091216</pub-id><pub-id pub-id-type="pmid">20202441</pub-id><pub-id pub-id-type="pmcid">PMC3206396</pub-id></element-citation></ref><ref id="bib0255"><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect Dis</source><volume>21</volume><year>2021</year><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></element-citation></ref><ref id="bib0256"><element-citation publication-type="journal" id="sbref0256"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy of convalescent plasma for the treatment of severe influenza</article-title><source>Crit Care</source><volume>24</volume><year>2020</year><fpage>469</fpage><pub-id pub-id-type="doi">10.1186/s13054-020-03189-7</pub-id><pub-id pub-id-type="pmid">32727526</pub-id><pub-id pub-id-type="pmcid">PMC7388480</pub-id></element-citation></ref><ref id="bib0257"><element-citation publication-type="journal" id="sbref0257"><person-group person-group-type="author"><name name-style="western"><surname>Yeo-Teh</surname><given-names>NSL</given-names></name><name name-style="western"><surname>Tang</surname><given-names>BL.</given-names></name></person-group><article-title>An alrming retraction rate for scientific publications on coronavirus disease 2019 (COVID-19)</article-title><source>Account Res</source><volume>28</volume><year>2021</year><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1080/08989621.2020.1782203</pub-id><pub-id pub-id-type="pmid">32573274</pub-id></element-citation></ref><ref id="bib0258"><element-citation publication-type="journal" id="sbref0258"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#8211;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect Dis</source><volume>21</volume><year>2021</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></element-citation></ref><ref id="bib0259"><element-citation publication-type="journal" id="sbref0259"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name><name name-style="western"><surname>To</surname><given-names>KK</given-names></name><name name-style="western"><surname>Wong</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses</article-title><source>Immunity</source><volume>53</volume><year>2020</year><fpage>864</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.07.026</pub-id><comment>e865</comment><pub-id pub-id-type="pmid">32791036</pub-id><pub-id pub-id-type="pmcid">PMC7402670</pub-id></element-citation></ref><ref id="bib0260"><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id><pub-id pub-id-type="pmcid">PMC7092803</pub-id></element-citation></ref></ref-list><sec id="sec0034" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0077a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1_lrg.jpg" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgements</title><p id="para0079">Authors thank Business and Decisions Life Science for editorial assistance and manuscript coordination, on behalf of GSK. Mary Greenacre provided medical writing support, Pierre-Paul Pr&#233;vot coordinated the manuscript development and provided editorial support.</p></ack><fn-group><fn id="sec0033" fn-type="supplementary-material"><p id="para0006a">Supplementary material associated with this article can be found, in the online version, at doi:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijid.2021.09.045" id="interref0002">10.1016/j.ijid.2021.09.045</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>